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Hepatitis C virus (HCV) affects nearly 200 million people worldwide and is a 
leading cause for serious chronic liver diseases. For the replication of HCV 
genome, the membrane-associated replication machinery needs to be formed 
by both HCV non-structural proteins including NS5A and NS5B, and human 
host factors. Recently, NS5A and NS5B have been identified to bind ER-
anchored human VAP proteins and this interaction may serve as a novel target 
for the design of anti-HCV drugs. So far, no biophysical characterization of 
these interactions has been reported.  
In this study, we dissected the 243-residue VAPB into 4 and 447-residue 
NS5A into 10 fragments, followed by CD and NMR characterization of their 
structural properties. Domain 1 of NS5A from HCV S1 strain has β-strands 
dominant structure, whereas domain 2 and domain 3 (D3) were intrinsically 
unstructured domains. NMR sequential assignment of D3 revealed the 
propensity to form α-helix at C-terminal region. Subsequently, binding 
interactions between these fragments have been extensively assessed by NMR 
HSQC titrations which can characterize very weak interactions. The studies 
revealed that a “fuzzy complex” is formed between the intrinsically-
unstructured D3 of NS5A and the well-structured MSP domain of VAPB, with 
an average dissociation constant (Kd) of ~5 µM. The binding-important 
residues on both NS5A-D3 and VAPB-MSP have been successfully mapped 
out, which provided experimental constraints for constructing the complex 
structure. In the complex, unstructured D3 binds to three surface pockets on 





Interestingly, two ALS-causing mutations T46I and P56S are also located on 
the D3-MSP interface and T46I mutation in MSP domain dramatically 
abolishes its interaction with D3. Moreover, NS5A-D3, FFAT-containing 
proteins and EphA4 appear to have overlapped binding interfaces on the MSP 
domain. Therefore, investigations into the interaction between different Eph 
receptors and MSP domain were achieved by using NMR titrations. Although, 
binding interfaces on MSP domain of all the studied receptors were quite 
similar but their perturbation profile was different. Among all the tested Eph 
receptors, perturbation of MSP peaks triggered by EphA2 and EphA5 
saturated at very low molar ratios as compared to other receptors. By fitting 
the shifted residues of MSP domain upon the addition of Eph A2 and EphA5, 
we have calculated the average Kd as ~8.7 µM and ~62.8 µM respectively. 
Interestingly, NS5A-D3 has been experimentally confirmed to compete with 
EphA4 in binding to the MSP domain. Overlap of binding surface of Eph 
receptor and NS5A interaction on MSP domain, and competition of NS5A 
with EphA4 suggest the association of HCV infection with ALS disease. Our 
study not only provides essential foundation for further deciphering structure 
and function of the HCV replication machinery, but may also shed light on 
rationalizing a recent observation that a chronic HCV patient surprisingly 
developed ALS-like syndrome.  
For the first time, we have also studied the interaction between NS5B, RNA 
dependent RNA polymerase and VAPB protein. Binding studies using NMR 
titration revealed that MSP domain of VAPB interacts with NS5B protein.  
In summary, for the first time, this study has provided the structural insight 





membrane protein VAPB which enhances our understanding of host viral 
interactions which has arisen as potential target of antivirals. Moreover, it also 
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1.1 Hepatitis C Virus: An Overview 
Hepatitis C virus (HCV) is a pathogen of global importance due to significant 
health problems throughout the globe. Although HCV was identified in 1989 
(Choo et al., 1989) but in past few years it has been recognized as a serious 
disease burden. Immediately after World War II, there was significant number 
of increase in the cases of post transfusion hepatitis (PTH) due to blood and 
plasma transfusion. Identification of specific viral and antigenic markers of 
hepatitis A virus (HAV) and hepatitis B virus (HBV) allowed the diagnosis of 
these viruses in patients suffering viral hepatitis. However, a significant 
number of hepatitis cases in individuals receiving blood transfusion could not 
be recognized as either HAV or HBV (Feinstone et al., 1975, Prince et al., 
1974), and the agent responsible was termed non-A, non-B hepatitis 
(NANBH). Regardless of extensive research in the 1970s and 1980s, the 
etiological agent(s) of NANBH remained unidentified, primarily because cell 
culture or animal models were not available for the propagation of the 
unknown agent. Eventually success in the transmission of the NANBH agent 
into chimpanzees made it achievable to demonstrate that NANBH was caused 
by a small, enveloped virus (Alter et al., 1978). However, low viral titres in 
the serum delayed the identification of this virus. Finally, in 1989 this virus 
was identified as positive sense single strand RNA by molecular cloning and 
subsequently classified within a separate genus (Hepacivirus) of the 
Flaviviridae family and designated Hepatitis C Virus (HCV) (Choo et al., 





Several reasons have been contributed for the increasing focus of intensive 
research on HCV in academic and pharmaceutical-industry laboratories 
(Lavanchy et al., 1999). First, high frequency of persistence during most 
infections, about 85% cases virus establishes a chronic infection, which can 
further leads to liver cirrhosis and hepatocellular carcinoma (20-50% cases). 
Second, infection of HCV is a major health problem throughout the world. 
Third, presently the only available therapy, which is combination treatment 
with pegylated interferon-α (IFN-α) and the nucleoside analogue ribavirin 
(RBV), is often difficult to tolerate and only 40% of all patients benefits from 
this treatment and settle with a sustained response. In present scenario, there is 
a pressing need to develop more effective and better tolerated therapies for 
chronic hepatitis C. A detailed understanding of the viral lifecycle underpins 
these efforts. 
1.2 The Silent Epidemic: Hepatitis C 
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV). HCV 
infection sometimes results in an acute symptomatic illness which leads to the 
development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma 
(HCC). Since infection of hepatitis C is usually mild in its early stages, it is 
seldom diagnosed and often not recognized until its chronic stages. With a 
typical cycle of disease from infection to symptomatic liver disease taking as 
long as 20 years, the true impact of this disease on our growing infected 
population will not be apparent for many years. For this reason, it is often 





HCV has chronically infected more than 200 million people globally, nearly 
five times more than human immunodeficiency virus (HIV)-infected 
individuals, and more than 350 000 people die from  hepatitis C-related liver 
diseases each year (Wasley et al., 2000; Perz et al., 2004; WHO). Hepatitis C 
virus Infection is frequently persistent, and sets in train an inexorable course 
of slowly progressive liver disease. Despite ongoing research, there is 
currently no vaccine to prevent hepatitis C virus infection. Hence, it is one of 
the greatest public health threats faced in this century (WHO).  
Epidemiological data is crucial in the prevention of deadly global diseases like 
hepatitis C as ultimate defense against any disease is awareness and 
knowledge. Although the survey for the incidents of the virus is not been done 
in every nation in the world, yet enough statistics have been compiled to 
demonstrate the threat posed by hepatitis C. Surprisingly, 75% of all cases of 
liver disease throughout the world are caused by hepatitis C and hepatitis B. 
Epidemiological studies shows that prevalence of HCV varies enormously in 
various part of the world, with highest incidents in less developed nations of 
Eastern hemisphere (Africa and Asia)  of the globe than Western parts. The 
prevalence of hepatitis C is lower in the industrialized nations in North 
America, northern and Western Europe and Australia (figure 1.1). Populous 
nations with low rates of prevalence include Germany (0.6%), Canada (0.8%), 
France (1.1%) and Australia (1.1%). Low, but slightly elevated seroprevalence 
rates have been reported in USA (1.8%), Japan (1.5-2.3%) and Italy (2.2%).  
However, higher rates of infection have been reported in Asian countries, 
including China (3.2%), India (0.9% - community based survey), Indonesia 





for many African nations, reaching as high as 22% in Egypt (Frank et al., 
2000; Shepard et al., 2005; Lavanchy D, 2011).  As per WHO report, about 
1% of Singapore’s population which estimates to 46090 individuals, is 
infected with HCV. 
1.3 Route of Transmission 
Better understanding of virus transmission is very much helpful to fight with 
the disease spread. In early nineteen century, use of unsterilized needles and 
syringes in the treatment of syphilis, or other injections resulted in hepatitis 
transmission in the society (Mortimer et al., 1995). Before 1990, blood 
transfusion was principal transmission route of HCV. Though since 1990, 
screening of the blood products for HCV antibodies in many Asian countries 
has significantly reduced transfusion-related HCV infection. However, due to 
the seronegative ‘window’ period of HCV infection, the risk of post-
transfusion infection is also there. Although the major route of transmission is 
via blood products from infected donors and unsafe therapeutic injections, 
intriguingly transmission factor could not be recognized in 40% of the cases 
(Memon et al., 2002, Shepard et al., 2005). A study estimated that 
contaminated medical injections were the cause of 2 million HCV infection 
cases globally in 2000 (Hauri et al., 2004). Likewise, the high prevalence of 
HCV in Egypt can be mostly attributed to poor medical practice, including the 
PAT campaign, where practice of reusing glass syringe became the route of 






Figure 1.1 Hepatitis C global prevalence in 2010 (%). (Figure reprinted with 

















Some groups of individuals such as intravenous drug users are at increased 
risk of getting infected with this disease irrespective of the geographical 
location. Injection of drug accounts for most newly acquired HCV infections 
in the developed countries, including USA, UK and Australia (Thomson et al., 
2009). Hepatitis C virus can also transmitted between sex partners and among 
household members, but the degree of risk is supposed to be low. Maternal-
infant transmission has also been recognized as a mode of transmission. 
However, coinfection with HIV-1 appears to increase the risk of both sexual 
and maternal–fetal transmission of HCV but it needs to be further studied 
(Willems et al., 2002). Due to large gap in understanding the global 
epidemiology of HCV, still many questions, concerning the role of risk factors 
and lifestyle conditions in the spread of HCV, have been unanswered.  
1.4 HCV Classification and Genetic Diversity 
According to the genome analysis, hepatitis C virus is a RNA virus and has 
been classified into Flaviviridae family which is further classified into three 
genera: flavivirus, pestivirus, and hepacivirus (Choo et al., 1991). The family 
Flaviviridae is compositionally diverse as the genus flavivirus contains the 
classical flaviviruses, such as yellow fever virus and Dengue virus, whereas 
viruses of agricultural importance like classical swine fever virus (CSFV) and 
bovine viral diarrhea virus (BVDV) are being kept in genus pestivirus.  The 
hepacivirus genus of this family includes HCV, GB virus B (GBV-B), GB 
virus C (GBV-C) which is most closely related human virus to HCV 





It is important to note that HCV virus has extraordinary genetic diversity 
among the many known isolates (Simmonds et al., 2004).  These isolates are 
described by an organization system with major grouping referred as 
genotypes (1,2,3…)  and the variants within genotypes designated as subtypes 
(1a, 1b, 2a,…) ( Kuiken et al., 2006; Simmonds et al., 2005). Within the 
subtype lowest classification is represented as strains. Currently, there are six 
major genotypes of HCV, with many subtypes, which have diverse prevalence 
across various regions of the world. These genotypes may differ considerably 
in their biological effects such as replication, mutation rates, type and severity 
of liver damage, and detection and treatment options. 
1.5 Molecular Features of HCV 
1.5.1 Virion structure 
Although tremendous progress has been obtained in determining the virion 
structures of other members of Flaviviridae family but due to the difficulties 
in getting pure viral particles, HCV has not been definitively visualized and its 
physicochemical data remains to be obtained. In infected individuals, HCV 
RNA-containing particles circulate in various different forms which includes, 
associated with low-density lipoproteins (LDL) and very-low-density 
lipoproteins (VLDL).VLDL and LDL are particles that export cholesterol and 
triglyceride from hepatocytes in the liver (Andre et al., 2002, Nielsen et al., 
2006). Particles resulting from the combination of HCV with LDL/VLDLs are 
referred as lipoviroparticles (LVPs). HCV also circulates as virions bound to 
immunoglobulins and free virions. These reasons explain the heterogeneity of 
viral particles. Recent findings suggest that VLDL production in the infected 





addition to lipoprotein, HCV virion is thought to have three virus-encoded 
components- RNA genome, a capsid and envelope glycoproteins. The capsid 
which holds the HCV genome is comprised of core proteins. The envelope 
glycoproteins E1 and E2 are presumably anchored to a host cell-derived 
double-layer lipid envelope that surrounds the capsid.  
On the basis of filtration and electron microscopic studies, the diameter of 
HCV particles are 40–70 nm (Wakita et al., 2005). Buoyant density analysis 
of viral particles revealed an interesting fact- intracellular virus particles show 
a buoyant density (1.15-1.20 g/ml) that is higher than that observed for 
secreted virions (1.03-1.16 g/ml) (Gastaminza et al., 2006). Therefore, it is 
suggested that the biochemical composition of HCV particles get modified 
with lipoprotein components during viral egress (Andre et al., 2002; Nielsen et 
al., 2006). 
1.5.2 Genome Organization of HCV 
HCV is a small, enveloped RNA virus, which has 9.6kb long positive-sense, 
single-stranded RNA genome. This genome sequence is consist of a single 
open reading frame (ORF) that is flanked by 5’- untranslated region (5’- UTR) 
of 341 bases and 3’-untranslated region (3’- UTR) of about 200 bases. ORF of 
HCV genome encode for a polyprotein precursor of 3,011 amino acids which 
is further cleaved by viral and host proteases into 10 mature structural and 
nonstructural regulatory proteins (Figure 1.2). Structural proteins, which are 
involved in viral particle formation, include the core protein (capsid) and 
glycoproteins E1 and E2 (envelope). Nonstructural proteins, which coordinate 






Figure 1.2 Genetic organization and polyprotein processing of hepatitis C virus (HCV). Schematic depiction of the 9.6-kb positive-strand RNA 
genome in which RNA secondary structures in the 5'- and 3'-NCRs, the core gene as well as 5B-SL3 are shown. IRES-mediated translation 
yields a polyprotein precursor that is processed into the mature structural and non-structural proteins. Solid diamonds denote cleavage sites of 
the polyprotein precursor by the endoplasmic reticulum signal peptidase. The open diamond indicates further C-terminal processing of the core 
protein by signal peptide peptidase. Arrows indicate cleavages by the HCV NS2–3 and NS3–4A proteases. Dots in E1 and E2 indicate the 





protease, NS3 serine protease and helicase, NS4A, NS4B, NS5A proteins and 
NS5B RNA-dependent RNA polymerase (RdRp) (Reed et al., 2000). 
1.5.2.1 5’- Untranslated Region 
The 5’- UTR of HCV genome is highly conserved 341 nucleotide long region 
which is located upstream of ORF translation initiation codon (Choo et al., 
1991; Han et al., 1991) (figure 1.2). It harbors an internal ribosome entry site 
(IRES) which is essential for cap-independent translation of the viral RNA 
(Tsukiyama-Kohara et al., 1992; Wang et al., 1993). Structural analysis of 5’- 
UTR revealed that it contains four highly structured domains, termed as I-IV 
(Brown et al., 1992). The IRES, is constituted by domain II, III, IV and first 
24–40 nucleotides of the core coding region, has the ability to form a stable 
pre-initiation complex by direct binding with 40S subunit of ribosome without 
the help of any initiation factor. This is believed to be first event in translation 
of HCV m-RNA (Pestova et al., 1998). Whereas, domain I forms a small, 
stem-loop structure that is not required for IRES activity (Honda et al., 1996) 
but domain I together with domain II is crucial for HCV RNA replication 
(Friebe et al., 2001).  
There are few host encoded factors which regulate both replication and 
translation of viral genome by binding to region within the 5’- UTR. Recently, 
abundant liver-specific microRNA (miRNA), miR-122 has been found to bind 
two regions between domain I and II of the 5’- UTR. This interaction is 





(Henke et al., 2008). These findings uncovered a new angle for the possible 
antivirals which inhibits the function of miR-122. 
1.5.2.2 3’- Untranslated Region 
The 3’- UTR is 225 nucleotide long and located right downstream of ORF of 
HCV genome (figure 1.2). It consists of a short variable region, a polyuridine / 
polypyrimidine (U/UC) tract and a highly conserved 98 nucleotide region 
termed as 3’ X-tail which has three stem loop structures (Kolykhalov et al., 
1996; Tanaka et al., 1995, 1996). The variable region seems to affect the 
efficiency of viral RNA replication whereas the 3’ X-tail and poly (U/UC) 
tract were found to be essential for viral replication (Friebe and 
Bartenschlager, 2002; Yi and Lemon, 2003).  
1.5.2.3 Core  
Core protein is the most amino terminal product of the HCV polyprotein and 
major structural protein component of viral nucleocapsid (Figure 1.2). It is 
produced as 23 kDa precursor protein by signal peptidase cleavage at signal 
sequence located between core protein and E1 glycoprotein. Further 
processing at the carboxyl-terminus by signal peptide peptidase yields mature 
21 kDa core protein (McLauchlan et al., 2002). The core protein is organized 
into three domains; N-terminal basic domain D1, C-terminal hydrophobic 
domain D2 and the tail domain (McLauchlan et al., 2009). D1 domain is 
responsible for RNA binding activity and homo-oligomerization of core 
protein (Klein et al., 2005). D2 domain is essential for the interaction of core 
with lipid droplets during viral replication and/or virion morphogenesis 





1.5.2.4 E1 and E2 glycoproteins 
E1 and E2 proteins, are integral membrane proteins, form a non-covalent 
complex which is the building block of viral envelope (Dubuisson et al., 
2002). The C-terminal transmembrane domain of E1 and E2 are involved in 
oligomerization and contain ER retention signals that are important for proper 
maturation of these proteins (Op De Beeck et al., 2000). The maturation of 
these glycoproteins is extremely complex process. It involves glycosylation, 
association with ER chaperones, disulfide bond formation and extensive 
interaction between E1 and E2 transmembrane anchors and ectodomain (Lavie 
et al., 2007). Little knowledge is available about the structure of these 
glycoproteins. Functionally, E2 has involvement in contacting cellular 
receptors involved in HCV entry. Modeling data also confirms the presence of 
fusion peptide activity which is required for virion entry (Krey et al., 2010).  
The function of E1 is not clear yet but it is believed that it is involved in 
interaction with core during assembly (Lo et al., 1996). 
1.5.2.5 p7  
p7 is a 63 amino acid hydrophobic protein which is located between E2 and 
NS2 protein of the HCV polyprotein (figure 1.2). p7 contains two 
transmembrane segments joined by a cytoplasmic loop. It has a double 
spanning topology in which N and C-termini are oriented towards ER lumen 
whereas loop is positioned in the cytoplasm (Carrère-Kremer et al., 2002). It is 
not found to be involved in HCV replication but it is essential for HCV 
infectivity in vivo (Sakai et al., 2003). It has been classified in viroporin 
family since it contains cation channel activity, which is required for its 






NS2 is a 23 kDa non-glycosylated transmembrane protein that represents the 
autoprotease activity of virus. Its transmembrane segments, which are 
responsible for ER membrane association, are clustered in the amino terminal 
domain (Santolini et al., 1995). The C-terminal domain of NS2 and amino 
terminal domain of NS3 (NS2-3 protease) constitute an autoprotease which 
cleaves the site between NS2 and NS3. It is important during complete 
replication cycle of HCV (Lohmann et al., 1999). Recent studies have shown 
its role in production of infectious viral particles (Pietschmann et al., 2006). 
1.5.2.7 NS3 
NS3 is 70 kDa multifunctional protein which has serine protease activity at N-
terminal and helicase/NTPase activity located at C-terminal two third of 
protein. NS3 interacts with NS4A non-covalently and this interaction helps 
NS3 to localize it on ER membrane. NS4A works as co-factor of NS3 protease 
and helicase activity (Beran et al., 2009).The NS3 helicase is a member of 
DExH/D-box helicase superfamily. NS3 dimerization is required for 
unwinding RNA (Serebrov and Pyle, 2004). Recently, mutagenesis studies in 
the helicase domain also have shown its role in viral particle assembly (Ma et 
al., 2008). 
1.5.2.8 NS4A 
NS4A is a 54 amino acid, hydrophobic integral membrane protein which 
serves as the membrane tether, through its N-terminal transmembrane helix. 
Being a co-factor of NS3 enzymatic activities, it holds NS3 in close proximity 





presence of NS4A allows tighter binding of RNA to ATP- bound state of NS3 
(Beran et al., 2009). Therefore, ATPase activity and RNA binding strength of 
NS3 are coupled and both of them are enhanced by NS4A.  Acidic C-terminal 
region of NS4A has also seemed to have impact on NS5A phosphorylation but 
significance of this observation is not clear yet (Lindenbach et al., 2007).  
1.5.2.9 NS4B 
NS4B is 27 kDa hydrophobic integral membrane protein that contains four 
central transmembrane spanning helices. However, its precise topology is 
complex and not well understood (Gouttenoire et al., 2010). Best 
characterized role of NS4B is to induce the formation of the membranous web, 
the alteration of membranes that serve as a scaffold for HCV replication 
complex (Egger et al., 2002). Recently, NS4B has been shown to influence the 
production of infectious viral particles (Jones et al., 2009). 
1.5.2.10 NS5A 
NS5A is a hydrophilic, membrane-anchored phosphoprotein that can be found 
in basally phosphorylated (56 kDa) and hyperphosphorylated (58 kDa) forms 
(Reed et al., 1997). It is a pleiotropic protein which plays crucial role 
throughout HCV life cycle (cellular and viral processes). However, precise 
role in these processes is yet to be elucidated but experimental evidences 
demonstrate that NS5A is involved in viral RNA replication, modulation of 
cell signaling pathways, interferon response, pathogenesis and apoptosis 
regulation through interaction with other HCV and host cell proteins 






NS5B is a 68 kDa RNA-dependent RNA polymerase (RdRp) that contains the 
GDD motif, required for its catalytic activity. It belongs to tail-anchored 
proteins, a class of integral membrane proteins, as C-terminal 21 amino acid 
region forms an alpha-helical transmembrane domain. This domain is 
responsible for its targeting to the cytoplasmic side of ER membrane for 
replication (Moradpour et al., 2004, Schmidt-Mende et al., 2001). This key 
enzyme is responsible for both synthesis of complementary negative-strand 
RNA from viral genome template and synthesis of positive strand RNA using 
negative-strand RNA as a template. Its crystal structure analysis revealed its 
similarity with the shape of a right hand as it contains classical fingers, thumb 
and palm subdomains (Lesburg et al., 1999, Ago et al., 1999). 
1.6 HCV life cycle 
1.6.1 Viral attachment and entry 
The initial step of HCV life cycle is viral attachment to the liver cells via 
attachment factors (figure 1.3). Interaction of viral particle to these attachment 
factors are usually nonspecific and help to concentrate virus on cell surface. 
These cell surface molecules serve as a capture molecules for viral particles. 
Glycosaminoglycan (GAG) heparin sulphate is an important cellular binding 
molecule which provides primary docking sites for HCV binding (Barth et al., 
2003). Furthermore, inhibition of HCV attachment with the pretreatment of 
cells with heparinase enzyme further confirmed its crucial role in attachment 
(Koutsoudakis et al., 2006). The low density lipoprotein receptor (LDL-R) has 





with HCV particles (Agnello et al., 1999). Moreover, a correlation between 
the accumulation of HCV RNA into primary hepatocytes, expression of LDL-
R mRNA and LDL entry has been observed (Molina et al., 2007). Studies 
have suggested that the cellular protein apolipoprotein E (apoE) is also 
important for HCV infection. Controversially, latest studies have demonstrated 
that LDL-R is not essential for infectious HCV particle entry while, 
physiological function of this receptor is important for RNA replication 
(Albecka et al., 2012). However, underlying molecular mechanism of these 
interactions is still uncertain; studies also suggest their roles in virus entry. 
Mannose binding C-type lectins DC-SIGN and L-SIGN are expressed on 
dendritic cells and liver sinusoidal endothelial cells respectively, serve as 
adhesion molecules by recognizing carbohydrate structures (glycoproteins) on 
pathogen. These interactions facilitate the capture of circulating HCV particles 
and transmission to adjacent hepatocytes (Cormier et al., 2004, Gardner et al., 
2003, Lozach et al., 2004).   
Subsequent attachment of HCV virions to the exterior of host cells, the virus 
interacts with specific receptors (entry factors), which are responsible for 
initiating a sequence of events that ultimately liberate the viral genome into 
the cytosol. So far, four cell surface receptors have been identified to show 
interaction with viral envelope glycoproteins E1 and E2 (Bartosch and 
Dubuisson, 2010). These receptors includes the tetraspanin CD81 (Pileri et al., 
1998), the lipoprotein receptor scavenger receptor BI (SR-BI) (Scarselli et al., 
2002) as well as two tight junction factors called occluding (OCLN) (Ploss et 
al., 2009) and claudin 1 (CLDN) (Evans et al., 2007). Fusion of the viral lipid 






Figure 1.3 Lifecycle of hepatitis C virus (HCV). Enveloped HCV virion 
particles enter into the cell by E2 binding and receptor-mediated endocytosis, 
uncoating results in the release of the positive-sense, single-stranded RNA 
(ssRNA) genome. an internal ribosome entry site (IRES) that directs 5′-cap-
independent synthesis of a polyprotein of ׽3000 amino acids (aa) that 
undergoes processing by viral and cellular proteases. Ten mature structural 
and nonstructural viral proteins are produced. In addition to its role as mRNA, 
the positive-sense RNA genome also serves as the template for RNA 
replication catalyzed by the viral RNA-dependent RNA polymerase (NS5B) 
that occurs in association with the ER membrane. Other components of the 
HCV replication complex include both viral proteins and cellular factors. The 
complementary minus-sense RNA produced then serves as the template for 
synthesis of positive-sense RNA that fulfills three functions, mRNA for 
translation, template for RNA replication, and progeny genome that undergoes 
encapsidation into new virions. SR-B, scavenger receptor class B; miR122, 






molecules in a tightly co-ordinated way. HCV enters by clathrin-mediated 
endocytosis (Blanchard et al., 2006) (figure 1.3). Once it is internalized, viral 
envelope fuses with the membrane of early endosome (Meertens et al., 2006). 
Moreover, the acidic pH of endosome activates the fusion event by inducing 
conformational changes in the envelope proteins. After the fusion the genome 
of HCV is liberated in the cell cytosol (figure 1.3). This fusion event is very 
complex and mechanism is not yet understood.  
1.6.2 Translation and polyprotein processing  
1.6.2.1 Translation 
Once the viral genome is released into the cytosol, translation of viral genome 
initiates. Viral RNA genome is a positive sense RNA, therefore it act as 
mRNA and directly gets translated at rough endoplasmic reticulum. 
Translation initiation of HCV mRNA occurs via a cap-independent 
mechanism which is driven by structured RNA sequences called internal 
ribosome entry sites (IRESs) that are positioned in the 5’- UTR of RNA 
genome. IRES mediated translation is initiated through the formation of binary 
complex by direct binding of 40S ribosomal subunit to the IRES. This binary 
complex further binds to eukaryotic initiation factor 3 (eIF3) and ternary 
complex (eIF2•Met-tRNAi•GTP) and forms a 48S like complex. 
Subsequently, the rate limiting step is the GTP-dependent association of the 
60S subunit that leads to the formation of an 80S complex (Otto and Puglisi, 
2004, Boehringer et al., 2005). This 80S initiation complex initiates protein 






1.6.2.2 Polyprotein processing 
Translation of HCV RNA yields a large polyprotein precursor that is 
subsequently co- and post-translationally processed by cellular and viral 
proteases into mature structural and non-structural proteins (Figure 1.2). The 
N-terminal structural proteins-encoding region of the polyprotein is cleaved in 
association with cellular membranes via the action of host signal peptidases. 
Signal peptidases cleave at Core/E1, E1/E2, E2/p7 and p7/NS2 junctions. 
Whereas, non-structural proteins-encoding region is processed by two distinct 
virally encoded protease activities. The protease activity resides in NS2 
protein which works as auto-catalytic papain-like cysteine protease and 
cleaves at NS2/NS3 (Grakoui et al., 1993). This process liberates N-terminal 
region of NS3 which has serine protease activity. NS3, serine protease then 
cleaves at all remaining junctions including NS3/NS4A, NS4A/NS4B, 
NS4B/NS5A, NS5A/ NS5B (Bartenschlager et al., 1994, Failla et al., 1995, 
Lin et al., 1994). 
1.6.3 RNA Replication 
1.6.3.1 Site of HCV Replication: Replication complex 
Like all positive-strand RNA viruses, HCV infection induces significant 
alteration of membranes which form sponge like inclusions, called as 
“membranous webs” (Egger et al., 2002). These membranous webs are 
derived mainly from ER membranes and the C-terminal domain of NS4B 
protein is chiefly responsible for their generation (Elazar et al., 2004). Studies 





RNA localize to the membranous web (Egger et al., 2002; Gosert et al., 2003). 
These data reveal that membranous webs serve as sites of HCV replication. It 
is not yet clear whether membrane rearrangements serve mainly to provide the 
physical support and organize replication complex, provide a high local 
concentration of replication components, or protect the viral RNAs from 
recognition by the innate immune system. Membranous web harbors many 
replication complexes which are composed of all required components of 
RNA synthesis, including the non-structural proteins and host cell proteins, 
replicating RNA and modified cellular membranes (Egger et al., 2002; Gosert 
et al., 2003; Mottola et al., 2002). So far precise composition of replication 
complex is not known. 
1.6.3.2 Replication 
However, the HCV replication process is not well understood but the 
development of tissue culture systems that support de novo HCV genome 
synthesis has revolutionized the determination of the factors required for HCV 
replication. The post-translational processing of polyprotein leads to the 
release of NS5B RNA-dependent RNA polymerase which replicates the HCV 
genome by the synthesis of negative strand RNA using genome as a template. 
Subsequently, it synthesizes the positive strand RNA using negative stand 
RNA as a template (Lohmann et al., 1999; Takehara et al., 1992). As 
mentioned earlier this whole process takes place at replication complex with 
the close co-ordination of viral nonstructural proteins and cellular proteins. 
NS3 helicase is involved in unwinding putative secondary structures of the 





formed by positive and negative RNA strands, have been visualized in 
positive-strand RNA viruses. Likewise, dsRNA has been detected in close 
proximity to Replication Complexes (RCs) in the actively HCV replicating 
cells. This observation suggests that the intermediates are protected within the 
RCs (Targett-Adams et al., 2008).  
Replication initiation takes place at the 3’- end of the positive and negative 
strands. It is triggered by interactions between RC proteins, domain I of 
5’UTR, 3′ X region of the 3’ UTR, a cis-acting replication element (5BSL3.2) 
(Astier-Gin et al., 2005; Friebe et al., 2005; You et al., 2004). 
1.6.4 Virus Assembly and release  
Due to the lack of cell culture system for the efficient production of infectious 
viral particles, later stages of HCV life cycle, including virion assembly and 
release could not be studied. However, report published in 2005 has 
demonstrated that genome of JFH1 strain could produce infectious virus in 
cell culture (Zhong et al., 2005; Wakita et al., 2005). It opened a new direction 
to study the mechanism of HCV particle assembly and release. Virion 
assembly initiation is supposed to require liberation of replicated genomes 
from the membranous web to allow contact with core protein and form viral 
capsid. Since, core protein is located on the cytosolic side of ER membrane, 
therefore, assembly perhaps initiates in the cytosol and then nascent particles 
are transferred and released by the secretory pathway. Basically, production of 
infectious particles can be achieved by two interconnected processes: an 
initiation phase on the cytosolic side of ER membrane, followed by maturation 





many host factors and viral proteins interactions are required for particle 
assembly and release but the major contributors from the host cell are LDs, 
and the VLDL assembly pathway (Jones and McLauchlan, 2010). 
Oxysterol-binding protein (OSBP) and ceramide transfer protein (CERT) play 
a essential role in sphingolipid biosynthesis which is required for HCV 
maturation in Golgi. Another important protein apolipoprotein E (ApoE), was 
shown to interact with HCV NS5A and to be crucial for HCV particle 
formation and release (Benga et al., 2010) 
1.7 Role of host factors in HCV replication 
Viruses as pathogens are triumphant due to their ability to replicate in host 
cells. This is accomplished by manipulating cell metabolism in such a way 
that it supports the infection process and allows viruses to suppress or escape 
host defense mechanisms. Therefore, host factors involved in replication are 
key determinants of viral pathology. Use of in vitro replicase assays, 
intracellular localization approaches, reverse genetics studies, genome-wide 
screens has not only facilitated the identification of host factors affecting viral 
replication but also provided better understanding of their roles (figure 1.4). 
The host factors, identified through such approaches are likely to have various 
roles: as enzymes involved in lipid metabolism to drive membrane 
proliferation; as regulators of the switch from translation to replication (by 
promoting template recognition); as chaperones that facilitate folding of viral 
proteins; as helicases or RNA chaperones that assist the folding of viral RNA 
and as mediators of the intracellular transport of viral proteins and viral RNA 





1.7.1 Membrane remodeling and lipid synthesis  
Dynamic remodeling of membrane which leads to the formation of ER derived 
membranous webs, is achieved by the help of many host cell factors. The host 
phosphatidylinositol 4-kinaseIIIα (PI4KIIIα), which is involved in PtdIns4P 
synthesis, was found to be essential for this process (Vaillancourt et al., 2009). 
The ER-bound HCV protein NS5A recruits PI4KIIIα and stimulates PI4KIIIα 
kinase activity which leads to the enrichment of membrane compartment with 
PtdIns4P (Berger et al., 2009; Reiss et al., 2011). PtdIns4P enriched 
membrane further facilitate the recruitment of viral proteins and other required 
host factors, for example oxysterol-binding protein 1 (OSBP1) (Amako et al., 
2009). Subsequently, it leads to the formation of the sterol-rich membranous 
webs. Studies have revealed that host factors which are involved in cholesterol 
and fatty acid biosynthetic pathways are also important in regulating the 
replication as RNA replication is sensitive to treatment with lovastatin (a 
cholesterol-lowering drug) (Ye et al., 2003). Eventually, FBL2, a 
geranylgeranylated cellular protein, was found to be associated with NS5A 
and needed for HCV replication (Wang et al., 2005). Another enzyme, Fatty 
acid synthase (FASN) which plays key role in catalyzing the terminal step in 
the de novo biogenesis of fatty acids, is also required for HCV propagation 
(Yang et al., 2008). 
1.7.2 Cellular chaperones  
Another potential class of host factors, required for HCV replication, is 
molecular chaperones. In HCV infected cells, viruses subvert molecular 









Figure 1.4 Putative model of HCV replication complex composed of viral and 







stability of viral proteins (Wang and Li, 2012). The heat shock protein (hsp)70 
and its co-chaperone, hsp40 were shown to interact with NS5A and to be 
required for HCV replication as well as IRES mediated translation. Hsp72 also 
have been reported to be involved in replication by interacting with viral 
NS5A, NS3, and NS5B (RdRp) (Chen et al., 2010). Another essential 
chaperone, hsp90 interacts with NS3 to enhance its stability. It also binds with 
NS5A and host FKBP8 immunophilin, and promotes the proper folding of 
viral protein and likely prevents the induction of unfolded protein responses 
(Ujino et al., 2009; Okamoto et al., 2006). 
By the use of siRNA-based approaches, a chaperone like activity possessing 
protein, cyclophilin A (CypA) that has withdrawn a lot of attention, has been 
identified to be required for HCV RNA replication and probably also 
assembly (Yang et al., 2008). It is a member of peptidyl prolyl isomerase 
(PPIase) family that catalyzes the isomerization of peptide bonds at proline 
residues and facilitates protein folding (Wang and Heitman, 2005). Although 
NS5A, NS5B and NS2 have been proposed to be the targets of CypA, there 
are convincing evidences which suggest that the connection between domain 
II of NS5A and CypA is crucial for HCV replication (Coelmont et al., 2010).  
1.7.3 Targeting viral replication proteins to the replication site 
Host proteins which are involved in targeting the HCV replication proteins to 
the replication sites, include the human vesicle-associated membrane protein-
associated protein (VAP). It is a SNARE-like protein which was identified to 
serve as a membrane anchor for HCV replication proteins during replication. It 





mediates the replication complex formation on lipid rafts (Tu et al., 1999; Gao 
et al., 2004).  
Conclusively, by the use of various advanced approaches, many host factors 
important for HCV life cycle have been swiftly identified. This information 
will not only facilitate the better understanding of viral life cycle but also will 
help to identify new targets for the development of antiviral drugs as targeting 
host factor is more advantageous then targeting viral proteins that mutate 
rapidly. Since, underlining mechanisms of many of these identified host 
factors are still unclear. Therefore, to develop new anti-virals, there is a 
pressing need for in depth understanding of their role in viral life cycle. 
1.8 Interaction of VAP proteins with NS5A and NS5B 
Presence of conserved hydrophobic stretches on viral replication proteins 
suggests their membrane retention ability during replication. Membrane 
association of viral replication complex on ER-derived membranes is crucial 
for HCV RNA replication and involves interactions between viral and host 
proteins. As mechanism of specific membrane association of RCs was mostly 
unknown.  
NS5A is an essential component of RCs and it plays important role in 
regulating many host signaling pathways through protein-protein interactions. 
Therefore, to investigate the role of NS5A in HCV replication, yeast two 
hybrid screens were performed by Tu et al. and they identified that a ER 
membrane protein, VAPA (hVAP-33) interacts with viral NS5A and NS5B 
(Tu et al.,1999). This report, for first time, sheds light on the possible 







Figure 1.5 Models of interaction between HCV NS proteins and VAP. 
Monomeric and hetero- or homodimeric forms of VAPs can interact with 







that is, through the binding with VAP proteins. Several reports suggest that 
HCV replication takes place on the detergent-resistant membrane fraction. 
NS4B together with viral NS5A and NS5B proteins are associated with the 
detergent-resistant membranes (lipid rafts). VAP-A was also localized in the 
detergent-resistant fraction, suggesting that it plays an important role in HCV 
replication. Dominant negative inhibition of the expression of VAPA protein, 
which is partially associated with the lipid rafts, consequences in relocation of 
NS5B from detergent-resistant to detergent-sensitive membranes and 
decreased the RNA replication of HCV (Gao et al., 2004; Aizaki et al., 2004). 
Moreover, Hamamoto et al. also reported the involvement of VAPB protein in 
HCV replication through interaction with NS5A and NS5B. By using 
mutagenesis approach, they suggested that NS5A might interact with coiled-
coil domain of VAPB via N-terminal 70 residues and 341 to 344 amino acids 
in the C-terminal polyproline cluster region (Hamamoto et al. 2005). 
Particularly, overexpression of VAPB significantly increased the expression of 
NS5A and NS5B, as well as the RNA replication. Whereas, 
hyperphoshorylation of NS5A disrupts its interaction with VAPA protein and 
results in negative regulation of RNA replication of HCV (Evans et al., 2004). 
Recently, VAPC has been identified to interact with NS5B and negatively 
regulates the HCV propagation (Kukihara et al., 2009).   
1.8.1 VAP proteins  
VAMP (vesicle-associated membrane protein)-associated proteins (VAPs) are 
type II integral endoplasmic reticulum (ER) membrane proteins which are 





VAPs is not only in ER membrane but also in a wide range of intracellular 
membranes, e.g. Golgi, the ER–Golgi intermediate compartment, recycling 
endosomes, tight junctions, neuromuscular junctions and plasma membrane. 
Firstly, it was identified as homologues of VAMP-associated protein (VAP) 
with a size of 33 kDa in Aplysia californica. This family includes: VAPA, 
VAPB, VAPC (figure 1.7A) and several newly-identified spliced variants 
(Skehel et al., 1995; Nishimura et al., 1999; Nachreiner et al., 2010). VAPA 
and VAPB shares 63% sequence identity and composed of three conserved 
domains: an N-terminal immunoglobulin-like β-sheet domain (crystal 
structure shown in figure 1.7B) which has 22% sequence identity with the 
nematode major sperm protein (MSP), a central coiled-coil domain (CCD) 
which is also found in VAMPs and other SNARE proteins, and a C-terminal 
transmembrane domain (figure 1.7). VAPC is an alternative spliced variant of 
VAPB and contains first 70 residues of VAPB followed by additional 29 
residues. 
Functions of VAPs are not completely understood. But they are involved in 
the vesicle-binding and exocytosis functions of the endoplasmic reticulum 
(ER)-Golgi apparatus, lipid transport and metabolism, the unfolded protein 
response (UPR), an ER housekeeping process that suppresses accumulation of 
misfolded proteins and microtubule organization (Lev et al., 2008). VAP 
proteins have been shown to interact with SNARE molecules which are 
conserved proteins of transport machinery, and regulate their function in 
vesicle fusion during the transport of secretory molecules. More precisely it 






Figure 1.6 Effects of the ALS-Associated VAPB Mutation. VAPB modulates 
diverse pathways including ER homeostasis and ceramide and sphingolipid 
metabolism. In addition, VAP is cleaved by an unknown protease, releasing 
MSP domain-containing fragments that are secreted. Extracellular cleavage is 
shown here; however, the cellular location of this event remains to be 
determined; the resulting VAP fragments bind to Eph receptors (EphRs) 
although again the location is unknown (Tsuda et al. suggest from their fly 
model that the location of VAP fragment binding to EphRs could be in the 
Drosophila flight muscles). VAP fragments could also act in an autocrine way 
to modulate neuronal activity, for example, via glutamate receptors (GluRs). 
The proline 56 to serine (P56S) mutation in VAPB has been observed in a 
subset of ALS patients with the rare familial form of the disease. This 
mutation results in aggregation of the mutant (red) and wild-type (yellow) 
VAP protein in the ER, upregulation of the unfolded protein response (UPR), 
and loss of VAP function including Eph receptor signaling and probably other 
ER-associated activities of VAP (Adopted from Ackerman and Cox, 2008 









                 
Figure 1.7 Domain organizations of VAP variants and structure of MSP 
domain. (A) Members of VAP family-VAPA, VAPB and VAPC. (B) Crystal 
structure of MSP domain of VAPB. (C) Structure of MSP domain showing 









for SNARE interaction or by some means stabilizing their interactions (Weir 
et al., 1998, 2001). 
Furthermore, VAP proteins interact with lipid-binding proteins carrying a 
short motif containing two phenylalanines in an acidic tract (FFAT motif) 
(Wyles et al., 2002). The FFAT motif has the consensus amino acid sequence 
EFFDAxE which is conserved in numerous lipid-binding protein families 
involved in the transport of lipids between the ER and other organelles, such 
as the Golgi, endosomes, and plasma membrane. Crystal structure analysis of 
the VAP-FFAT complex revealed that FFAT motif binds to a highly 
conserved positive patch on the surface of VAP MSP domain (Kaiser et al., 
2005). Recent report suggested that intracellular proteins, including Nir1, 
Nir2, and Nir3 interact with VAPB protein via their FFAT motif and result in 
differential affects on the organization of ER. In the HCV infected cell, VAPs 
might be involved in the transport of lipid components to the HCV replication 
complex through the interaction with NS5A and NS5B, resulting in the 
upregulation of HCV replication. As VAPB was also reported to interact with 
Nir2 protein and remodel ER membrane structure. It can therefore be 
speculated that VAPs are associated with remodeling of the HCV replication 
complex in the ER membrane through interaction with Nir2 protein. 
1.8.1.1 Interaction of VAPB with Eph receptors 
The erythropoietin-producing hepatocellular carcinoma (Eph) receptors, which 
belong to transmembrane receptors tyrosine kinase (RTK) family, have been 
implicated in various cellular functions such as cell signaling and 





cytoskeleton, cell-substrate adhesion, intercellular junctions, cell shape, and 
cell movement (Pasquale EB, 2008). Two types of Eph receptors have been 
identified in human genome which includes: nine EphA receptors, which 
promiscuously bind to five GPI-linked ephrin-A ligands; and five EphB 
receptors that bind to three transmembrane ephrin-B ligands. Interactions of 
some Eph receptors with the ephrins of other class have also been identified in 
recent years.  In the developing nervous system, Eph receptors and ephrins are 
highly expressed and play essential role in the establishment of neuronal 
connectivity. Therefore, it was speculated that Eph receptors signaling in 
expressing cell might be crucial in mediating the susceptibility of motor 
neurons in ALS (Amyotrophic lateral sclerosis) patients. In fact, Tsuda et al. 
demonstrated that the N-terminal MSP domain of VAPB protein is cleaved 
and secreted from cells by unknown mechanism and then interact with EphA4 
receptor (Tsuda et al., 2008). This discovery supports the previous study, in 
which the presence of hVAP MSP domain was discovered in blood serum by 
mass spectrometry (Omenn et al., 2005). Interaction of hVAP MSP domain 
with extracellular ligand binding domain of EphA4 receptor was also 
confirmed by pull down assay (Tsuda et al., 2008). This work has also 
revealed a novel pathway in which secreted MSP domain of VAP protein 
interacts with Eph receptors present on neuron cells, which may be crucial for 
motor neuron survival or muscle functions.  
1.8.1.2 Association of VAPB with Amyotrophic Lateral Sclerosis Disease  
Strikingly, in the VAPB MSP domain, two point mutations P56S and T46I 
have been identified, which lead to the rapid progression of familial 





2011, Nishimura et al., 2005, Chen et al., 2010). However, the role of VAPB 
mutations and underlying mechanism of pathogenesis of these motor neuron 
diseases are not yet understood. While, recent studies have revealed the 
possible mechanism in which MSP domains of VAP proteins are cleaved and 
secreted to serve as ligands for Eph receptors (figure 1.6). Secreted MSP 
domain is proposed to act as diffusible hormones for Eph receptors and point 
mutation P56S, results in the failure of its secretion that lead to the 
accumulation of inclusions in the endoplasmic reticulum and unfolded protein 
response in ALS patients (Tsuda et al., 2008). Accumulation of inclusion of 
VAPB leads to the failure of MSP domain secretion which thereby reduces its 
interaction with Eph receptors and enhances the signaling through ephrin 
ligand interaction with Eph receptors. This has also confirmed by recently 
published study (Van Hoecke et al., 2012) which has revealed that ALS 
patients have higher activity and expression of EphA4 receptor. This report 
shows that EphA4 can modulate motor neuron degeneration and disease 
progression in ALS, suggesting that inhibition of EphA4 signalling through 
the ephrin binding, could be developed as a therapeutic strategy.  Indeed, 
investigations showed that the genetical and pharmacological inhibition of 
EPHA4 in rodent models of ALS can delay the onset of disease and improve 
survival. The higher activity of EphA4 receptor leads to the increase in the 
size of motor neurons which are more susceptible to degeneration in ALS 
(Van Hoecke et al., 2012). Indirectly, these results indicate that secreted MSP 
domain competes with ephrin to interact with the Eph receptor and might 





in vitro interaction study; in which MSP domain competes with ephrin ligand 
for the inetraction with EphA4 (Lua et al., 2011).         
Being a critical interaction between MSP domain and Eph receptor in ALS 
disease, it has only been characterize with EphA4 receptor in our lab (Lua et 
al., 2011). However, the detailed characterizations with various Eph receptors 
have never been achieved. Thus, to gain better insight, we have attempted to 
study the interaction of MSP domain with various Eph receptors.  
1.8.2 Viral proteins: NS5A and NS5B 
NS5A is a pleiotropic protein that appears to have multiple and diverse 
function during viral life cycle and in cellular signaling pathways by 
interacting with viral and host proteins. It is not only involved in RNA 
replication but also critical in the assembly of infectious viral particles. 
Though, the specific roles of NS5A are still unclear (Bartenschlager et al., 
2010). Due to its diverse function during HCV life cycle, it has emerged as 
potential antiviral target. A potential NS5A inhibitor BMS 790052, which has 
attracted a lot of attention, has shown to suppress HCV replication. However, 
its mechanism of action is still not understood (Lemm et al., 2010; Gao et al., 
2010). NS5A is 447 amino acid residues protein which has N-terminal 31 
residue amphipathic helix, which mediates the association with cytoplasmic 
membranes, followed by three domains, separated by short flexible linker 
regions. Domain 1 of NS5A contains a zinc-binding site and has RNA-binding 
capacity which is essential for RNA replication. Crystal structure of domain 1 
has revealed its dimeric nature and presence of a groove, potentially involved 





have suggested that all three domains of NS5A are involved in RNA binding 
(Foster et al., 2010). Domain 2 of NS5A has shown to interact with NS5B 
(RNA dependent RNA polymerase), cyclophilin A (Coelmont et al., 2010) 
and contains the IFN sensitivity determining region. Recently solution NMR 
studies have revealed that domain 2 is intrinsically unfolded (Hanoulle et al., 
2010; Liang et al., 2007). Similarly, domain 3 solution NMR and CD results 
have proven that it is also natively unfolded and works as substrate of 
cyclophilin A (Hanoulle et al., 2009; Verdegem et al., 2011). 
On other hand NS5B protein is a highly conserved RNA dependent RNA 
polymerase which binds to RNA to replicate HCV RNA (Behrens et al., 1996; 
Lohmann et al., 1997). It is proposed that NS5B localizes itself to the 
perinuclear region and form replication complex with other viral proteins. The 
crystal structure of NS5B has revealed that the fingers and thumb subdomains 
of polymerase interact extensively which lead to a unique shape that serves to 
encircle the active site of enzyme (Lesburg et al., 1999).  Particularly, the 
signature sequence for RdRp, called GDD motif, is located at Gly317-Asp318-
Asp319 positions respectively. The C-terminal hydrophobic region of NS5B 
acts in membrane association of the enzyme (Lohmann et al., 1997). 
During the different phases of replication, NS5B interacts directly or indirectly 
with various viral proteins e.g. NS3/4A, NS4B, NS5A and 3’ UTR. Moreover, 
it has also been demonstrated to interact with many host factors. Little 
understanding of some of NS5B functions, leaded to the identification of many 
promising inhibitors which inhibit the action of NS5B and affect HCV 





interactions with viral/host factors is needed now. The interaction between 
NS5B and host protein VAPB was identified in 1999, but till now 
characterization of this interaction to get deeper insight could not be achieved. 
Therefore, we took the initiative to study the interaction between NS5B and 
VAPB. To conduct this study at atomic level, we have utilized Nuclear 
Magnetic Resonance spectroscopy extensively; therefore, basic knowledge 
about it and its application used in this work in explained here. 
1.9 Nuclear Magnetic Resonance 
1.9.1 Introduction  
Generally, all biological macromolecules, especially proteins, are composed of 
thousands of atoms and get activated when folded into a particular and 
atomically-organized spatial conformation which is termed as a three-
dimensional protein structure. Determination of 3D structure of a protein 
provides insight into the molecular mechanisms of cellular machineries. 
Nuclear magnetic resonance (NMR) and X-ray crystallography are the only 
two techniques that can provide 3D structures of proteins at atomic resolution. 
Among these two, NMR spectroscopy is the only method that allows all the 
experiments to be carried out in solution phase. Therefore, for various study 
objectives, the solution conditions such as pH, temperature, salt concentration 
etc can be easily adjusted to either physiological condition or extreme non-
physiological conditions. Moreover, apart from determination of 3D structure 
of protein, NMR can also provide information about dynamics, folding, 





1.9.2 The principle of NMR spectroscopy 
The Nuclear magnetic resonance phenomenon is based on the fact that nuclei 
of atoms have magnetic properties that can be utilized to get chemical 
information.  When the nuclei of certain atoms are kept in static magnetic field 
and a second oscillating magnetic field is applied, nuclear magnetic resonance 
occurs. This phenomenon is only applied to the nuclei with specific spin 
property. Nuclear spin (I), which is described as angular momentum quantum 
number, is a fundamental property of a nucleus. It comes from the spin of 
subatomic particles (proton and neutron) of nucleus. Nucleus with spin is like 
a tiny magnet which generates a magnetic moment (µ). In the atoms with even 
number of proton and neutron, spin are paired and cancel out each other. 
These nuclei have zero spin (I = 0) and no magnetic moment, thus are NMR 
inactive (eg 12C, 16O, 32S). However, nuclei with nuclear spin I = ½ (eg 1H, 
15N, 13C) can provide simple and interpretable signals and therefore are 
commonly used in NMR study. Nuclei with I > ½ (like 2H, 14N) have 
unsymmetrical distribution of charge, which result in quadrupolar moment 
besides their magnetic moment.  
The nuclear spin which gives rise to a magnetic dipole moment- 
μ = γ I 
According to quantum theory angular momentum is quantized and depends on 
the atom type.  
The energy associated with a magnetic dipole moment in a magnetic field of 
strength B0 is given by E, which is-  





When an external magnetic field (B0) is applied to such nucleus (1H) or 
proton, the spin vector of the nucleus orients itself parallel or antiparallel with 
the external field. These two orientations are called spin states and associated 
spin quantum numbers are -1/2 and +1/2 respectively. The energy difference 
ΔE between the two energy levels is proportional to the external magnetic 
field. The energy difference ΔE= 2µB0 
In order to cause transition between the two spin states, a second radio 
frequency field is applied perpendicular to the original field. When the value 
of this electromagnetic radiation reaches the precessional frequency of the 
nucleus, absorption of energy will occur. Importantly, the frequency of the 
electromagnetic radiation required to induce the transitions from one nuclear 
spin state to other is exactly equal to the precessional frequency ω0 of the 
nucleus. The resonance frequency, called Larmor frequency (ω0) or 
precessional frequency, is directly proportional to the applied magnetic field 
strength and also to the gyromagnetic ratio.  






In NMR spectroscopy the signal results from the difference between the 
energy absorbed (lower to higher energy state transitions) and the energy 
emitted by spins (higher to lower energy state transitions). Therefore, the 
difference between the populations of both states contributes to the NMR 
signal. Thus, NMR signal sensitivity is directly related to gyromagnetic ratio 
γ, intrinsic property of a nucleus, and applied magnetic field B0.  
The first published NMR spectrum of a biological macromolecule was the 
40MHz 1H spectrum of pancreatic ribonuclease reported in 1957. Subsequent 
developments in instrumentation and methodology have enormously increased 
the power of NMR in biological sciences. The most important developments 
are: 
1. The construction of higher field spectrometers,  
2. The development of pulse Fourier transform methods, 
3. The development of multi-dimensional NMR. 
1.9.3 Relaxation process 
According to the Boltzmann distribution of the nuclei, in the applied magnetic 
field, population in the lower energy state is slightly higher than high energy 
spin state. This little difference leads to the NMR signal which is detected by 
sensitive detection system. In the magnetic field, when resonance frequency 
radiation is given, the nuclei simultaneously undergo transition in opposing 
directions. Absorbance results in transitions into higher energy state while 
relaxation process causes the transitions from upper to lower energy states. 
Since, higher populations in lower energy state will have more transitions 





ground state nuclei and further weakening of the intensity of NMR signal. In 
order to reestablish the Boltzmann excess of ground state, there are few 
mechanisms involving radiationless transitions by which nuclei in the upper 
energy state can relax back to the lower spin state. The result is that while the 
Boltzmann excess of nuclei is somewhat diminished, it is not totally 
eliminated and an equilibrium state is established at an intermediate value, so 
that NMR signal can continue to be obtained. There are two main type of 
relaxation process by which nuclei in upper state can relax back to lower 
states. These are spin-lattice relaxation (longitudinal relaxation), T1 and spin-
spin relaxation (transverse relaxation), T2.  
1.9.4 Chemical shift  
The resonance frequency is dependent not just on applied magnetic field and 
gyromagnetic ratio of nucleus, but also on a third factor – molecular 
environment of the nucleus. The change in the environment of the nucleus is 
characterized by chemical shift parameter in NMR. It is caused by the 
shielding or de shielding effect. Due to this effect atoms in different 
environment will have different resonance frequency and give NMR signal at 
different characteristic values in the spectrum. One important reason for this is 
the electronic clouds circulating around the nucleus which shield or protect the 
nucleus, to an extent, from the influence of applied magnetic field. The 
circulation of these electrons results in the generation of a small but finite 
induced magnetic field which is oriented so as to oppose the external field. 
Therefore, the nucleus experiences a magnetic field which is slightly less than 





environment is characterized by unique chemical shift. Therefore, for 
identifying individual nucleus and assigning the resonances in the spectrum to 
its site in chemical structure, chemical shift is a key parameter (Wuthrich 
1986). Due to effect of chemical environment, same atom in different 
environment has different resonance frequency for transition which makes 
NMR more informative and useful. Basically, the factors affecting chemical 
shift of any nucleus are electron density, electronegativity of neighbouring 
groups and anisotropic induced magnetic field effects. 
In protein NMR spectrum, each atom with spin will have specific chemical 
shift, which makes protein studied by NMR possible. Moreover, chemical 
shift deviation from random coil values can provides useful information about 
the secondary structure of protein. Characteristic chemical shift deviations of 
Hα, Cα, and Cβ from random coil values provide a convenient and sensitive 
probe for the existence of α-helix or β-sheet (figure 1.8) secondary structures, 
delineating flexible regions, finding hydrogen bonds or detecting aromatic 
interactions (Wishart DS et al., 1991; Wishart and Sykes, 1994).  
1.9.5 J coupling 
Nuclei experiencing the same chemical environment are called equivalent, 
whereas nuclei experiencing different environment or having different 
chemical shifts are called non-equivalent. Nuclei those are connected by 
covalent bonds and are close to each other, exert an influence on the each 
other′s effective magnetic field. Because of these magnetic interactions on 
each other, mutual splitting of the NMR signal from each non-equivalent 








Figure 1.8 Histogram of Chemical shift deviations of Hα, Cα, Cβ from 
random coil values (adopted from Spera and Bax, 1991 with their kind 
permission) 
 
                
 
Figure 1.9 The empirically-derived Karplus relationship between the vicinal 






also known as scalar-, indirect-, or spin –spin coupling. Practically, the effect 
of J coupling can be observable if distance between non-equivalent nuclei is 
less than or equal to three bond lengths.  Together with chemical shift, J 
coupling can construct characteristic patterns of couplings in many types of 
the amino acids, which are helpful to identify amino acid types. Moreover, J 
coupling contains information about dihedral angles, which can be estimated 
using the Karplus equation:  
ܬሺߠሻ ൌ ܣ cosଶ ߠ ൅ ܤ cos ߠ ൅ ܥ 
 
Where J is the 3J coupling constant, ߠ is the dihedral angle, and A, B, and C 
are empirically-derived parameters. The information on conformations of 
peptide backbone and amino acid side chains can be obtained by determining 
the torsion angles ߮ and χ1 by using 3JNHHα and 3JHαHβ (Pardi et al., 1984). 
Similar to chemical shift deviation of residues in structured region from those 
in random coil, deviation of 3JNHHα values from random coil values provides 
information about the secondary structure of protein. In the folded protein, α-
helical structures are characterized by values in the range 3~5 Hz, while large 
coupling constant values in the range 8~10 Hz is characteristic of β-strands. 
On other hand, due to the fact that conformational fluctuation averages the 
coupling constants, unfolded proteins have coupling constants about 6~7.5Hz 
(figure 1.9).  
1.9.6 NOE (Nuclear Overhauser Effect) 
In 1953 Albert Overhauser proposed overhauser effect which demonstrated 
that the microwave irradiation of the conduction electrons could enhance 





which is the transfer of spin polarization from one spin population to another 
via cross-relaxation in nuclear magnetic resonance spectroscopy. Originally, 
overhauser effect was illustrated in terms of polarization transfer between 
electron and nuclear spins, but now it is mostly used for transfer between 
nuclear spins, and called NOE. In another words, the effect of polarization 
transfer from one magnetically active nucleus to another magnetically active 
nucleus through space is known as the Nuclear Overhauser Effect (NOE). 
NOE is different from spin coupling as it is observed trough space not through 
bonds. It is a relaxation parameter which has been used as prime tool for 
determination of 3D molecular structure. Very common NMR technique 
which is used to measure NOE is NOESY experiment.   
The nuclear overhauser effect (NOE) is defined as the NMR signals intensity 
changes produced by dipolar cross-relaxation from neighboring spins, which 
can normally be detected between nuclei separated by a distance of less than 
5Å. NOE is proportional to the inverse sixth power of the distance between the 
interacting dipole (1/r6). Basically, NOE signal intensity is converted into the 
distance constraints between nuclei, therefore facilitating the determination of 
3D structure of protein. Commonly, NOE intensities are classified into three 
different categories: strong –with distances of 1.8-2.7 Å, medium-2.7-3.3 Å 
and weak- 3.3-5.0 Å. Conclusively, NOE data provide information for 
establishing connection among amino acids as well as help in determining 
protein secondary and tertiary structure.  
Moreover, dynamics of protein can also be addressed by using NMR 





longitudinal relaxation times (T1), transverse relaxation times (T2) and 
heteronuclear Overhauser effects (NOEs). 
1.9.7 Structural studies by using NMR 
Strategy of protein structural studies is well established. First step in this 
process is sample preparation. With the help of advances in molecular biology 
in 1990s, recombinant expression technique has made the production of 
uniformly labeled protein with stable isotopes, possible. In general, 15N 
nitrogen and 13C carbon containing salts are used in the media for 
overexpression. Easier labeling has drove the development and wide-spread 
use of three-dimensional spectra. After preparation of sample for NMR, 
initially 1H-NMR (1D) and 1H-15N-NMR (2D) spectra are collected to get 
information about the quality of the sample in specific conditions. Proteins 
have so many protons which give many signal overlap in one-dimensional 
proton NMR spectra. Nevertheless, in few second spectra recording time, it 
can provide a quick indication on whether the protein adopts the 3D structure 
or not (Figure 1.12). 1H-15N HSQC spectra offer a great piece of information 
about the quality of sample for structure determination by NMR. Generally, a 
good well folded protein sample has well dispersed 1H-15N HSQC spectrum 
whereas, unfolded or partially folded protein has spectrum dispersion in 
narrow range. According to the quality of spectrum, sample conditions can be 
optimized to get best quality of HSQC spectrum. Once the conditions (temp, 
pH and buffer conditions) are optimized, structure can be determined. The 
overall strategy for determining structure from 2D NMR for proteins up to 






Figure 1.10 Definition of sequential 1H-1H distances dαN and dNN and  
medium range distances dαN(i, i+2), dαN(i, i+3) dNN(i, i+2) and dαβ(i, i+3) in the 
polypeptide chain (adopted from Wagner et al., 1986). 
 
 
Figure 1.11 Survey of sequential and medium range 1H-1H NOEs and the 
spin-spin coupling constant 3JHNα in the following secondary structures: 
parallel or antiparallel β sheet, α helix, 310 helix, turn of types I, II, I′ and II′ 
and half turn derived from a type II tight turn. The number at the bottom 
represent the amino acid residues in secondary structure elements and the 
value of 3JHNα. Short 1H-1H distances are indicated by lines linking the 
residues that contain the connected hydrogen atoms; the thickness of lines is 
proportional to r-6 and thus represents the NOESY cross-peak intensities 






1980s. Based on this approach, more sophisticated NMR experiments suitable 
for larger proteins based were developed later. In general, the strategy using 
NMR to solve structure is mainly composed by 4 steps which are shown in the 
form of flow chart (figure 1.13). Initially, a set of heteronuclear 
multidimensional experiments are recorded for chemical shift assignments 
(1H, 15N, 13C). It is followed by identification of torsion angles. The 
mostimportant experiment is recording NOESY spectra to measure distances 
between pairs of atoms within the molecule. 
1.9.8 Resonance Assignment 
Measurement of CBCANNH (HNCACB) and CBCA(CO)NNH spectra, with 
the use of 15N,13C labeled protein is the most simple and straight forward 
method of backbone resonance assignment. Due to the slow tumble motion, 
large proteins give worse NMR spectra. Therefore, for larger proteins (>150 
residues), above two experiments are often not sufficient for full assignment.  
Thus, HNCA, HN(CO)CA, HNCO and HN(CA)CO spectra can be used to 
carry out full assignment of larger proteins.  
Standard triple resonance backbone assignment of proteins is based on the 
CBCANNH (HNCACB) and CBCA(CO)NNH spectra. The idea is that the 
CBCANNH correlates each NH group with the Cα and Cβ chemical shifts of 
its own residue (strongly) and of the preceding residue (weakly). Therefore it 
provide the chemical shift information for each amide (HN and NH) peak in the 
HSQC spectrum of the residue (residue i) and the chemical shift information 









Figure 1.12 1H-NMR spectrum of a protein showing the chemical shift of 

















Step1: Sequential resonance assignment 
Step2: Identification of torsion angle restraints 
Step3: Identification of distance restraints by through-space 







Figure 1.14 Sequential back bone assignment strategy by using CBCANNH 
(HNCACB) and CBCA(CO)NNH spectrum. (A) shown in amino acid 
sequence (B) In practise, using the CBCANH and CBCA(CO)NH spectra  








On the other hand, The CBCA(CO)NNH only correlates the NH group to the 
preceding Cα and Cβ chemical shifts. Therefore, it gives the chemical shift 
information for each amide (HN and NH) peak in the HSQC spectrum of the 
residue (residue i) and the chemical shift information of the Cα and Cβ 
carbons of only the previous residue (residue i-1). With the help of these two 
spectra sequential assignment of protein can be achieved. 
 
For smaller protein or peptide, backbone assignment can be achieved by using 
just 15N labeled protein sample. The spectra which are used for this case are: 
15N-HSQC-NOESY and 15N-HSQC-TOCSY.  The 15N-HSQC-NOESY will 
show for each NH group all 1H resonances which are within about 5-7Å of the 
NH hydrogen. Assignment is done on the assumption that the two neighboring 
NH groups are always visible. Thus two NH groups can be linked because 
they each have an NOE to the other NH group. Further help with assignment 
is provided by the 15N-TOCSY-HSQC. This should show links from the 
backbone NH group to all side-chain hydrogens of that residue. 
After back bone assignment, side chain assignment is achieved to get the 
information of hydrogen and carbon side chain chemical shifts for each 






neighbouring atoms. Back bone assignment could be used to generate the 
chemical shift index plot which can help to provide information about the 
secondary structure of protein sequence as shown in the figure 1.8. This 
information can help in assigning NOEs in the NOESY spectrum. According 
to NOE intensity, these NOEs can be categorized into “strong”, “middle”, 
“weak” and the corresponding distance are 2.5Å, 3.4Å and 5.0Å. Dihedral 
angle restraints are usually calculated by TALOS, which is free software 
calculates protein backbone torsion angle by inference from measured Cα and 
Cβ chemical shifts. 
1.9.9 Mapping the regions of protein-protein interaction 
NMR has proven particularly well-geared to efficiently mapping the regions of 
interaction between macromolecules. The quick way to achieve this is by 
monitoring HSQC spectrum of uniformly 15N-labeled protein with and without 
the unlabeled biological partner like a DNA, a RNA, another protein, or even a 
small chemical ligand. HSQC spectrum is almost like the protein’s 
fingerprinting. Particularly, the chemical shift of N-H protein is quite sensitive 
to their environment (distance in space to other atoms, pH, and temperature). 
Therefore, with the help of chemical shift perturbation analysis upon the 
addition of ligand surfaces involved in the interaction can be explored or 
identified (figure 1.15). Limitation of this method is the protein concentration 
needed to make NMR signal detectable. Nevertheless, development of 
cryoprobes has reduced the sample needed for detection. This approach is very 
powerful for detecting not only strong interaction but also weak interaction 










Figure 1.15 Mapping the variations in chemical shift to determine the regions 
of protein-protein interaction. It illustrates the underlying principle: the protein 
of interest is uniformly labeled with 15N nitrogen. Then, the HSQC spectrum 
generated is used to correlate the proton and nitrogen chemical shifts of each 
N-H peptide bond. Adding the unlabelled partner induces variations in the 
chemical shift of certain signals corresponding to amino acids interacting with 















binding site and mode. It can also be utilized in screening new ligands or new 
inhibitors of pharmacological targets by coupling spectrometers with sample 
changers.  
In this thesis, NMR has been used for structural characterization and 
interactional studies of proteins in all the sections. This has given us very 
























1.10 Intrinsically Unstructured Proteins 
After the determination of first protein structure in 1959, structural biology 
field has grown explosively and enhanced our understanding on protein 
functions. There has been a central dogma which recommends that, a folded 
protein structure is necessary for biological function. However, this paradigm 
is now challenged based on systematic studies of intrinsically unstructured 
proteins (Wright and Dyson, 1999; Dunker et al. 2001) which are disordered 
in their native and functional states. These proteins cannot be described by 
single equilibrium 3D structures as they exist as an ensemble of rapidly 
interconverting conformations that resemble the denatured states of ordered 
proteins (Tompa, 2002). Moreover, most of these proteins have basic 
regulatory roles in key cellular processes. This implies that conformation 
flexibility and heterogeneity might be important for their functions. As 
compare to X-ray crystallography, Nuclear Magnetic Resonance is a very 
powerful tool to characterize the intrinsically unstructured proteins (IUPs). 
Recent advances in NMR have increased the number of identified IUPs in 
protein database exponentially.  
According to the protein database survey, structural disorder is rather a 
common phenomenon in higher eukaryotes. 10% of all human proteins are 
fully disordered and further 40% proteins have at least one 30 residues long 
disordered region. These structural disorders are most prevalent in proteins 
involved in regulatory functions. These observations indicate that structural 
disorder is a common phenomenon in physiological conditions, rather than 





1.10.1 Characterizations of Intrinsically Unstructured Proteins 
There are several ways to distinguish intrinsically unstructured proteins from 
ordered protein. Sequence signature of intrinsic disorder is the occurrence of 
low sequence complexity, low overall hydrophobicity, high polar and charged 
residues and compositional bias toward hydrophilic residues.  
Structurally, intrinsically disordered proteins have low content of ordered 
secondary structure and high intra-molecular flexibility. Generally, in the 
presence of disordered sequence, IUPs cannot bury sufficient hydrophobic 
core to fold into organized 3D structures. They have larger hydrodynamic 
dimensions compared to typical native globular proteins with corresponding 
molecular mass. However, most of intrinsically disordered proteins have the 
ability to adopt relatively rigid conformation in the presence of natural ligands 
(Uversky, 2002). 
1.10.1.1 Methods to Characterize IUPs 
Bioinformatics tools 
With the great development of bioinformatics, primary sequence of protein 
can be analyzed by using various computer programs. These programs can be 
utilized for predicting the intrinsically disordered nature of proteins.  
Experimental Characterization  
Intrinsically unstructured proteins have been characterized by using several 
physicochemical methods including, Nuclear Magnetic Resonance, Circular 
Dichroism, hydrodynamic measurements, Fluorescence spectroscopy, 





NMR is an extremely powerful method for obtaining systematic site-specific 
information on IUPs. Isotope-edited and triple-resonance NMR experiments 
could be utilized for obtaining chemical shift deviations of Hα, Cα, and Cβ 
from random coil values. These CSD values are good indicators for the 
existence of residual secondary structure over the sequence. Another useful 
parameter is the 15N-1H hetereonuclear NOE, which gives positive values for 
(more slowly tumbling) ordered residues and relatively smaller value or 
negative values for (more rapidly tumbling) disordered residues ((Dyson and 
Wright, 2005).  
1.10.2 Functions of IUPs 
Although intrinsically disordered proteins do not form stable 3D structure 
under physiological conditions, but they accomplish significant regulatory and 
signaling jobs in the cell. Cellular processes in which these proteins have been 
identified to be involved as regulators are - cell cycle activities, transcription, 
translation, signal transduction, self-assembly of multiprotein, cargo transport, 
apoptosis etc. During the regulation of these processes, the flexible structure 
of IUP provides distinctive advantages, including- 1) possibility of high 
specificity coupled with low affinity (Dunker, 2001), 2) ability of binding to 
several different targets (Romero et al. 1998b), 3) capability to overcome 
steric restrictions, enabling essentially larger interaction surfaces in the 
complex that could be obtained for the rigid partners (Uversky, 2002), 4) 
precise control and simple regulation of the binding thermodynamic, 5) the 
increased rates of specific macromolecular association , and 6) the reduced 





mechanism of rapid turnover of the important regulatory molecules (Wright 
and Dyson, 1999). 
To pursue their function, IUPs often use molecular recognition, in which they 
bind to a partner molecule with high specificity and fast 
association/dissociation rate.  Equilibrium among many conformations of the 
ensembles can be modulated by binding of a partner, leading to binding of 
multiple, unrelated ligands. During the interaction with a partner, IUPs often 
adopt a well- defined structure. This coupled folding- binding process can take 
place between two IUPs or IUP binding to a globular protein. These types of 
IUPs are characterize in a class of proteins, where structure multiplicity is 
useful for ligand selection, but act as “traditional” protein after binding. 
However, this type of disorder to ordered transition is only seen in few 
interactions. A closer inspection of the complexes of IUPs reveals that they do 
not always become fully ordered, but maintain functionally significant 
disorder in the complex with their binding partners. Such a disorder in bound 
state can vary from static to dynamic and have significant contribution to the 
function. Due to the similarity to fuzzy logic in mathematics, these complexes 
are named as “fuzzy complexes”. "Fuzziness" is the ultimate extension of 
structural disorder to the functional native state of proteins (Tompa and 
Fuxreiter, 2008). Fuzziness is often beneficial as it adds up the adoptability, 
versatility and reversibility to the binding of IUPs and thereby it eases the 
regulation of protein-protein interactions. Fuzziness of complexes has been 
classified into four categories (Tompa and Fuxreiter, 2008; Fuxreiter and 





1. Polymorphic complex  
Complex in which at least one of the binding partner adopts alternative 
conformations (one/multiple) that can cause different biological functions.  
2. Clamp complex 
In these types of complexes, IUPs interact with their partner in a bi-partite 
way where two bound, folded regions are connected by a disordered linker 
region. Linker region does not establish direct contact with ligand and 
remains disordered in bound state also, thereby facilitate the 
conformational freedom. Whereas, ordered bound regions serve as clamps. 
3. Flanking complex 
To form these types of complexes, IUPs frequently utilize a short 
recognition element, embedded in a disordered environment, to establish 
specific contact with their partners. This flanking segment not only helps 
in locating the target site but also promotes the complex formation from 
transient interactions. However, flanking segments retain its 
conformational variability in the complex but increase the binding affinity 
as their deletion reduces the Kd of the complex.  
4. Random complex  
 
This is an extreme version of dynamic disorder in protein complexes 
where IUPs interact with their partners via transient contacts which 
apparently do not induce their (even partial) folding. Basically, IUPs 
remain disordered in the bound state in random complexes. In various 
biophysical techniques, IUPs behave as their free form and do not show 






1.11 Objectives and scope of the study 
It has been estimated that up to 3% of world’s population is chronically 
infected with HCV. Current treatment of its infection is still frequently limited 
by side effects and by the low genetic barrier to viral resistance against direct-
acting antiviral agents. A complementary strategy is to target the host cellular 
factors that support the HCV life cycle. There are several host proteins which 
helps virus during its replication by interacting viral proteins. Targeting these 
interactions can be an effective approach against HCV infection. In spite of 
recent advances, our current understanding of virus replication and virus–host 
interactions is far from complete. Viral nonstructural protein NS5A and NS5B 
was identified to interact with VAPB protein during the replication complex 
formation on the membrane. It has been speculated that VAPB which is an ER 
membrane protein serve as an anchor for NS5A and NS5B during replication 
complex formation and facilitate the replication process. However, the 
characterization and deeper insight into these interactions could not be 
achieved since they were identified.  
In this study we aimed to understand and characterize these interactions in 
vitro. Thus, molecular biology, protein chemistry and structural biology 
approaches were employed to characterize the interaction of NS5A and NS5B 
with VAPB protein. The scope of this study covered the following features:  
1.11.1 Expression, Purification and Structural characterization of NS5A 
and VAPB constructs 
NS5A consist of three domains which are separated by flexible loops.  On 





transmembrane domain) which are separated by flexible loop. Initially various 
constructs of NS5A and VAPB will be designed and cloned into expression 
vectors. Expression and purification conditions will be optimized and 
structural characterization of all fragments will be achieved by using NMR 
and CD. 
1.11.2 Characterization of VAPB-NS5A Interaction 
After purification and structural characterization of all the designed NS5A and 
VAPB constructs, interactional studies will be performed by using NMR 
titrations in a systematic way. Initially full length protein (VAPB) will be 
titrated with full length NS5A and then various fragment of one protein 
(VAPB) will be titrated with full length NS5A to figure out which domain is 
required for interaction. Subsequently, further narrow downing of regions 
involved in the interaction will be done. 
1.11.3 Characterization of VAPB-Eph receptor Interaction and its 
competition with NS5A 
Signaling through the interaction between VAPB and Eph receptor has been 
identified to be important for normal motor cell as mutation in VAPB protein 
can lead to the ALS disease.  So, the VAPB interaction with various available 
Eph receptors will be tested and relation between ALS and HCV infection will 
also be examined by in this section of the study. 
1.11.4 Characterization of NS5B-VAPB interaction 
Characterization of interaction between NS5B and VAPB will be studied by 





Thus, in this thesis, we will explore how VAPB protein interacts with NS5A 
and NS5B and correlates its function with its normal functioning. This study 
will not only facilitates the better understanding of HCV life cycle more 
precisely, HCV host interactions but also may open a new direction in the field 




















Expression, Purification and Structural 













Expression, Purification and Structural characterization of 
NS5A and VAPB constructs 
2.1 Introduction  
To understand the life at the molecular level is the challenging aim of 
molecular biology. Proteins are major key players of any living organism; 
therefore, studying the roles of individual proteins can facilitate us to 
understand the processes in which they are involved. High quantity and purity 
of protein is required to perform all kinds of studies to understand the 
functions of that specific protein. Obtaining high quantities of specific protein 
directly from native source is usually challenging, especially in case of human 
proteins. To conquer this problem, heterologous expression systems have been 
extensively used by cloning the genes into expression vectors. The most 
common organism used for the expression of heterologous proteins is E. coli 
due to vast fund of information about its genetics, biochemistry and molecular 
biology. It is easily and inexpensively grown organism in which genetic 
manipulations are easier to accomplish. Thus, E. coli has been used as the 
expression organism in this project.  Initially, both NS5A and VAPB 
constructs were designed and cloned into expression vectors. Various 
bioinformatics tools were utilized to design and analyze the constructs. 
Designing constructs is most crucial step of this project as very little is known 
about the interaction region. Therefore, for extensive studies we have designed 
the constructs in such a way that it covers whole protein and simultaneously 
structure of that part is not lost. C-terminal transmembrane domain of VAPB 





constructs. VAPB protein was dissected in MSP and Coiled coil domain 
(CCD) whereas NS5A protein was dissected in all the three known domains 
and domains with the loop (low complexity regions). Domain 3 of NS5A was 
further dissected in smaller constructs to map the binding region.  
In this study pET expression system and Glutathione S-transferase (GST) 
Gene Fusion System have been used for expression of various constructs.  
2.1.1 pET expression system 
The pET system is a powerful cloning and expression system. It is a T7-lac 
promoter system in which target genes are cloned in pET plasmids under 
control of strong bacteriophage T7 transcription and (optionally) translation 
signals. Expression of protein is induced by IPTG which facilitate the 
replication of T7 RNA polymerase in the host cell. This RNA polymerase 
binds to the T7 promoter and lead to high expression of target gene. In this 
study, DNA constructs were cloned in such a way that expressed protein will 
have polyhistidine-tag at terminal. 
2.1.2 GST Gene Fusion System 
GST Gene Fusion System is an integrated system that utilizes trp-lac (tac) 
promoter system found in pGEX vectors. In this expression system lactose 
analog isopropyl b-D-thiogalactoside (IPTG) is being used to induce the 
expression of GST fused target protein. GST-tag not only increases the 
solubility of peptides or proteins but also facilitate the affinity purification of 
the fusion protein by binding to the Glutathione Sepharose 4B. 
Expression of protein was monitored at small scale culture by running the 
samples on SDS-PAGE and then large scale expression was performed. 





nitrilotriacetic acid (Ni-NTA) was used to purify the polyhistidine tag 
containing expressed protein from pET system as polyhistidine tag can form 
co-ordinate bonds with cobalt or nickel ions. On other hand GST-tagged 
protein was purified by binding to the Glutathione Sepharose 4B. After 
affinity purification of expressed protein, additional column chromatography 
methods were used to increase the purity of protein. Subsequently, purity of 
expressed proteins was checked on SDS-PAGE electrophoresis. The 
molecular weight and homogeneity of the protein samples were determined by 
electrospray ionization-mass spectrometry (ESI-MS).  
To perform NMR studies, isotope labelling of protein is required. The isotope 
labels are introduced in protein by growing bacteria in minimal medium 
supplemented with isotopically labelled carbon and nitrogen sources. 15N-
labelled protein is used to record NMR HSQC experiment which can give the 
information about the folding and the quality of protein sample. 
2.2 Materials and Methods 
2.2.1 Materials 
Escherichia coli BL21 (DE3) Star strain was purchased from Invitrogen 
(Grand Island, NY, USA). XL1-Blue cells were from Stratagene (La Jolla, 
CA, USA).  pfu DNA polymerase and Taq polymerase were purchased from 
Promega (Mountain View, CA, USA). However, dNTP mix, Restriction 
endonucleases and T4 DNA ligase were obtained from New England Biolabs 
(Beverly, MA, USA). 
Fragments were cloned in pET-M (a modified pET-32a vector, devoid of 





oligonucleotides, Luria-Bertani broth and agar were purchased from 1st Base 
Pte. Ltd. (Singapore).  Precision Plus Protein™ Dual-Colour Standards 
(marker for SDS-PAGE) and DNA ladders were purchased from Bio-Rad 
(Hercules, CA, USA). Acetonitrile and trifluoroacetic acid solvents were 
purchased from Merck KGaA (Darmstadt, Germany). RP-Jupiter C18, C4 
columns were from Phenomenex (Torrance, CA, USA). [15N](NH4)2SO4, D-
[13C6] glucose and D2O were purchased from Cambridge Isotope 
Laboratories, Inc. (Andover, MA). HiLoad 16/600 Superdex 200 pg, HiLoad 
16/600 Superdex 75 pg, HiTrap Q column and HiTrap S column were from 
GE Healthcare Life Sciences. Nickel-NTA agarose and QIAquick Gel 
Extraction Kit and QIAprep Spin Miniprep Kit 250 were purchased from 
Qiagen GmbH (Hilden, Germany). Empty columns for gravity flow were 
obtained from Bio-Rad (Hercules, CA, USA). Water was purified with a 
Millipore MilliQ system (Billerica, MA, USA). Analytical grade chemicals 
and reagents were used for the study. 
2.2.2 Design of Constructs and their cloning  
The DNA fragments encoding the hVAPB (1-195), MSP domain (1-125), 
VAPB150 (1-150) and coiled-coil (152-195) domain were amplified from 
HeLa cell cDNA library by using two designed gene specific primers. Forward 
primers were having BamHI restriction site, whereas reverse primers were 
having XhoI restriction site. Three to four extra nucleotides were incorporated 
at 5’ end of each primer to facilitate subsequent digestion by restriction 
endonucleases and stop codon was incorporated in reverse primers. All the 





Whereas, DNA fragment encoding NS5A gene was generated from HCV 
genotype 1b strain S1 (GenBank-AF356827.1) and strain con1 (GenBank- 
CAB46677.1). 
With the use of specific pair of primers, NS5A from S1 strain was dissected 
into various fragments which include: NS5A (33-447), NS5A-D1 (33-202), 
NS5A-D2-D3 (251-447), Long NS5A-D2 (251-380), NS5A-D2-D3 Loop 
(313-366), Long NS5A-D3 (300-445), NS5A-D3(359-445), D3A (394-445), 
D3B (407-445) and D3C (427-445).  DNA fragment encoding NS5A, NS5A-
D1, NS5A-D2-D3, Long NS5A-D2 were amplified by PCR and cloned into 
modified pET32a vector by using BamHI and XhoI restriction sites. However, 
NS5A-D2-D3 Loop, D3B and D3C DNA constructs were cloned with GST 
tag into pGEX-4t1 vector. Whereas, pET22b, which is a C-terminal his-tag 
containing vector, was used for cloning NS5A-D3 (359-445) and D3A (394-
445), and pET28a was utilize for cloning Long NS5A-D3 (300-445). HCV 
genotype 1b strain con1 was used to amplify DNA fragment encoding domain 
1(33-202), referred as NS5A-D1con1, and cloned into modified pET32a 
vector. 
PCR reactions were set to amplify the designed DNA fragments. The PCR 
mixture of 50µl contained, 1 µl of 10 mM of each primer, 1 µl of 10 mM 
dNTPs, 5 µl of 10X pfu polymerase buffer, 1µl of pfu DNA polymerase, 
template and rest autoclaved water. The PCR conditions were optimized 
according to the primer annealing temperature.  After PCR, amplified products 
were run on agarose gel and then purified by QIAquick Gel Extraction Kit 














































Figure 2.2 Designed and cloned 10 constructs of NS5A from HCV genotype 
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double digested with respective restriction endonlucleases.  Generally, double 
digestion reaction mixture consisted of 1 µl each RE enzyme, 2 µl 10X buffer, 
500 ng of vector or insert DNA and total volume was raised to 20 µl each with 
autoclaved water. Reaction mixtures were incubated at 37°C for 2 h and 
subsequently, purified by gel extraction. Ligation reaction, which was carried 
out at 16°C for 12 h or room temperature for 1h, contained 3:1 molar ratio of 
insert to vector, 2 µl of 10X ligation buffer, 1 µl of T4 DNA ligase (NEB) and 
total volume was raised to 20 µl with autoclaved water. The Ligation product 
was transformed into E.coli XL1 Blue.  
2.2.3 Preparation of competent cells 
For transformation, E. coli XL1 and E. coli BL21 (DE3) star competent cells 
were prepared by using chemical method. Frozen stock of E. coli cells were 
thawed and streaked on LB agar plate to get the single isolated colony. Next 
day, a colony was inoculated into 2 ml of LB medium without antibiotics and 
grown overnight with vigorous shaking at 37°C. Following day, 1 ml of 
inoculum was used to inoculate 100 ml of LB medium (without ampicillin) 
which was grown to an OD600 of 0.6-1.0 at 37°C with vigorous shaking at 200 
rpm. Then, cells were harvested in two 50 ml chilled falcon tubes at 3000 rpm 
for 10 min at 4°C. All the steps were done in sterile conditions. Harvested cell 
pellet was resuspended in 1 ml of chilled 100 mM CaCl2 followed by addition 
of 49ml of 100 mM CaCl2. Cell suspension was incubated on ice for 40 min 
and centrifuged at 3000 rpm for 10 min at 4°C. Obtained cell pellet was gently 
resuspended in 2 ml of autoclaved 50% glycerol and 6 ml of 100 mM CaCl2, 





aliquots were frozen by immersing them in liquid nitrogen. Later, the 
competent cells were stored at -80°C until used.   
2.2.4 Heat shock transformation 
A competent cells vial was thawed on ice for 10 min and then whole ligation 
mixture or 1 µl of recombinant plasmid was added to competent cells. It was 
incubated in ice for 30 min and subsequently, heat shock was given by 
incubating the cells for 60 seconds at 42°C and immediately keeping on ice for 
another 5 min. Later, 200 µl of LB medium was added to the cells and 
incubated at 37°C for 60 min with shaking at 200 rpm. Then the cells were 
plated onto LB agar plate containing respective antibiotics (according to the 
plasmid resistance marker) and incubated overnight at 37°C. 
2.2.5 Plasmid DNA isolation 
After transformation of ligation product, obtained each colony was inoculated 
separately in 3 ml LB broth containing 100 μg/ml ampicillin and incubated at 
37°C with shaking at 200 rpm for 16 h. Plasmid DNA was isolated by using 
QIAprep Spin Miniprep Kit, according  to the protocol recommended. 
NanoVue (GE healthcare) was used to determine the concentration and purity 
of plasmid DNA.    
2.2.6 DNA sequencing and Analysis 
The nucleotide sequence of the gene was determined by ABI PRISM® Big 
Dye Terminator Cycle Sequencing Ready Reaction Kit (version 3.0) (PE-
Applied Biosystems, CA, USA). The sequencing reaction was prepared by 





forward or reverse vector specific primer (T7 promoter or terminator primer 
for pET32a and pET22b, pGEX forward or reverse primer for pGEX-4t1) in 
total volume of 5 µl reaction. The PCR conditions were as follows: 30 cycles 
of denaturation at 96ºC for 10 s, annealing at 50ºC for 15 s and extension at 
60ºC for 4 min. The PCR amplified products were purified with CleanSEQ 
magnetic beads as recommended by the manufacturer. The purified DNA were 
eluted in autoclaved water and loaded on an automated ABI PRISM® 3130XL 
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Analysis of 
the sequence data was carried out using Chromas 2, GeneRunner and 
DNAMAN software. 
2.2.7 Bacterial Expression of Proteins  
After confirming the sequence by DNA sequencing analysis, recombinant 
plasmid was transformed into BL21 (DE3) star competent cells as described 
earlier. Single colony was inoculated in 15 ml LB medium containing 100 
µg/ml of ampicillin and then incubated at 37ºC overnight at 200 rpm. Next 
day, this culture was used as an incolum for 1 L of LB medium containing 100 
µg/ml of ampicillin. It was incubated at 37ºC, 200 rpm until the OD600 reaches 
~0.6 and then induced with IPTG (isopropyl β-D-thiogalactoside) and 
incubated for 16 h at optimized temperature before the culture was harvested. 
IPTG concentration and induction temperature for each construct was 
optimized at small scale 10 ml culture. Optimized IPTG concentration and 
induction temperature was used for the expression of respective protein. For 
expression of VAPB, VAPB150, MSP and CCD, 0.4 mM IPTG and 20ºC 





temperature were used for the expression of NS5A-D2-D3, LongNS5A-D2 
and LongNS5A-D3. While, 0.2 mM IPTG and 16ºC temperature for NS5A-
D1, NS5A-D1con1 and NS5A-D2-D3Loop, and 0.3 mM IPTG and 20ºC 
temperature for NS5A, NS5A-D3, NS5A-D3A, NS5A-D3B and NS5A-D3C 
were used as expression condition at large scale culture. To prepare NMR 
sample, isotope labeling was done by expressing the protein in M9 minimal 
media containing (15NH4)2SO4 salt, for 15N labeling and (15NH4)2SO4/13C-
glucose for 15N-/13C- double labeling. In the case of some constructs 
expression in minimal media, induction conditions were optimized at small 
scale level. After induction at respective optimized conditions cells were 
harvested at by centrifuging the cultures at 6,000 rpm for 30 min at 4°C and 
cell pellet was stored at -80°C until further use. The expression of recombinant 
protein was analyzed by SDS-PAGE on a 15% or 12% polyacrylamide gel. 
2.2.8 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) 
Bio-Rad Mini-PROTEAN™ gel system was used to run SDS-PAGE. The 
12% or 15% polyacrylamide gels were casted as indicated in Appendix (Table 
A.1). In order to prepare the samples, 4 μl of 5x loading dye was mixed with 
16 μl of the sample and then boiled for 10 min. After spinning it in a 
microcentrifuge, 10 μl was loaded on to the gel. For the molecular weight 
ladder, 5 μl of Precision Plus Protein™ Dual-Colour Standards was run in one 
lane. Electrophoresis was carried out at 120 V until the visible marker reached 






2.2.9 Purification of proteins 
To purify the protein, bacterial cell pellet was thawed and lysed in cold lysis 
buffer, which contained: 50 mM Tris, 150 mM NaCl, 10 mM DTT, 20 mM 
Imidazole (Sigma) and pH 7.5, in case of all VAPB constructs purification. 
However, NS5A constructs were lysed in 50 mM Tris, 300 mM NaCl, 10 mM 
β-mercaptoethanol, 10% glycerol, 0.1% Triton X-100, 20 mM Imidazole and 
pH 7.5 buffer containing protease inhibitor cocktail (Roche). Lysis was 
performed by ultrasonication at 4°C and then lysate was cleared by 
centrifugation at 18,000 rpm for 30 min at 4°C. Subsequently, the supernatant 
was used for affinity purification by Ni-NTA resin for his-tagged protein or by 
Glutathione Sepharose 4B beads for GST-tagged protein. For affinity 
chromatography, supernatant was incubated with pre-equilibrated affinity 
resin for 2 h at 4°C with gentle shaking. After incubation, flow through was 
collected and resin was washed extensively with equilibration buffer. To 
remove tag, bound protein was kept for cleavage on beads by thrombin at 
room temperature for overnight and then cleaved protein was eluted form 
beads in elution buffer. His-tag of all the VAPB constructs and GST-tag of 
NS5A-D3B, NS5A-D3C, and NS5A-D2-D3Loop were cleaved by thrombin as 
mentioned and eluted in 50 mM Tris, 300 mM NaCl, 10 mM β-
mercaptoethanol and pH 7.5 elution buffer. Whereas, other his-tagged NS5A 
constructs were directly eluted with his-tag from beads by elution buffer (250 
mM imidazole 50 mM Tris, 300 mM NaCl, 10 mM β-mercaptoethanol and pH 
7.5 buffer). Expression and purification of protein was checked by running 





After affinity purification, the obtained elute was subjected to further 
purification step to get higher purity of the sample. Therefore, VAPB, 
VAPB150, MSP and NS5A-D1 were subjected to size exclusion 
chromatography in 50 mM Tris, 150 mM NaCl, 10 mM β-mercaptoethanol 
and pH7.5 buffer. For crystallization use, VAPB and MSP were further 
purified by anion exchange chromatography (MonoQ column). On other hand, 
GST-tag cleaved NS5A-D3B, NS5A-D3C, NS5A-D2-D3Loop and his-tagged 
NS5A-D3A were purified by loading to Reverse Phase-HPLC C18 column.  
Elution was done using solvent A (0.1% (v/v) TFA) and solvent B (80% (v/v) 
acetonitrile in 0.1% (v/v) TFA). The elution profile of all purification was 
monitored at 215 nm and 280 nm. While, LongNS5A-D2, LongNS5A-D3, 
NS5A, NS5A-D3 were purified by ion exchange chromatography (HiTrap Q 
column). After purification, protein samples were concentrated by using 
Amicon Ultra (Millipore). Purity of proteins was confirmed by SDS-PAGE 
and ESI-MS. 
2.2.10 Protein concentration determination 
Protein concentration of sample was determined by using the Beer-Lambert 
Law: A= ε * l *C where A is the Absorbance, ε is the molar absorption 
coefficient (M-1cm-1), l is the path length (cm) and C is protein concentration 
(M). To measure the concentration of protein, absorbance A is measured at 
280nm. The absorption of a protein at 280nm depends on the content of Trp, 
Tyr, and Cys (disulfide bonds), extinction coefficient ε can be determined by 
following equation: 





Here, #Trp, #Tyr and #Cystine are the numbers of each corresponding residue 
in a protein (Pace et al., 1995). Protein sample was denatured in 6 M 
guanidine hydrochloride and A280 was measured by UV/visible 
spectrophotometer using quartz cuvette. 
2.2.11 Circular Dichrosim Spectroscopy Experiments  
CD experiments were performed on a Jasco J-810 spectropolarimeter equipped 
with a thermal controller. Sample preparation for collecting the CD spectra was 
done by dialyzing the protein in 2 mM sodium phosphate, pH 7.5 buffer.  
Secondary structure of purified protein can be determined in the far UV 
spectral region (190-260 nm). Above mentioned buffer was used as a blank, 
and the far-UV CD spectrum of each protein was recorded from 190-260 nm at 
a protein concentration of ~20 μM and temperature 25ºC by using 1 mm path 
length cuvette with 0.1 nm spectral resolution. Data from three independent scans 
were added and averaged. To evaluate the stability of VAPB, thermal unfolding 
was carried out by recording the CD spectra at increased temperature 5ºC to 
95 ºC. The secondary structure fraction was analyzed by use of CONTINLL 
program (lamar.colostate.edu/~sreeram/CDPro/ReadMe.htm). 
2.2.12 NMR sample preparation and NMR structure determination 
experiments  
2.2.12.1 Sample preparation 
To pursue NMR studies, protein sample of 100 µM concentration, was 
prepared in 10mM NaH2PO4, 10mM DTT (in case of VAPB, VAPB150, 
MSP, NS5A and NS5A-D1) 0.01 (w/v) sodium azide, pH 6.8 buffer, with an 





2.2.12.2 NMR experiments  
NMR experiments were acquired on an 800 MHz Bruker Avance spectrometer 
equipped with pulse field gradient units and a shielded cryoprobe. After 
purification of each protein fragment, one dimensional 1H NMR and two 
dimensional 1H-15N HSQC were collected for structural characterization. For 
sequential backbone assignment of NS5A-D3, triple resonance NMR 
experiments including HNCACB and CBCA(CO)NH were acquired on 
double-labeled sample at a protein concentration of 300 µM. While, for 
NS5A-D3A sequential assignment, three-dimensional heteronuclear NMR 
experiments including HSQC-TOCSY and HSQC-NOESY were acquired on a 
15N-labeled sample at a protein concentration of 500 µM. NMR data were 
processed with NMRpipe (Delaglio F et al., 1995) and analyzed with 
NMRview (Johnson BA and Blevins RA, 1994).  
The NOESY assignment is based on previously determined chemical shift 
values that result from chemical shift assignment. To determine three 
dimensional structure of D3A, NOE restraints were extracted from three 
dimensional 15N HSQC-NOESY. This information was used to calculate 
initial structure with CYANA (Güntert P, 2004), subsequently more NOEs 
were confirmed and added to the structure calculation. Many rounds of 
refinement, the final set of unambiguous NOE were utilized for structure 
calculation. The 10 lowest-energy structures selected by CYANA, were 







2.3 Results and Discussion  
2.3.1 Cloning, expression and purification of dissected domains/fragments 
of VAPB 
To study the interaction between NS5A and VAPB, firstly both proteins were 
dissected in various fragments. This approach can help us to map out the 
binding region on both proteins. Therefore, 243-residue human VAPB protein 
was dissected in 4 domains/fragments (figure 2.1A): VAPB (1–195) only with 
the transmembrane fragment deleted, VAPB (1–150), VAPB (1–125) and the 
coiled-coil domain designated as VAPB-CC (151–195). Subsequently, DNA 
encoding these fragments were amplified by using PCR and subcloned into 
modified pET32a His-tagged expression vector. Cloned plasmids were 
transformed into E. coli BL21 (DE3) star cells. Subsequently, optimization of 
expression conditions was accomplished by changing different parameters 
such as IPTG concentration (0.1-1 mM) and induction temperature (15, 20 and 
37ºC). The small scale expression optimization of VAPB protein at various 
IPTG concentrations was done and supernatant fraction was allowed to bind 
on Ni-NTA beads. Beads and pellet fractions were run on 15% SDS-PAGE 
and recombinant VAPB protein band was observed in all soluble fractions at 
~22 kDa (Figure 2.3A). Similarly, expression conditions for remaining 
domains/fragments of VAPB in soluble fractions were also optimized. From 
the result of small scale expression, 0.4mM IPTG concentration and 20°C 
temperature was chosen as large scale expression conditions of VAPB, 





            
 
 
             
 
Figure 2.3 15% SDS-PAGE analysis of expression. Samples were resolved on 
15% SDS-PAGE gel and stained with Coomassie Brilliant Blue-R250. (A) 
Small scale expression and solubility of VAPB in E. coli at three (0.2, 0.4, 
0.6mM) IPTG concentration. Black bar shows the optimized concentration of 
IPTG used for large scale expression. (B) Large scale (1lit) expression profile 
of VAPB protein at 0.4mM IPTG concentration. (C) Expression of coiled coil 
domain at 0.4mM IPTG concentration. Arrow shows the band of recombinant 
protein. M: Precision Plus Protein™ Dual-Colour Standards, BI: before 
induction whole cells, P: pellet fraction after induction, S: Supernatant after 
induction, B: Ni-NTA beads after binding with supernatant, FT: Flow through, 
W: wash, E: Elute, Enr: Elute in non reducing loading dye 
M   BI  P        S         P        S         P        S         P       S
20kDa
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Figure 2.4 Gel filtration chromatography purification profile of recombinant 
proteins under native conditions. (A) Purification of VAPB by HiLoad 16/600 
Superdex 200 pg column under native conditions. (B) and (C) Gel filtration 
column chromatography profile of VAPB150  and MSP respectively by using 
HiLoad 16/600 Superdex 75 pg column. Black bar represent the area of pure 


















































Expressed recombinant proteins, were firstly purified by Ni2+-affinity 
chromatography and then N-terminal His-Tag was cleaved by Thrombin. 
Cleaved VAPB protein was further purified by HiLoad 16/600 Superdex 200 
gel filtration column in which monomer protein peak was eluted at 83.5 ml 
(Figure 2.4A). However, cleaved VAPB150 and MSP domain were purified 
by loading on to the superdex 75 gel filtration column. Both VAPB150 and 
MSP were eluted in single symmetric monomer peak at ̴ 92 and  ̴ 97 ml 
respectively (Figure 2.4B, 2.4C). Fractions under the protein peak were pooled 
together and run on 15% SDS-PAGE to check the purity of protein which 
showed high intensity single band. Almost pure recombinant proteins were 
obtained after gel filtration chromatography. Molecular weight of protein was 
further confirmed by ESI-MS.  Coiled-coil domain of VAPB was obtained 
almost pure from overnight on gel cleavage by thrombin. 
2.3.2 Cloning, expression and purification of dissected domains/fragments 
of NS5A 
On the basis of domain organization, NS5A of HCV-S1 isolate was dissected 
into 10 domains/fragments which are shown in figure 2.1. N-terminal 
amphipathic helix (32 residues) of NS5A was removed and NS5A (33-447) as 
well as NS5A-D1 (33-202) were successfully subcloned into modified pET32a 
expression vector. Remaining other NS5A domains/fragments were also 
successfully subcloned in either His- or GS-tagged expression vector (figure 
2.1 and 2.2). Cloned plasmids were transformed into BL21 (DE3) star cells 
and recombinant protein expression was optimized in soluble fraction at small 
scale level. Subsequently, the optimized expression conditions were used for 





therefore could not be purified further studies. All other domains/fragments 
were successfully purified for further studies. NS5A-D1 and NS5A-D1con1 
was first purified by Ni-NTA affinity chromatography and then gel filtration 
chromatography by loading on to HiLoad 16/600 Superdex 75 pg column. 
Elution fractions were run on 15% SDS-PAGE and NS5A-D1 band was at ~ 
23kDa. Two protein peaks were obtained in gel filtration chromatography. 
First peak at ~44 ml shows the aggregated protein and second peak at ~70ml 
shows the monomer NS5A-D1 or NS5A-D1con1 protein (figure 2.5A and 
2.5B). Fractions under the second peak were pooled and concentrated and 
used for further studies. Likewise, NS5A, Long NS5A-D2 (251-380) and 
Long NS5A-D3 (300-445) were successfully expressed and purified by Ni-
NTA affinity chromatography (figure 2.6A, B and C). Recombinantly 
expressed NS5A, Long NS5A-D2 and Long NS5A-D3 protein band on SDS-
PAGE were observed at ~50kDa, ~17kDa and ~19kDa respectively. Elution of 
affinity chromatography was dialyzed, concentrated and used for further 
studies. The C-terminal his-tagged NS5A-D3 (359-445) and D3A (394-445) 
were also first purified by Ni-NTA affinity chromatography and then obtained 
elute were further purified by anion exchange chromatography Hitrap Q 
column.  
The GST-tagged fragments, NS5A-D2-D3 Loop (313-366), D3B (407-445) 
and D3C (427-445) were firstly purified by affinity chromatography by 
binding the supernatant to Glutathione sepharose 4B beads and then on 








Figure 2.5 Purification of NS5A-D1 by affinity chromatography and gel 
filtration chromatography. (A) Superdex 75 column chromatography profile of 
elution of affinity chromatography of NS5A-D1under native conditions (5% 
glycerol containing buffer). C13 and E11 fractions, are top point of two 
obtained peaks, were run on SDS-PAGE (fig2.4B). Black bar denotes the 
fractions pooled for further studies. (B) 15% SDS-PAGE gel profile in which 
affinity chromatography elute (E), wash (W) and flow through (FT) were run 
in second, third and fourth lane respectively. Fraction C13 and E11 from gel 
filtration chromatography were run in fifth and seventh lane.  Black Arrow 




























   
        
 
Figure 2.6 Expression and purification profile of NS5A domains/ fragments. 
(A) Expression and affinity purification samples of Long NS5A-D2 run on 
15% SDS-PAGE. E1, E2 and E3 are three subsequent elutions (B) Expression 
and affinity purification samples of Long NS5A-D3 run on 15% SDS-PAGE. 
(C) After affinity purification NS5A elute sample run on 12 % SDS-PAGE. 
Arrow indicates the band of purified recombinant protein. M: Precision Plus 
Protein™ Dual-Colour Standards, BI: before induction whole cells, AI: after 
induction whole cells, P: pellet fraction after induction, S: Supernatant after 
induction, B: Ni-NTA beads after binding with supernatant, FT: Flow through, 
W: wash, E: Elute 
 


















    
 
Figure 2.7 Purification profile of NS5A-D3 and its shorter fragments after 
affinity purification. (A) Purification profile of NS5A-D3 affinity elute by 
anion exchange HiTrap Q column when 25mM tris, pH 7.5 buffer was used as 
buffer A and buffer B contained 25mM tris, 1M NaCl, pH 7.5. Protein was 
eluted from column with a linear gradient of 10 to 70% of buffer B. (B) 
Purification profile of NS5A-D3A affinity elute by reverse phase-HPLC C18 
column. NS5A-D3A was eluted from the column with gradient of 20 % to 50 
% of solvent B (80% acetonitrile (v/v) in 0.1% (v/v) TFA). (C) and (D) are 
RP-HPLC C18 column purification profiles of NS5A-D3B and NS5A-D3C 
respectively. Both NS5A-D3B and NS5A-D3C were eluted from the column 
with gradient of 20 to 70 % and 20 to 50 % of solvent B (80% acetonitrile 
(v/v) in 0.1% (v/v) TFA). Arrows indicate the peak for the expressed and 
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overnight with thrombin enzyme. Glutathione sepharose beads before 
cleavage and after cleavage were run on 15% SDS-PAGE and GST band shift 
was observed. Subsequently, GST tag removed NS5A fragments were purified 
successfully by RP-HPLC C18 column. ESI-MS was used to determine the 
Molecular weight of eluted protein. Expression and purification of NS5A and 
VAPB fragments are also listed in table 2.1 
2.3.3 Preliminary CD and NMR characterization of VAPB 
domains/fragments 
After successful purification of each VAPB domain/fragment, the structural 
properties first investigated by using CD spectroscopy. As seen in figure 2.8A, 
VAPB (1-195) has a far-UV CD spectrum for a protein containing both α-
helix and β-sheet secondary structures. It shows two minima at ~208nm and 
~218nm. On the other hand, far-UV CD spectra of MSP domain and 
VAPB150 have maximal negative signal at ~218 nm and positive signal at 
~199 nm (figure 2.8B and C). Basically, MSP (1-125) and VAPB150 (1–150) 
have similar far-UV CD spectra which shows the presence of β-dominant 
MSP fold that has already been characterized in previous report (Shi J et al., 
2010). This observation implies that the extra C-terminal 25 residues in 
VAPB150 is largely unstructured and its presence does not alter the MSP-fold. 
Indeed, in a NMR structure (PDB ID: 2CRI) of the mouse VAPA (1–140) 
fragment, residues 125–140 are predominantly disordered. On the other hand, 
VAPB-CC has a far-UV CD spectrum characteristic of a helical conformation 





                                         
                                   
Figure 2.8 Far-UV CD spectra of VAPB domains/fragments. (A) Far-UV CD spectrum of 20µM protein concentration of VAPB protein in2mM 
phosphate buffer, pH 7.5 at 25 °C. (B) Far-UV CD spectrum of MSP domain under same conditions. (C) Far-UV CD spectrum of VAPB150 




















































































Figure 2.9 NMR characterizations of VAPB domains and thermounfolding of 
VAPB protein. (A) Superimposition of 1H-15N NMR HSQC spectra of VAPB 
(1–195) (black); VAPB150 (1-150) (red) and VAPB-CC (151–195) (green). 
(B) Superimposition of 1H-15N NMR HSQC spectra of VAPB150 (1–150) 
(red); MSP (1–125) (blue). (C) Thermounfolding of VAPB monitored by far 
UV CD spectra at various temperatures at 40uM protein concentration. (D) 
Thermal unfolding curve monitored at 222 nm. 
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Figure 2.10 Disorder tendency prediction and CD spectra of NS5A fragments 
(A) Prediction of disorder tendency of the full-length NS5A with IUPred 
server (http://iupred.enzim.hu/). Here score above 0.5 indicate the disorder 
tendency in that region (B) Far-UV CD spectra of NS5A (33–447) (blue); 
NS5A-D1 (33–202) (green); long NS5A-D2 (251–380) (red) and long NS5A-
D3 (300–447) (brown). Spectra were collected from 190-260nm rage of 









To check the thermal stability of VAPB, thermounfolding was performed and 
it was monitored by far-UV CD spectra at various temperatures from 5-85°C. 
Analysis of CD spectrum of VAPB suggested that structure of VAPB is 
affected at temperatures 45°C and above. Acquired CD spectra at various 
temperatures were used to calculate VAPB Tm. The melting temperature of 
VAPB protein was estimated as ~52.2°C. 
Subsequently, to acquire 1H-15N NMR HSQC spectra, 15N-isotople labeling of 
all these fragments were done by growing the transformed bacterial cell in M9 
minimal media. Labeled fragments were purified with the similar strategies 
which were used to purify the unlabeled proteins. Afterward, 1H-NMR spectra 
and 1H-15N NMR HSQC spectra were acquired. As shown in Figure 2.9A, 
VAPB (1–195) has a well-dispersed HSQC spectrum, indicating that it 
contains a well-folded domain. Interestingly, the HSQC spectrum of VAPB 
(1–195) appears to be almost the superimposition of the spectra of isolated 
VAPB150 and VAPB-CC (Figure 2.9A), suggesting that VAPB150 (1–150) 
and VAPB-CC have no significant packing interaction in VAPB (1–195). 
Furthermore, as shown in Figure 2.9B, most HSQC peaks of MSP domain (1–
125) are also superimposable to those of VAPB150 (1–150), indicating that 
the C-terminal 25 residues of VAPB150 (1–150) have no significant packing 
with the MSP fold assumed by the N-terminal 125 residues. Taken together, 
CD and NMR results demonstrate that VAPB (1–195) is composed two 
structural domains, namely the well-folded β-dominant MSP fold and helical 






2.3.4 Preliminary CD and NMR characterization of NS5A 
domains/fragments 
After purification, preliminary structure characterizations of NS5A 
domains/fragments were carried out by using CD and NMR spectroscopy. Far-
UV CD spectrum of NS5A (33–447) showed one positive peak at ~192 and 
two minima at ~208nm and ~220nm. However, NS5A-D1 (33–202) CD 
spectrum showed one minima at ~208nm (figure 2.10B). These observations 
revealed that NS5A (33–447) and NS5A-D1 (33–202) are well-formed 
secondary structures containing proteins. This study is consistent with the fact 
that the NS5A-D1 domain has well-formed secondary and tertiary structures 
(Tellinghuisen TL et al., 2005; Love RA et al., 2009). 1D-NMR spectra of 
NS5A-D1 also demonstrated that it is well structured domain.  By contrast, the 
fragments consisting of D2 or/and D3 domains have far-UV CD spectra 
typical of proteins of being predominantly disordered (minima at ~200nm), 
consistent with previous reports on NS5A D2 and D3 of other HCV isolates 
(Liang Y et al., 2007; Hanoulle X et al., 2009, 2010; Verdegem D et al., 
2011). The disorder tendency of NS5A was also assessed by IUPred 
(Dosztányi Z et al., 2005). Interestingly, it showed that D1 has the lowest and 
D3 has the highest disorder tendency, while D2 appears to be only partially 
disordered (figure 2.10A). Therefore, D2 is not a classic intrinsically-
unstructured domain. In the recent finding in the lab, it is been revealed that 
such partially disordered domains are prone to aggregation or/and undergo 
large conformational exchanges on the ms-ms time scale (Song J, 2009). Thus, 
probably due to the existence of the dynamic aggregation NMR 











Figure 2.11 Structure characterization of NS5A-D3 by CD and NMR. (A) 
Far-UV CD spectrum of NS5A-D3 which was taken at 20 µM protein 
concentration and at 25°C. (B) 1H-15N NMR HSQC spectrum of NS5A-D3 
was acquired in 10mM NaH2PO4, pH6.8 buffer at 25°C. (C) Residue-specific 
13Cα conformational shift of NS5A-D3 (359–447) derived from analysis of 
triple-resonance heteronuclear NMR spectra including HNCACB and 
CBCA(CO)NH. Triple resonance heteronuclear spectra were collected in 



















































sizes or/and existence of conformation exchanges on µs-ms time scale, well-
dispersed HSQC spectra could not be obtained for 15N-labeled NS5A (33-447) 
and NS5A-D1 (33-202) samples. Furthermore, the recombinant 89-residue 
NS5A-D3 protein was characterized extensively by Circular Dichroism and 
NMR spectroscopy. Far-UV CD spectrum of NS5A-D3 exhibits the presence 
of minima at ~199nm (figure 2.11A) which indicates that this domain is 
largely unstructured proteins, consistent with previous reports on NS5A-D3 of 
other HCV isolates. This conclusion is further evident from the very narrow 
1H-(1.8 ppm) and 15N-(19.5 ppm) spectral dispersions of its HSQC spectrum 
(figure 2.11B), which also indicate the absence of a tight tertiary packing in 
D3. Nevertheless, reasonably high solubility of NS5A-D3 allowed the 
preparation of 15N-/13C-double labeled NS5A-D3 NMR sample at a protein 
concentration of 300 µM for collecting triple-resonance NMR data. After 
collecting the data, it was processed by NMRDRAW and analyzed. By 
analyzing the data, the sequential assignment of NS5A-D3 was achieved 
successfully and Cα conformational shifts were obtained (figure 2.11C). It has 
been well-established that Cα chemical shift deviations from their random-coil 
values are very sensitive indicators of protein secondary structures, thus 
representing a powerful probe for detecting residual secondary structures in 
unfolded or partially folded proteins (Dyson HJ and Wright PE, 2001; Bai Y et 
al., 2001). Larger and positive Cα conformational shifts of residues show the 
presence of helical secondary structure. However, from small but positive Cα 
conformational shifts over most D3 residues (figure 2.11C), it can be 
concluded that the helical conformations are weakly populated over several 







Figure 2.12 Far-UV CD and NMR characterization of various D3 constructs. 
(A) Overlay of far-UV CD spectra of NS5A-D3, NS5A-D3A, NS5A-D3B and 
NS5A-D3C. Spectra were collected at 20 µM protein concentration and 25°C 
in 2 mM NaH2PO4 pH 7.2 buffer. Blank was subtracted from the spectra. (B) 
1H-15N NMR HSQC spectrum of 100 µM D3A in 10 mM phosphate pH6.8 




























Figure 2.13 Sequential Assignment and structural characterization of NS5A-
D3A. (A) Residue-specific Hα conformational shift of NS5A-D3A (394–447) 
derived from analysis of three-dimensional 15N-edited HSQC-TOCSY 
spectrum. (B) Characteristic NOE connectivities of NS5A-D3A (394–447) 
defining secondary structures derived from analysis of three-dimensional 15N-
edited HSQC-NOESY spectrum. The three-dimensional spectra were collected 

































Furthermore, smaller fragments of NS5A-D3 including, NS5A-D3A, NS5A-
D3B and NS5A-D3C were also first characterized by far-UV CD spectra and 
then by NMR. The lyophilized powder of these fragments was dissolved in 2 
mM phosphate pH 7.2 buffer and pH was adjusted. As seen in figure 2.12A, 
the 54-residue D3A, 41-residue D3B and 21-residue D3C are all highly 
disordered in solution as evident from their far-UV CD spectra (figure 2.12A). 
Moreover, CD spectra of these fragments were almost similar to the CD 
spectrum of NS5A-D3.   
Longest fragment among these fragments, NS5A-D3A was further extensively 
characterized by NMR. The narrow HSQC spectral dispersion of NS5A-D3A 
clearly indicated the lack of tight tertiary packing in it (figure 2.12B). To gain 
detailed insights into the solution conformation of D3A, a pair of three-
dimensional heteronuclear NMR spectra, namely 15N-edited HSQC-TOCSY 
and HSQC-NOESY was collected and subsequently the sequential assignment 
was achieved. As judged from its negative Hα conformational shifts for most 
residues (figure 2.13A), D3A appears to have helical conformations weakly-
populated over two segments: Ser401-Ser412 and Asp427-Val445, consistent 
with Cα conformational shifts of the corresponding residues in D3 (figure 
2.11C). The existence of two helical segments is further supported by 
characteristic NOEs (figure 2.13B) over the two regions defining the helical 
conformation, including dNN(i, i+1), dNN(i, i+2), dαN(i, i+2), dαN(i, i+3) and dαN(i, i+4). 
However, as only two dαN(i, i+4) NOEs are observed, the helical conformations 
in D3A appear to be mainly dynamic 310-helix, rather than α-helix, consistent 







For extensive characterization of interaction between VAPB and NS5A, 
various constructs were cloned and expressed. Recombinant expression in 
bacteria was used to obtain protein in high quantity for their primary structure 
characterization. This chapter describes the experimental designs and results 
of recombinant protein expression in bacterial system, purification and 
structural characterization. Systematic optimization approach at small scale 
level was used to optimize the expression of designed plasmids. After 
expression, purification of VAPB, VAPB150 and MSP was done by affinity 
chromatography followed by gel filtration chromatography. Similarly, NS5A 
constructs were also successfully purified by various approaches. Domain 1 
was purified by Ni-NTA affinity purification and then size exclusion 
chromatography. Similar approaches are used by other group also for its 
purification (Tellinghuisen et al., 2004; 2005). Purified protein was having 
less solubility in low salt and without glycerol buffer condition. Preliminary 
structure characterization of VAPB domains/fragments demonstrate that 
VAPB protein is a well structured protein which have both α helix and β 
strands secondary structures. Furthermore, CD spectra of MSP and VAPB-CC 
demonstrate that they have β strands and α helices respectively, which is 
consistent with the previous studies too. Well dispersed HSQC spectra of 
VAPB, VAPB150 and MSP domain also revealed that they are well folded 
proteins. Superimposition of HSQC spectra of these protein revealed that    
VAPB (1–195) is composed two structural domains, namely the well-folded β-





On the other hand, NS5A protein which is composed of three domains, 
showed the far-UV CD spectrum of a protein with well formed secondary 
structure. Moreover, CD and NMR results of NS5A-D1 demonstrated the 
occurrence of β-strands as secondary structures and tertiary packing in this 
domain. Whereas, fragments containing D2 and D3, were largely disordered. 
Extensive NMR study of NS5A-D3 and NS5A-D3A by triple resonance 
experiments demonstrated the presence of helical structures in the C-terminal 
region of D3. These results also demonstrated that domain 3 of NS5A from 
genotype 1b S1 strain is intrinsically unstructured domain which has helical 
propensity at C-terminal region. These results are consistent with other reports 
of domain 2 and domain 3 from different HCV genotype isolate (Hanoulle et 
al., 2009; 2010; Liang et al., 2007; Verdegem et al., 2011).   
2.5 Conclusions 
Study in this chapter; have used biophysical approaches to characterize the 
NS5A protein and its various constructs from HCV genotype 1b strain S1 for 
the first time. This study showed that domain 1 of NS5A contains β-strands 
predominantly, whereas other two domains – domain 2 and domain 3 are 
intrinsically unstructured domains. Further investigations on domain 3 
indicated that its C-terminal region have a propensity to form α‐helical 
secondary structures. This has given an understanding of NS5A protein which 






































Characterization of VAPB-NS5A Interaction 
3.1 Introduction 
Living organisms are tightly regulated and very complex systems which have 
precisely coordinated communications at every level of organizational 
hierarchy. These communications are mainly intervened by protein-protein 
interactions (PPIs). Hence, protein-protein interactions are very crucial for 
biological processes. On the basis of strength, PPIs can be classified in three 
subclasses: (1) Strong and permanent association with high affinity (Kd<10-
9M) (2) strong and transient interactions which can be triggered and (3) weak 
and transient interactions with low affinity (Kd>10-4M) (Perkins JR et al., 
2010). PPIs, with Kd<10-6 binding affinity have been extensively characterized 
in previous years. Whereas, knowledge about weak PPIs remain limited due to 
two main reasons, (1) the technical difficulties associated with their 
investigation and (2) the belief that the weak PPIs are physiologically 
irrelevant. In recent years, weak interactions have been increasingly 
appreciated and identified to be crucial for various biological processes for 
example, reversible cell–cell contacts, transient assembly and/or disassembly 
of large signaling complexes, and dynamic regulation of enzymes 
(Vinogradova and Qin J, 2012). 
Various methods have been developed over the years to study protein–protein 
interactions. Typically, protein-protein interaction study begins with an initial 





tag based approach, yeast two-hybrid system, quantitative proteomic 
techniques. After identification of new binding partners, validation and 
characterization of interactions can be perused by various strategies which 
include: co-immunoprecipitation, surface plasmon resonance (SPR), 
isothermal titration calorimetry (ITC), NMR and X-ray crystallography 
(Berggård et al., 2007). SPR is a widely used technique, which uses biosensors 
to measure the change in the refractive index of solvent near the sensor surface 
during complex formation or dissociation. It can characterize binding reaction 
in real time without labeling and qualitative as well as quantitative information 
can be obtained. However, ITC offers a direct measurement of the binding 
enthalpy (ΔH) during the interaction. It can provide information about all the 
thermodynamic parameters of the molecular interactions.  In all mentioned 
methods, NMR is a most powerful tool to study weak interactions at atomic 
level resolution and at near physiological conditions. Most common approach 
to assess and characterize the interaction by NMR is chemical shift 
perturbation mapping, which is used to study the interaction between NS5A 
and VAPB.  
3.1.1 Chemical Shift Perturbation Mapping 
The resonance frequencies of individual atoms in a particular protein are 
known as chemical shift, which strongly depend on their local environment. 
Therefore, they are considered as fingerprints of protein structure. The 
complex formation during interaction leads to the change in the local 
environment of atoms of the interacting surface. The chemical shift patterns of 





shift perturbations, as the result of complex formation, provide an extremely 
sensitive tool for mapping the binding interface. In this method, 15N –labeled 
protein is titrated with unlabeled ligand and resultant change in 1H–15N HSQC 
spectrum is monitored, which facilitates the identification of binding surface 
on the labeled protein. This experiment is very useful and popular due to its 
straightforward nature and high sensitivity. The spectral change, named as 
chemical shift perturbations (CSP), are typically associated with a particular 
set of amino acids that either (1) directly participate in interaction or are 
situated very closely to the binding site or (2) reflect binding-induced 
conformational rearrangements (e.g., a disorder–order transition). First case, 
which shows small CSP with little or no conformation change in the backbone 
of well folded domains, happens more frequently for weak interactions. Thus, 
binding interface can be determined by identifying perturbed residues during 
the complex formation. Moreover, this method also allows the determination 
of the Kd of the interaction with fast exchange by concentration-dependent 
titrations. This information can be combined with computational method to 
generate the complex model. 
In this section, to characterize the interaction between NS5A and VAPB, 
firstly labeled VAPB protein HSQC spectrum was monitored, while unlabeled 
NS5A was titrated in different ratio. Sequentially, HSQC of various labeled 
VAPB constructs were collected, when NS5A full length was titrated. This 
helped to identify the binding domain or fragment of VAPB. Various NS5A 
domain/fragments were further titrated to map out the region which interacts 
with identified VAPB domain/ fragment. Perturbed residues were mapped 





docking model was generated by HADDOCK software.  NMR titrations were 
also used to determine the Kd of this interaction. T46I mutation in MSP 
domain, which has been reported to be the cause of ALS disease in the 
patients, was also used for testing the interaction with the identified NS5A 
fragments. 
3.2 Materials and Methods 
3.2.1 ITC titration experiments  
All isothermal titration calorimetric (ITC) experiments were conducted by 
using a Microcal VP ITC machine. Sample of protein was placed in 1.8 ml 
sample cell, while ligand was taken in 300 μL syringe. Titrations of NS5A 
peptides to the MSP domain were conducted in 10 mM phosphate buffer at pH 
7.5. Generally, the MSP samples were placed in the cell, while the NS5A 
peptides were taken in syringe. Degassing of samples was done for 15 min to 
remove bubbles before titrations were initiated. Same parameters were used 
for control experiment which was performed to subtract the ligand dilution 
contribution. After subtraction, results were fitted using the built-in software 
ORIGIN to acquire the thermodynamic binding parameters. 
3.2.2 NMR characterization of interactions 
For NMR HSQC characterization of the binding interactions between NS5A 
and VAPB fragments/domains, two-dimensional 1H-15N HSQC spectra of the 
15N-labeled proteins were acquired at a protein concentration of 50 µM in the 
absence or presence of the unlabeled binding partners at different molar ratios. 





with unlabeled ligand at various molar ratios, the shifted or disappeared HSQC 
peaks could be identified and further assigned to corresponding residues. The 
degree of binding-induced perturbation was represented by an integrated 
chemical shift difference (CSD), which was calculated by following formula 
(Liu J. et al, 2006)- 
[(Δ1H)2 + (Δ15N)2/5]1/2 
The CSD values for individual residues at various molar ratios were fitted by 
using one binding site model to obtain the residue specific dissociation 
constants (Kd).  
3.2.3 Molecular docking  
To obtain the complex model, molecular docking of MSP and NS5A-D3B was 
performed by using Haddock 2.0 (High Ambiguity Driven protein-protein 
Docking) software (de Vries SJ et al., 2007) in combination with CNS 
(Brunger AT et al., 1998). It makes use of chemical shift perturbation data to 
derive the docking while allowing various degrees of flexibility. Three steps 
are performed in the docking procedure, which are as follows: first step, 
randomization and rigid body energy minimization; second, semi-flexible 
simulated annealing; and third, flexible explicit solvent refinement. Briefly, all 
D3B and MSP residues with HSQC peaks disappeared or significantly shifted 
were set to be ‘‘active’’ residues, whereas neighbors of active residues were 
defined as ‘‘passive’’ residues according to HADDOCK definition. The 
crystal structure of VAPB-MSP (3IKK) we previously determined (Shi J et al., 
2010) was used here while an extended D3B structure was utilized for 





docking, and the best 50 structures were selected for semi-flexible simulated 
annealing, followed by water refinement. Three structures with the lowest 
energies were selected for detailed analysis and display by the PyMOL 
molecular graphics system (W. L. DeLano, DeLano Scientific LLC, San 
Carlos, CA). 
3.3 Results  
3.3.1 Identification of the VAPB domain binding NS5A 
To characterize the interaction between VAPB and NS5A, initially, domain of 
VAPB which interact with NS5A was identified. To identify the human VAPB 
domain for binding with the viral NS5A, we first titrated the 15N-labeled 
VAPB (1–195) sample with the unlabeled NS5A (33–447) protein. As seen in 
figure 3.1A, addition of unlabeled NS5A (33–447) triggered the disappearance 
of a subset of HSQC peaks of VAPB (1–195). This observation confirms that 
NS5A does indeed interact with VAPB. Previously described investigation 
shown in figure 2.8A and B, indicated that HSQC peaks of VAPB (1-195) are 
almost superimposable to MSP domain HSQC peaks. On the basis of NMR 
sequential assignment for MSP (1-125) and close examination of perturbed 
peaks during VAPB and NS5A interaction, revealed that the disappeared and 
significantly shifted peaks are all from the N-terminal 125 residues which 
adopt the MSP fold. This examination was further confirmed by titration 
between 15N-labeled MSP domain and NS5A (33-447). Superimposition of 
HSQC spectra at different molar ratios showed that interaction between MSP 
domain and NS5A indeed triggers the shift and disappearance of MSP domain 







Figure 3.1 Identification of interaction between VAPB and NS5A. (A) 
Superimposition of 1H-15N NMR HSQC spectra of VAPB (1–195) in the 
absence of (black) and in the presence of unlabeled NS5A (33–447) (red) at a 
molar ratio of 1:2.5 (VAPB/NS5A). (B) Superimposition of 1H-15N NMR 
HSQC spectra of VAPB-CC (151–195) in the absence of (black) and in the 
presence of unlabeled NS5A (33–447) (red) at a molar ratio of 1:2.5 (VAPB-














Figure 3.2 Identification of interaction between MSP and NS5A. 
Superimposition of 1H-15N NMR HSQC spectra of MSP (1–125) in the 
absence of (black) and in the presence of unlabeled NS5A (33–447) (red) at a 
molar ratio of 1:2 (MSP/NS5A). Titrations were performed in 10 mM 











bind to MSP domain. To check the interaction between VAPB-CC domain 
with NS5A, 15N-labeled VAPB-CC sample was titrated with unlabeled NS5A 
(33–447), but detected no significant change of the HSQC spectra (figure 
3.1B), indicating that the VAPB coiled coil domain is not physically 
interacting with NS5A, or the binding is very weak.Taken together, the results 
suggest that the human VAPB binds to NS5A via its N-terminal MSP domain. 
3.3.2 Identification of VAPB binding NS5A domain/ fragment 
Once VAPB domain which interacts with full length NS5A was identified, 
next step was to identify which region or domain of NS5A is majorly involved 
in this interaction. To achieve this objective various NS5A constructs were 
designed, which not only cover domains but also low complexity regions 
between domains (figure 2.2). These NS5A domain/fragments were 
successfully purified and characterized (chapter 2).  To identify the NS5A 
domain for binding VAPB, firstly, 15N-labeled VAPB (1–195) protein was 
titrated with unlabeled NS5A-D1 (33–202) proteins with amino acid 
sequences derived from both Singapore and Con1 isolates. Superimposition of 
obtained spectra revealed no significant change in the HSQC spectra during 
titration till high molar ratios (figure 3.3A). Furthermore, 15N-labeled 
VAPB150, MSP domain and CC domain were also titrated with unlabeled 
NS5A-D1 protein, but found no considerable change of their HSQC spectra 
(figure 3.3B, C and D). Moreover, D1 from HCV strain Con1 was also titrated 
with 15N-labeled VAPB domains and obtained similar results. These results 
are suggesting that domain 1 of NS5A is not directly involved in binding with 





protein was titrated with unlabeled Long NS5A-D2 (251–380), and found no 
change in the HSQC spectrum. Furthermore, to confirm the previous result, 
VAPB150 and CC domain were also titrated with Long NS5A-D2, again 
found no significant change in the 1H-15N HSQC spectra (figure 3.4). Taken 
together the NMR titration results with Long NS5A-D2 clearly indicate that it 
does not interact with VAPB. Similarly, NS5A-D2-D3 Loop (313–366) 
proteins was also titrated with 15N-labeled VAPB, MSP and CC, and again 
found no significant changes of the HSQC spectra of VAPB (1–195), MSP 
and VAPB-CC (figure 3.5), indicating that the linker between D2 and D3 of 
NS5A do not physically interact with NS5A, or the binding is too weak to be 
detected by NMR.  
However, once we titrated 15N-labeled VAPB (1–195) with Long NS5A-D3 
(300–445) which contains both D3 and the linker between D2 and D3, many 
HSQC peaks of VAPB (1–195) disappeared or shifted (figure 3.6A). The 
perturbation pattern induced by Long NS5A-D3 was very similar to that 
induced by NS5A (33–447), implying that NS5A (33–447) and Long NS5A-
D3 (300–445) use the similar regions to bind with VAPB. In other words, 
Long NS5A-D3 contains at least the majority of the residues critical for 
binding to VAPB. To further investigate the domain of VAPB that interacts 
with Long NS5A-D3, the 15N-labeled VAPB150 and MSP were titrated with 
unlabeled Long NS5A-D3 (300–447) and found that the disappeared or shifted 
HSQC peaks are almost identical to those trigged by NS5A (33–447) (figure 
3.6B, C). By contrast, addition of unlabeled long NS5A-D3 (300–447) caused 
no significant perturbation on the VAPB-CC HSQC peaks (figure 3.6D), again 







Figure 3.3 Identification of interaction between VAPB protein and NS5A-D1. 
(A) Superimposition of 1H-15N NMR HSQC spectra of VAPB (1–195) in the 
absence of (black) and in the presence of unlabeled NS5A-D1 (33–202) (red) 
at a molar ratio of 1:2 (B) Superimposition of 1H-15N NMR HSQC spectra of 
VAPB150 (1-150) in the absence of (black) and in the presence of unlabeled 
NS5A-D1(red) at a molar ratio of 1:2 (C) Superimposition of 1H-15N NMR 
HSQC spectra of MSP (1-125) in the absence of (black) and in the presence of 
unlabeled NS5A-D1(red) at a molar ratio of 1:2 (D) Superimposition of 1H-
15N NMR HSQC spectra of VAPB-CC (151–195) in the absence of (black) 
and in the presence of unlabeled NS5A-D1 (red) at a molar ratio of 1:2 























Figure 3.4 Identification of interaction between VAPB protein and Long 
NS5A-D2. (A) Superimposition of 1H-15N NMR HSQC spectra of VAPB (1–
195) in the absence of (black) and in the presence of unlabeled Long NS5A-
D2 (251-380) (red) at a molar ratio of 1:2 (B) Superimposition of 1H-15N 
NMR HSQC spectra of VAPB150 (1-150) in the absence of (black) and in the 
presence of unlabeled Long NS5A-D2 (red) at a molar ratio of 1:2 Titrations 















Figure 3.5 Identification of interaction between VAPB protein and NS5A-D2-
D3 Loop (313–366). (A) Superimposition of 1H-15N NMR HSQC spectra of 
VAPB (1–195) in the absence of (black) and in the presence of unlabeled 
NS5A-D2-D3 Loop (313–366) (red) at a molar ratio of 1:2 (B) 
Superimposition of 1H-15N NMR HSQC spectra of MSP domain (1-125) in the 
absence of (black) and in the presence of unlabeled NS5A-D2-D3 Loop (red) 
at a molar ratio of 1:2 Titrations were performed in 10 mM NaH2PO4, 10 mM 














Figure 3.6 Identification of interaction between VAPB protein and Long 
NS5A-D3. (A) Superimposition of 1H-15N NMR HSQC spectra of VAPB (1–
195) in the absence of (black) and in the presence of unlabeled Long NS5A-
D3 (300–445) at a molar ratio of 1:2 (cyan) and 1:4 (red) (B) Superimposition 
of 1H-15N NMR HSQC spectra of VAPB150 (1-150) in the absence of (black) 
and in the presence of unlabeled Long NS5A-D3 at a molar ratio of 1:2 
(green) and 1:4 (red) (C) Superimposition of 1H-15N NMR HSQC spectra of 
MSP (1-125) in the absence of (black) and in the presence of unlabeled Long 
NS5A-D3(red) at a molar ratio of 1:2 (D) Superimposition of 1H-15N NMR 
HSQC spectra of VAPB-CC (151–195) in the absence of (black) and in the 
presence of unlabeled Long NS5A-D3 (red) at a molar ratio of 1:4 Titrations 




















Conclusively, NS5A interacts with VAPB by its Long NS5A-D3 fragment, 
which contains D3 as well as loop between D2 and D3, and binds to MSP 
domain of VAPB. 
Now, next step was to figure out which region of Long NS5A-D3 is really 
involved in the interaction with MSP domain. As previously described from 
NMR titrations, the loop between D2 and D3 does not perturb the HSQC 
spectrum of VAPB, VAPB150 and CC, indicating that most likely this loop 
does not physically interact with VAPB protein. Moreover, NS5A (300–447) 
protein containing D2 residues has a relatively low solubility and is not 
suitable for collecting high quality NMR data for sequential assignment. 
Therefore, 15N-labeled MSP (1–125) was titrated with unlabeled NS5A-D3 
(359–447) which contains only D3 of NS5A. Remarkably, as shown in figure 
3.7, addition of D3 sample not only induced the disappearance of almost the 
same set of HSQC peaks as induced by NS5A(300–447), but also triggered 
significant shifts of many extra residues(figure 3.7B). This implies that the 
majority of the NS5A residues critical for binding VAPB are located on 
NS5A-D3. As a consequence, after deleting the D2 and linker residues 300–
358 which is not significantly involved in binding, NS5A-D3 (359–447) 
would be expected to have a tighter binding ability to VAPB. Indeed, 
disappearnce and larger perturbation of many peaks indicate that NS5A-D3 
affinity might be higher than Long NS5A-D3 as extra loop region can increase 
the entropy of the system.  
Conclusively, NMR titration experiments with various domain/ fragments of 
NS5A indicated that NS5A, Long NS5A-D3 and NS5A-D3 cause same set of 






Figure 3.7 Comparison of interaction between MSP domain with Long NS5A-D3 and NS5A-D3. (A) Superimposition of 1H-15N NMR HSQC 
spectra of MSP (1-125) in the absence of (black) and in the presence of unlabeled Long NS5A-D3(red) at a molar ratio of 1:2 (B) 
Superimposition of 1H-15N NMR HSQC spectra of MSP (1-125) in the absence of (black) and in the presence of unlabeled NS5A-D3 at a molar 
ratio of 1:1 (green) and 1:2 (red). All the titrations were performed in 10 mM NaH2PO4, 10 mM DTT pH 6.8 buffer. 
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Moreover, NS5A-D3 interaction with MSP leads to the perturbation of many 
extra peaks which indicates that it binds much tighter (figure 3.7A and B). 
Therefore, NMR sequential assignment of NS5A-D3 was achieved (Chapter 2) 
and used to identify the perturbed residues during the interaction with MSP 
domain. After sequential assignment, Cα conformational shift was calculated, 
which demonstrate that NS5A-D3 is largely disordered except the helical 
conformations, that are weakly populated over several segments of the 
sequence (figure 2.10C). 
Despite being highly disordered, addition of the unlabeled MSP domain (1–
125) did lead to significant shifts and disappearance of many NS5A-D3 HSQC 
peaks (figure 3.8A). On the basis of sequential assignment of NS5A-D3, 
perturbed and disappeared residues during the titration with MSP were 
identified. Interestingly, those residues were found to be located on the C-
terminal half of NS5A-D3 (figure 3.8A and 3.8B). From the extensive NMR 
study of NS5A-D3 (chapter 2), it is evident that NS5A-D3 is a member of 
intrinsically-unstructured proteins which is highly-disordered but still 
functionally-active (Dyson and Wright, 2005). Remarkably, binding of MSP 
domain with NS5A-D3 does not significant increase of the spectral dispersion 
of the NS5A-D3 HSQC spectra, implying that NS5A-D3 still remains largely 
unstructured even upon complexing with MSP domain.  
Since the significantly perturbed residues are located over the C-terminal half 
of NS5A-D3 (figures 3.8A and B), we then subcloned and expressed three 






Among three, D3A was 15N-labeled and its sequential assignment was 
obtained by 15N-edited HSQC-TOCSY and HSQC-NOESY NMR 
experiments. 
Subsequently, 15N- labeled NS5A-D3A was titrated with unlabeled MSP 
domain (1-125) and HSQC spectra were collected. Significant shifts and 
disappearance of NS5A-D3A HSQC peaks upon the addition of unlabeled 
MSP domain demonstrated that NS5A-D3A has an ability to bind to the MSP 
fold (figure 3.9A). Based on the sequential assignment, significantly perturbed 
and disappeared residues has been identified to be mostly located on the 
second helical segment, while only Ser414 and Met416 are located on the first 
one (figure 3.9C). Strikingly, the binding with the MSP fold again results in no 
significant increase of the HSQC spectral dispersion, implying that the D3A 
still remains largely unstructured even upon complexing with VAPB-MSP. 
3.3.3 Critical MSP residues for binding NS5A 
To map out the MSP residues critical for binding NS5A, we titrated the 15N-
labeled MSP (1–125) with all four unlabeled D3 fragments including D3 
(figure 3.7B), D3A, D3B and D3C (figure 3.10A, B and C) in 10 mM 
NaH2PO4, 10 mM DTT, pH 6.8 buffer at 25°C. Figure 3.11A-C present the 
chemical shift differences (CSD) of the MSP domain upon adding unlabeled 
D3, D3A and D3B proteins at a molar ratio of 1:4 (MSP/D3 peptide). 
Interestingly, three peptides trigger almost the same shifting pattern and 
similar amplitude for the MSP125 residues, suggesting that 41-residue D3B 
carries almost all residues key for binding the MSP domain. Upon titration 






Figure 3.8 Conformational and binding properties of NS5A-D3 (A) 
Superimposition of 1H-15N NMR HSQC spectra of NS5A-D3 (359–447) in the 
absence of (blue) and in the presence of unlabeled MSP (1–125) at molar 
ratios of 1:1 (green) and 1:2 (red) (D3/MSP). (B) Residue-specific 13Cα 
conformational shift of NS5A-D3 (359–447) derived from analysis of triple-
resonance heteronuclear NMR spectra including HNCACB and 
CBCA(CO)NH. Red bars are used to indicate residues undergoing significant 
shift or disappearance of their HSQC peaks in the presence of unlabeled MSP 








Figure 3.9 Sequence, conformational and binding properties of NS5A-D3 fragments (A) Superimposition of 1H-15N NMR HSQC spectra of 
NS5A-D3A (394–447) in the absence of (black) and in the presence of unlabeled MSP domain (1–125) at molar ratios of 1:1 (cyan) and 1:2 
(red) (D3A/MSP). All the titrations were done in 10 mM NaH2PO4, 10 mM DTT, pH 6.8 buffer at 25°C. (B) Amino acid sequence alignment of 
NS5A-D3A, D3B and D3C. (C) Residue-specific Hα conformational shift of NS5A-D3A (394–445) derived from analysis of three-dimensional 
15N-edited HSQC-TOCSY spectrum. Red bars are used to indicate residues undergoing significant shift or disappearance of their HSQC peaks in 


















Figure 3.10 Identification of interaction between MSP domain and NS5A- D3 fragments. Superimposition of 1H-15N NMR HSQC spectra of 
MSP (1-125) in the absence of (black) and in the presence of unlabeled NS5A-D3A (A) and NS5A-D3B (B) at a molar ratio of 1:1 (green) and 
1:2 (red). (C) Superimposition of 1H-15N NMR HSQC spectra of MSP (1-125) in the absence of (black) and in the presence of unlabeled NS5A-

















Figure 3.11 NMR identification of VAPB-MSP residues binding to NS5A-D3 
fragments. Residue-specific changes of integrated 1H and 15N chemical shifts 
of VAPB-MSP(1–125) in the presence of unlabeled NS5A-D3 (A), D3A (B), 
D3B (C) and D3C (D) at a molar ratio of 1:4 (MSP/D3 fragments). 
Significantly-shifted residues with CSD (chemical shift difference) >1 
standard deviations are colored in red and labeled while two regions with 









Arg51-Asn57 were found to completely disappear even at a molar ratio of 1:1 
(MSP/D3 peptide).  
Interestingly, these peaks were also found to disappear in the HSQC spectra of 
VAPB (1–195) upon titration by NS5A (33–447). On the other hand, upon 
titration by D3, D3A, D3B, additional HSQC peaks undergo gradual but 
significant shifts, which include Gln6, Met89-Val90-Gln91, Asp116, Leu119 
and Val122 (figure 3.14 and 3.11A, B and C). 
After identifying the disappeared and significantly shifted residues, they were 
mapped back to the VAPB- MSP domain structure which was previously 
determined in lab (Shi J et al, 2010).  They are all found to be located on the 
one side of the β-barrel fold (figure 3.12A and B). Interestingly, the residues 
with disappeared HSQC peaks upon binding to D3 fragments constitute the 
interfaces for binding to FFAT-motif containing ORP1 (figure 3.12B), and 
Nir2 peptides (Kaiser SE et al., 2005; Lua S et al., 2011). However, additional 
binding pockets on the MSP fold appear to be involved for binding with NS5A 
(3.12A and B). Also it is worthwhile to point out that two ALS-causing 
mutations, T46I and P56S, are all located over two β-strands with HSQC 
peaks of most residues disappeared. 
On the other hand, unlike NS5A-D3, NS5A-D3A and NS5A-D3B, the 21-
residue NS5A-D3C peptide is no longer able to induce the disappearance of 
any MSP residues (figure 3.10C). Instead, as seen in figure 3.10C and 3.11D, 
it is only able to induce peak shifts of some MSP residues of small amplitudes 
even at a molar ratio of 1:5 (MSP/D3C). When the CSD pattern induced by 





was observed that the residues, which were disappeared in case of other D3 
fragments, were shifted in case of NS5A-D3C (figure 3.11). Although the 
overall perturbation pattern by D3C shares some similarity with those by D3, 
D3A and D3B, D3C appears to have no significant perturbation on Gln8. 
These results imply that D3C has a dramatically-reduced binding affinity, as 
well as smaller contact regions on the MSP fold. This result supports the 
above conclusion that NS5A-D3 residues Ser414, Met416 and Asp425 are 
indeed critical for binding VAPB-MSP (figure 3.9B). 
3.3.4 Binding affinity estimation 
NMR titrations results with D3 and its fragments clearly suggest their 
interaction with MSP domain. Furthermore, to quantitatively assess the 
binding, we subsequently fitted the shift tracings of the MSP HSQC peaks to 
obtain dissociation constants (Kd). The CSDs of each shifted peaks of MSP 
domain at different molar ratios of D3 fragments during the titration were 
calculated and Kd values were determined by single binding fitting model. 
The fitting is exemplified in figure 3.13 and Kd values are summarized in 
Table 3.1. Overall, residue-specific Kd values titrated by D3, D3A and D3B 
are very similar, with average Kd values of 4.5, 8.0 and 4.7 mM respectively. 
For CSDs titrated by D3C, they are very small (figure 3.11D) as well as 
remained largely unsaturated (Figures 3.13B and C) even at a molar ratio of 
1:5 (MSP/D3C). Unfortunately further increase of the molar ratio was not 
possible due to the low solubility of the D3C peptide. As such, precise Kd 






Figure 3.12 Mapping of binding surface on MSP domain. (A) Crystal structure of the human VAPB-MSP (1–125) we previously determined 
with disappeared (red) and significantly-shifted (yellow) residues mapped out. Two ALS-causing mutants T46I and P56S are displayed in 






Figure 3.13 Fitting of chemical shift tracings to obtain dissociation constants (Kd). Experimental (dots) and fitted (lines) values are shown for 
the integrated 1H and 15N chemical shift changes of three representative residues: Gln6 (A), Val90 (B) and Asp116 (C) of VAPB-MSP (1–125) 










Figure 3.14 Identification of interaction between MSP domain and NS5A- 
D3B fragment. Superimposition of 1H-15N NMR HSQC spectra of MSP (1-
125) in the absence of (black) and in the presence of unlabeled NS5A-D3B at 
a molar ratio of 1:0.5 (green), 1:1 (pink) and 1:3 (blue). Inset showing the shift 
of MSP peak corresponding residues 116V, 121C and 90V at molar ratio 




















Table 3.1 Residue-specific Dissociation Constants (Kd) for Binding of 















This suggests that the residues deleted in D3C also play a key role in binding 
with MSP. We also attempted to perform the ITC measurements on the 
binding of the MSP domain (1–125) with different D3 peptides but failed to 
obtain high-quality data, probably due to the complex binding mode, or/and 
the fact that many NS5A-D3 residues still remain largely flexible even in the 
complex.  
3.3.5 Docking model of the D3-MSP complex 
We have attempted to co-crystallize MSP domain (1–125) with D3 peptides 
several times but only obtained the crystal of MSP domain (1–125) alone, 
probably due to the relative weak binding affinity, or/ and complex binding 
mode. On the other hand, the extensive disappearance of NMR resonances 
upon binding with D3 peptides prevented from determining the complex 
structure by NMR spectroscopy. In this regard, to better capture the binding 
properties, by using the well-established HADDOCK docking procedure with 
the NMR titration results, we constructed the models of the MSP-D3B 
complex. HADDOCK is a recent but well-established docking procedure that 
makes use of NMR chemical shift perturbation data in conjunction with the 
CNS program to drive the molecular docking of protein-protein complexes. 
Here, X-ray structures solved in our lab were used to build up the docking 
model. Assemble of ten structures of NS5A-D3B solved by NOE assignment 
was used for docking.  
Figure 3.15A shows the superimposition of the three models with the lowest 








Figure 3.15 Docking model of MSP-D3C complex. (A) Superimposition of 
three lowest energy docking models of the MSP-D3C complex. MSP 
structures are colored in blue and D3C structures in pink. (B) The lowest 
energy docking model of the MSP-D3C complex, with disappeared and 
significantly-shifted MSP residues colored in red. Three D3 regions critical for 







Figure 3.15 Docking model of MSP-D3C complex (A) The lowest energy docking model of the MSP-D3C complex, with MSP structure 
displayed in surface and three discrete D3 regions critical for binding with MSP are displayed in spheres of different colors. Three MSP surface 
pockets are labeled as P1, P2 and P3 respectively. (B) The lowest energy docking model of the MSP-D3C complex, with the MSP electrostatic 
potential displayed, with blue, red and grey corresponding to positive, negative and neutral potential values. (C) Hydrogen bonds between D3C 
and MSP in the complex. Only the residues having the interfacial hydrogen bonds are displayed in sticks and the hydrogen bonds are indicated 






Interestingly, although the initial D3B structure used for docking is an 
extended conformation without any preferred secondary structures, in all three 
complex models the D3B peptide acquires helical conformations over two 
segments: Pro418-Glu420 and Ser429-Trp433. 
Indeed, these two segments were experimentally characterized to have 
populated helical conformations, which is clearly evident from their 
conformational Hα shifts (figure 3.9C) and NOE connectivities (figure 2.12B). 
As seen in figure 3.15B, the significantly-perturbed D3B residues have 
extensive contacts with the MSP surface where two ALS-causing mutations 
P56S and T46I are located. In particular, Thr46 appears to have many close 
contacts with D3B residues Val436 and Ser437. Moreover, three D3B regions 
(figure 3.9B) appear to bind to three distinctive MSP surface patches (figure 
3.15A): the D3B region over Ser414-Met416 contacts relatively 
electrostatically neutral pocket of MSP (designated as P3), while other two 
regions over Asp425-Ser432 and Val436-Ser441 interact with other two 
electrostatically-positive pockets (designated as P2 and P1 respectively, figure 
3.15B). As such, there are many hydrogen bonds established between MSP-
P1/P2 and D3B residues (Figure 3.15C). More specifically, over P1 pocket, 
there are hydrogen bonds between backbone O of NS5A-Glu438 and 
sidechain NH of MSP-Gln57; between sidechain O of NS5A-Glu438 and 
sidechain NH of MSP-Arg55; between sidechain O of NS5A-Ser437 and 
sidechain NH of MSP-Thr46; between sidechain OH of NS5A-Ser437 and 
backbone O of MSP-Val45; between backbone N of NS5A-Ser437 with 
sidechain OH of MSP-Thr46; between backbone NH of NS5A-Val436 with 





sidechain O of NS5A-Asp425 and sidechain NH of MSP-Arg120; between 
sidechain O of NS5A-Asp425 and sidechain NH of MSP-Lys87; between 
sidechain O of NS5A-Asp425 and sidechain NH of MSP-Arg120; between 
sidechain O of NS5A-Asp427 and sidechain NH of MSP-Lys118; between 
sidechain O of NS5A-Asp427 and sidechain NH of MSP-Lys85.  
3.3.6 Interaction of T46I MSP mutant with NS5A-D3A 
ALS disease causing mutant of MSP domain, in which Thr46 is mutated into 
Isoleucine residue, has been extensively studied in our lab. Study has shown 
that stability and solubility of T46I MSP domain is lower then wild type MSP 
domain. In addition, T46I MSP domain has been found to have lower affinity 
with Nir2 peptide (FFAT motif containing) and ligand binding domain of 
EphA4 receptor (Lua S et al., 2011). Though T46I mutation in MSP domain 
does not abolish the MSP structure and has been found to be associated with 
disease, thus this mutant was used to check its interaction with NS5A.  
We also assessed the binding of D3B to the ALS-causing T46I mutant by 
NMR titrations. HSQC spectra of T46I MSP domain were collected while 
unlabeled NS5A-D3B was titrated at different molar ratios. Remarkably, as 
shown in figure 3.16, even at a molar ratio up to 1:6 (T46I/D3B), only a small 
set of T46I HSQC peaks were found to shift slightly of very small amplitude. 
With the help of NMR sequential assignment, all the perturbed residues were 
identified and CSD tracings were plotted. Residues which were perturbed 







Figure 3.16 Interaction between T46I MSP domain and NS5A-D3B fragment. 
(A) Superimposition of 1H-15N NMR HSQC spectra of T46I MSP (1-125) in 
the absence of (black) and in the presence of unlabeled NS5A-D3B at molar 
ratio 1:4 (green) and 1:6 (red) (B) Residue-specific changes of integrated 1H 
and 15N chemical shifts of VAPB-MSP(1–125) T46I mutant in the presence of 
unlabeled NS5A-D3C at a molar ratio of 1:6 (MSP/D3C). Significantly-shifted 
residues with CSD (chemical shift difference) >1 standard deviation are 





























binding by docking model. Residue 89M and 119L were disappeared in NMR 
titration. As the shift tracings remain highly unsaturated, it is impossible to fit 
out the CSD tracings to obtain Kd values. However, perturbation of very less 
number of peaks and small amplitude of shifted peaks and their nature of 
being highly unsaturated with the addition of NS5A-D3B during titrations, 
indicated that T46I MSP domain has very low binding affinity towards NS5A 
as compared to wild-type MSP domain. Nevertheless, the results clearly 
indicate that T46 does play an important role in binding to NS5A-D3 as also 
reflected by the docking model.  
3.4 Discussion 
Formation of the host membrane associated replication complexes appears to 
be a common property for RNA viruses such as HCV (Tao and Ye, 2010; 
Denison, 2008). Although currently little is known about the structure of the 
complexes, it is anticipated that studies of RNA virus replication machineries 
will have a critical impact on antiviral drug development due to their specific 
roles in virus replication (Tao and Ye, 2010; Denison, 2008). On the other 
hand, despite being reported 8 years ago, there has been no in vitro structural 
and binding characterization on the NS5A-VAP interactions to date. 
Therefore, to bridge the gap, we initiated a systematic investigation on the 
NS5A-VAPB interactions by first dissecting both VAPB and NS5A proteins 
into 14 domains/fragments, followed by extensive structural and binding 
characterizations with heteronuclear NMR spectroscopy which is powerful in 
detecting even very weak binding. Chemical shift perturbation mapping 





the perturbed residues but also facilitated the estimation of residue specific Kd 
values. Our study first time revealed that NS5A interact with MSP domain of 
VAPB protein. Further deeper investigation revealed that C-terminal half of 
NS5A-D3 is indeed capable of binding to VAPB-MSP, with an average 
dissociation constant (Kd) of ~5 µM. 
CD and NMR characterizations (chapter 2) demonstrate that NS5A-D3 of the 
Singapore HCV isolate is also highly disordered without any tight tertiary 
packing and stable secondary structure. Nevertheless, it is active in binding to 
the MSP domain of VAPB, thus demonstrating that it is an intrinsically 
unstructured domain. On the other hand, by analyzing triple-resonance 
heteronuclear NMR spectra, NMR assignments have been achieved, which 
allows identification of helical conformations weakly populated over NS5A-
D3 (chapter 2). Importantly, the NS5A-D3 residues critical for binding to 
VAPB-MSP have been mapped out to be clustered over three relatively 
discrete regions, which is further confirmed by three N-terminally truncated 
fragments of NS5A-D3. NMR titration studies of NS5A-D3 fragments named 
NS5A-D3A, NS5A-D3B and NS5A-D3C showed that all three fragments 
interact with MSP domain but with different affinity.   Remarkably, finally we 
obtain a 41-residue fragment D3B, which has N-terminal 48 residues deleted 
but retains almost the same binding affinity and mode as the 89-residue D3.  
Very surprisingly, even upon binding to the VAPB-MSP domain, D3 peptides 
are still lacking of very tight tertiary packing required to manifest large 
spectral dispersions of the HSQC spectrum. In fact, several years ago, we have 
found a similar phenomenon on a transcriptional activator ApLLP for long-





but intriguingly remains largely unstructured even upon forming a complex 
with DNA (Liu and Song, 2008). Similarly, no high-quality ITC profile could 
be obtained on the ApLLP-DNA interaction. Now it is starting to be 
recognized that this phenomenon in fact exists in a large number of protein-
protein, protein-DNA complexes involved in intrinsically unstructured 
proteins, thus being designated as “Fuzzy Complex” (Tompa P and Fuxreiter 
M, 2008; Fuxreiter M, 2012). The fuzzy or dynamic property for the NS5A-
VAPB complex is most likely to result from the fact that even in NS5A-D3B; 
many residues are not significantly engaged in binding to VAPB-MSP and 
thus remain flexible (figure 3.9B). Here it is tempted to speculate that the 
dynamic feature for the NS5A-VAPB interaction may in fact facilitate the 
functional actions of the HCV RNA replication machinery which is expected 
to undergo dynamic assembly and disassembly. 
Previously, we have determined the crystal structure of the human VAPB-
MSP domain but in the present study, we failed to obtain the co-crystal of the 
MSP-D3B complex, probably due to the relatively-weak binding affinity 
or/and dynamic nature of this fuzzy complex. The crystallization may be 
significantly interfered by the presence of large regions that remain disordered 
in the fuzzy complexes. Nevertheless, by use of NMR spectroscopy, we have 
successfully mapped out both NS5A and VAPB residues key for forming the 
NS5A-VAPB complex, which thus allow the construct of a complex model by 
use of a well-established NMR constraint-based docking procedure. In the 
complex, the NS5A-D3 binds to one side of the MSP fold which was also 
characterized to interact with FFAT-containing peptides. More precisely, three 





and 2 are electrostatically positive while pocket 3 is relatively electrostatically 
neutral.  
Interestingly, ALS-causing mutation P56S is located in the pocket 1 while 
T46I sites in between pocket 1 and pocket 2. Binding study of T46I MSP 
domain with NS5A-D3B showed perturbation of lesser number of residues 
with small amplitudes. These perturbations were never reached to the 
saturated condition which indicates that binding affinity of mutant MSP is 
much lower than wild type in binding with NS5A-D3B which is shown in the 
form of model in figure 3.17B.  
 
    
 
Figure 3.17 Model showing the interaction of NS5A and VAPB on the ER 
membrane. (A) Wild type MSP domain interacting with NS5A. (B) T46I 








As shown in model (figure 3.17), studies in this section have demonstrated 
that NS5A protein of HCV binds to the MSP domain by its C-terminal 41 
residues and ALS causing mutation in MSP domain reduced this interaction 
by many fold.  In the future, it would be of significant interest to explore the 
design of peptides/small molecules to target the intrinsically unstructured 
NS5A-D3 or/and its well-folded binding partner, VAPB-MSP as previously 
demonstrated on other systems. Extensive and systematic study of the VAPB 
and NS5A interaction in this section clearly showed that NS5A interacts with 
MSP domain, which modifies the previous belief that coiled coil domain of 
VAPB interacts with NS5A ((Tu et al., 1999; Hamamoto et al., 2005).  
3.5 Conclusion 
ER membrane protein VAPB was identified as anchor during the replication 
complex formation by the interaction with NS5A protein of HCV. 
Nevertheless, precise information of this interaction was unknown. Therefore, 
our study in this chapter, have demonstrated a systematic study which 
describes that NS5A binds to MSP domain of VAPB by its C-terminal 41 
residues with the dissociation constant of ~5 µM. This study first time gives 
the deeper insight into the interaction between NS5A and VAPB and open up 
another direction for new antiviral against HCV infection. The “fuzzy 
complex” between MSP and NS5A-D3B might be very important for diverse 















Characterization of VAPB-Eph receptor 


















Characterization of VAPB-Eph receptor Interaction and its 
competition with NS5A 
 
4.1 Introduction  
The erythropoietin-producing hepatocellular carcinoma (Eph) receptors, which 
belong to transmembrane receptors tyrosine kinase (RTK) family, have been 
implicated in various cellular functions such as cell signaling and development 
(Pasquale EB, 2008). Two types of Eph receptors have been identified in 
human genome which includes: nine EphA receptors, which promiscuously 
bind to five GPI-linked ephrin-A ligands; and five EphB receptors that bind to 
three transmembrane ephrin-B ligands. In the developing nervous system, Eph 
receptors and ephrins are highly expressed and play essential role in the 
establishment of neuronal connectivity. Therefore, it was speculated that Eph 
receptors signaling in expressing cell might be crucial in mediating the 
susceptibility of motor neurons in ALS (Amyotrophic lateral sclerosis) 
patients. In fact, Tsuda et al. demonstrated that the N-terminal MSP domain of 
VAPB protein is cleaved and secreted from cells by unknown mechanism and 
then interact with EphA4 receptor (Tsuda et al., 2008). Two point mutation 
P56S and T46I in the MSP domain have been identified to cause ALS disease 
probably by misfolding of wt-VAPB and triggering VAPB protein aggregation 
(Kanekura et al., 2006; Chen et al., 2010). Reports have suggested that these 
two mutations also have a unique dominant negative effect on co-expressed 
wt-VAPB or normal cells expressing wt-VAPB. Therefore, these two 





from the cell and thus prevent its interaction with Eph receptors. Possibly, 
reduced signaling between VAP-Eph receptor may be responsible for the ALS 
pathogenesis. Investigation of this interaction between MSP domain and 
EphA4 receptor has been characterize in our lab (Lua et al., 2011). However, 
interactions with other Eph Receptor have not been investigated. 
Despite of intense research, the underlying mechanism and etiology of 
sporadic ALS pathogenesis remains poorly understood. However, because of 
the selective vulnerability of motor neurons to certain viruses, viral etiology of 
amyotrophic lateral sclerosis (ALS) has been hypothesized for over decades. 
In recent years, ALS pathogenesis has been reported to be associated with 
human immunodeficiency virus type 1 (HIV) infection (Verma A and Berger 
JR, 2006). There are many clinical evidences which suggest this association of 
ALS with HIV but their relationship is not known. It was observed in a recent 
report that a chronic HCV patient surprisingly developed an ALS-like 
syndrome (Akhvlediani T et al., 2009; Bastos AF et al., 2011). These reports 
triggered us to compare the binding interface of MSP domain with Eph 
receptor and NS5A-D3B. As in one hand, two point mutations in MSP 
domain, which leads to the aggregation of VAPB protein, have been found to 
cause ALS pathogenesis. These mutations also inhibit the secretion of MSP 
domain and thereby prevent the interaction of MSP domain with Eph receptor 
and facilitate the onset of ALS disease. On other hand, in our findings, NS5A 
protein of HCV virus has been identified to interact with MSP domain. This 
interaction facilitates and possibly regulates the replication of HCV genome 





receptor and NS5A on MSP domain can give an insight in to the relation of 
ALS with HCV infection. 
To pursue this objective, firstly all the Eph receptors which have been 
characterize in our lab were used for binding studies with MSP domain. For 
binding studies NMR chemical shift perturbation method was used as it is a 
powerful tool for binding studies. Perturbed residues of MSP domain were 
identified and map back to the structure of MSP domain. After that 
competition binding experiments were performed to check whether Eph 
receptor binding can compete with the binding of NS5A-D3B with MSP 
domain. It is been hypothesize that if Eph receptor could not compete with the 
NS5A-D3B binding with MSP domain, it suggests that during the infection of 
HCV, VAPB proteins are more involved in HCV replication and preventing 
the interaction with Eph receptor, and leading to the ALS like syndrome.  
4.2 Methods  
4.2.1 Expression and purification of Eph receptors  
Sequences encoding the ephrin binding domain of Eph receptors (EphA2, 
EphA3, EphA4, EphA5, EphA6, EphA7, EphA8 receptor) were cloned into 
His-tag containing pET vectors. Cloned vectors were sequenced and 
transformed into Rosetta gami DE3 competent cells with the same method 
mentioned earlier in chapter 2. After transformation cells were plated on LB 
plate containing ampicillin, kanamycin, tetracycline, and chloramphenicol 
antibiotics. Single colony was inoculated in 10 ml LB media containing 





transferred to 1L LB media and induced with 0.3mM IPTG when OD600 
reached to 0.6. After the addition of IPTG, culture was incubated with shaking 
at 20°C for overnight (16 hrs). Next day, cells were harvested and then 
resuspended into PBS, 10 mM imidazole containing pH 7.4 lysis buffer. After 
lysis supernatant was allowed to bind with Ni-NTA beads for 1 h with gentle 
shaking at 4°C. After binding, washing step was performed; this was followed 
by on column His-tag cleavage by Thrombin enzyme at room temperature for 
14 hrs. Cleaved protein was eluted in PBS pH 7.4 buffer and further purified 
by size exclusion chromatography column (superdex 200). Eluted protein from 
superdex column was run on SDS-PAGE to check the purity of protein. Pure 
protein fractions were pooled together and concentrated by using Amicon.   
4.2.2 Circular Dichroism experiments 
To collect the far UV CD spectra of all available Eph receptor same procedure 
was used which has been explained in chapter 2. 20 µM protein samples in 2 
mM phosphate buffer pH 6.8 were used for CD spectra collection.  
4.2.3 NMR titrations for interaction studies 
To study the interaction chemical shift perturbation mapping was chosen due 
to its high sensitivity for weak interactions. Although, both MSP domain and 
Eph receptors have well dispersed HSQC spectra, 15N-labeled MSP domain 
was used to titrate with all Eph receptors. Thus, HSQC spectra of 50 µM 15N-
labeled MSP domain were collected while unlabeled Eph receptor was titrated 
at different ratios. All disappeared and shifted peaks in the HSQC spectra were 





the MSP structure and then compared with the binding interface of EphA4 
receptor (Lua S et al, 2011) and NS5A-D3B (Gupta G et al., 2012) on MSP 
domain.  
For competition experiment, initially 15N-labeled MSP domain was saturated 
by unlabeled NS5A-D3B peptide with the molar ratio of 1:4. After saturation 
unlabeled EphA4 receptor was added at different ratios till 1:12.  HSQC of 
15N-labeled MSP domain after saturation with NS5A-D3B was superimposed 
with the HSQC at different ratios of EphA4 receptor and perturbed peaks were 
analyzed. 
4.3 Results  
4.3.1 Expression and Purification  
Expression of all Eph receptors on SDS-PAGE revealed their successful 
expression in bacterial system. Expressed Eph receptors were first purified by 
affinity chromatography and then His-tag was removed successfully. In gel 
filtration column all Eph receptors were eluted as single peak. All the 
purification was done in oxidizing conditions so that disulphide bonds remain 
intact.  However, MSP domain was purified in reducing condition with the 
similar method mentioned earlier. In all Eph receptors, EphA3 receptor would 
not be used for further studies due to its precipitation during concentration. 
Obtained concentration of EphA3 receptor after precipitation was too less for 
interaction studies with NMR titration. Therefore, EphA2, EphA4, EphA5, 
EphA6, EphA7and EphA8 receptors were used for further studies. Here 








                
 
Figure 4.1 Expression and purification profile of EphA8 on SDS-PAGE. (A) 
Large scale (1lit) expression profile of EphA8 receptor at 0.3 mM IPTG 
concentration. Arrow shows the band of recombinant protein. M: Precision 
Plus Protein™ Standards, BI: before induction whole cells, P: pellet fraction 
after induction, S: Supernatant after induction, B: Ni-NTA beads after binding 
with supernatant, F: Flow through, W: wash, E: Elute after cleavage. (B) 


















4.3.2 Secondary structure characterization by Using CD 
Extensive studies on the function and structure of Eph receptors have been 
done by many groups in the world. It is well established that Eph receptors 
have well folded structures with higher β strands in their secondary structure. 
To characterize the secondary structures of purified Eph receptors from 
bacterial system, far-UV circular dichroism spectra were collected. CD 
spectrum of EphA2 receptor shows three signals – positive signal at 196 nm, 
negative signal at 212 nm and 228 nm. Positive signal at 196 nm and minima 
at 212 nm clearly indicated the presence of β sheet in the secondary structure 
of EphA2 (figure 4.2). CD spectra of all other Eph receptors were also similar 
to the spectra of EphA2 (figure 4.2, 4.3) with the positive signal at 196 nm, 
minima at 212 nm and 228 nm. CD structure characterization of Eph receptors 
indicated the presence of β sheet secondary structures and well folded nature 
of purified protein. These observations are consistent with the previous reports 
on the structure of Eph receptors. However, CD spectrum of EphA6 showed 
lesser signal at 228 nm (figure 4.2D) whereas EphA8 showed more signal at 
228 nm as compare to other receptors (figure 4.3B). Signal at 228 nm in the 
CD spectrum may arise from the Bb band absorbance of the indole-side chain 
of tryptophan (Woody, 1994). 
Basically, preliminary structure characterization by using far-UV CD spectra 
clearly indicated that all the purified Eph receptors were in their native 
structures in which very high proportion of β strands were demonstrated. 









Figure 4.2 Far-UV CD spectra of Eph receptors_a (A) Far-UV CD spectrum 
of 20µM protein concentration of EphA2 receptor in 2 mM phosphate buffer, 
pH 6.8 at 25 °C. (B) Far-UV CD spectrum of 20µM protein concentration of 
EphA4 receptor in 2 mM phosphate buffer, pH 6.8 at 25 °C. (C) Far-UV CD 
spectrum of 20µM protein concentration of EphA5 receptor in 2 mM 
phosphate buffer, pH 6.8 at 25 °C. (D) Far-UV CD spectrum of 20µM protein 











































































Figure 4.3 Far-UV CD spectra of Eph receptors_b (A) Far-UV CD spectrum 
of 20µM protein concentration of EphA7 receptor in 2 mM phosphate buffer, 
pH 6.8 at 25 °C. (B) Far-UV CD spectrum of 20µM protein concentration of 



































4.3.3 Interactional studies of Eph receptors with MSP domain 
As chemical shift perturbation method is quite powerful to study the 
interactions, we also used this method to gain the molecular details for the 
binding interaction between Eph receptors and MSP domain. HSQC NMR 
titrations were used to study the chemical shift perturbation during 
interactions. Firstly, we monitored the change of HSQC spectrum of 15N-
labelled MSP domain upon the gradual addition of the unlabeled EphA4 
ligand binding domain. As shown in figure 4.4, addition of EphA4 induced 
significant disappearance of set of peaks as well as gradual shift of few peaks. 
These perturbation of HSQC peaks clearly indicated that indeed MSP domain 
interacts with EphA4 receptor (figure 4.4A). Subsequently, residues 
corresponding to the disappeared and shifted HSQC peaks were identified 
with the help of NMR sequential assignment of MSP domain. After 
identification of disappeared and shifted residues, they were map back to the 
structure of MSP domain (Shi J et al., 2010). On the MSP structure, the 
significantly-perturbed residues were found to be located on E-F loop and 
several β-strands: C-strand carrying Thr46, F- and G-strands. However, 
residue on A-B loop, C-D loop and A, D and E strands were also found to be 
disappeared during NMR titrations. Moreover, few residues on F-G loop were 
also shifted during the NMR titrations at higher molar ratios (figure 4.4B), 
whereas no perturbations were identified on B strand of MSP domain. 
Interestingly, disappearnce of Thr46 during the titration indicated its direct 
involvement with the interaction with EphA4. These results were found to be 





Subsequently, interactions of MSP domain with other Eph receptors were also 
tested by NMR titrations. 15N-labeled MSP domain was titrated with unlabeled 
ligand binding domain of EphA2, EphA5, EphA6, EphA7, EphA8 receptors. 
Titration results with Eph receptors showed similar perturbation pattern of 
HSQC peaks of MSP domain as observed in case of EphA4 receptor. Same set 
of HSQC peaks were disappeared and shifted while unlabeled Eph receptors 
were added (figure 4.5 and 4.7). Therefore it can be concluded that all the Eph 
receptors indeed bind to the MSP domain of VAPB protein. However, further 
investigation described that saturation of perturbation of HSQC peak was at 
different ratios with different Eph receptors. Perturbations of HSQC peak of 
MSP domain with the addition of EphA2 and EphA5 were almost saturated at 
molar ratio of 1:2. These two receptors triggered maximum number of MSP 
peaks disappearnce (figure 4.5A and B). With the help of NMR sequential 
assignment, all the disappeared and shifted MSP residues were identified and 
map back to the MSP domain structure. Similar to EphA4, significantly-
perturbed residues were located on E-F loop and β-strands: C-strand carrying 
Thr46, F- and G-strands (figure 4.6A and B). Moreover, EphA2 and EphA5 
binding with MSP domain triggered perturbation of few other nearby residues 
which were not perturbed in case of EphA4 receptor. Unlike EphA4, residues 
of B- strand of MSP domain were also perturbed in this case. These results 
clearly indicated that MSP domain interacts with Eph receptors with the 





                       
Figure 4.4 Interaction of MSP domain with EphA4. (A) 15N-1H HSQC of MSP domains in the absence (blue) and presence of the EphA4 ligand 
binding domain at molar ratio1:6 (red) (MSP/EphA4). Arrows are indicating the disappeared HSQC peaks. (B) The MSP structure with the 
perturbed residues mapped back for the interactions between the WT-MSP and EphA4. Blue is to indicate residues with unperturbed HSQC 
















Table 4.1 List of perturbed residues of MSP domain during the interaction 
with EphA4 and EphA2 
MSP interaction with EphA4 MSP interaction with EphA2 
Disappeared  
residues 
Shifted residues Disappeared  
residues 
Shifted residues 
Q6 16L Q6 4V 
V7 23T V7 5E 
18F 54V 18F 8L 
20G 55R 20G 9S 
45K 77D 43K 10L 
46T 78Y 44V 16L 
48A 82E 45K 22F 
53C 84S 46T 23T 
72M 91Q 48A 28T 
73L 101D 72M 30L 
74Q 106W 73L 31K 
79D 110K 74Q 50R 
89M 116D 79D 53C 
90V 120R 89M 55R 
92S 121C 90V 71V 
117S 122V 92S 76F 
119L  115M 77D 
  117S 78Y 
  119L 79D 
   82E 
   91Q 
   101D 
   103E 
   104A 
   106W 
   110K 
   112E 
   114L 
   116D 
   118K 
   120R 
   121C 
   122V 








Figure 4.5 Identification of MSP domain interaction with EphA2 and EphA5 
ligand binding domain. (A) 15N-1H HSQC of MSP domains in the absence 
(blue) and presence of the EphA2 ligand binding domain at molar ratios 1:1 
(cyan) and 1:2 (red) (MSP/EphA2). (B) 15N-1H HSQC of MSP domains in the 
absence (blue) and presence of the EphA5 ligand binding domain at molar 















Figure 4.6 Mapping of binding surface on MSP with the binding with EphA2 receptor. (A) and (B)The MSP structure with the perturbed 
residues mapped back for the interactions between the WT-MSP and EphA2. Magenta color is to indicate residues with unperturbed HSQC 
peaks, while green and blue color is for residues with shifted and disappeared HSQC peaks respectively. Two point mutation P56 and T46 


















Figure 4.7 Identification of MSP domain interaction with EphA ligand binding domain. (A) 15N-1H HSQC of MSP domains in the absence 
(blue) and presence of the EphA6 ligand binding domain at molar ratio 1:6 (red) (MSP/EphA6). (B) 15N-1H HSQC of MSP domains in the 
absence (blue) and presence of the EphA7 ligand binding domain at molar ratio 1:6 (red) (MSP/EphA7). (C) 15N-1H HSQC of MSP domains in 
















        
Figure 4.8 NS5A competes with EphA4 in binding with MSP. (A) Superimposition of 1H-15N NMR HSQC spectra of VAPB-MSP (1–125) 
saturated with the pre-existence of D3A at a molar ratio of 1:2 (MSP/D3A), in the absence of (blue) and in the presence of 181-residue EphA4 
ligand binding domain at a molar ratio of 1:10 (red) (MSP/EphA4). Significantly-shifted residues are labeled. (B). Crystal structure of the human 








Figure 4.9 Fitting of chemical shift tracings to obtain dissociation constants (Kd) of EphA2 interaction. Experimental (dots) and fitted (lines) 
values are shown for the integrated 1H and 15N chemical shift changes of three representative residues: 78Y (A), 79D (B) and 53C (C)  of 

































Figure 4.10 Fitting of chemical shift tracings to obtain dissociation constants (Kd) of EphA5 interaction. Experimental (dots) and fitted (lines) 
values are shown for the integrated 1H and 15N chemical shift changes of three representative residues: 78Y (A), 79D (B) and 53C (C)  of 






























NMR titrations with ligand binding domain of EphA6 (figure 4.7A), EphA7 
(figure 4.7B) and EphA8 (figure 4.7C) shown almost same pattern of 
perturbation of HSQC peak of MSP domain that was observed in case of 
EphA4 binding. Likewise, peak perturbations did not even saturated at molar 
ratio 1:6. Taken together all the titration results, all the Eph receptors do bind 
to the MSP domain of VAPB protein, however, the binding affinity and 
dynamics of complex might differ according to the receptor.  
Previous published reports have suggested that estimation of binding affinity 
and complex structure of MSP with EphA4 could not be achieved due to its 
complex binding mode (Lua S et al., 2011). However, we tried to obtain the 
dissociation constant of the interaction of EphA2 and EphA5 receptors with 
MSP domain by fitting the chemical shift deviation values. As mentioned 
earlier, most of the HSQC peaks of MSP domain disappear upon the addition 
of Eph receptors, however, addition of increasing ratio of EphA2 and EphA5 
receptors triggered the increasing shifts of HSQC peaks of MSP domain.   
Therefore, we identified the shifted peaks and fitted them using Datafit 
software to obtain the dissociation constant of binding. Interestingly, the 
average dissociation constant of EphA2 was calculated as ~8.7 µM, whereas 
the Kd of EphA5 receptor interaction with MSP domain was estimated as 
~62.8 µM (figure 4.9 and 4.10).    
4.3.4 NS5A competition with EphA4 in binding VAPB 
In chapter 3, we have already described that HCV protein NS5A interact with 
the VAPB protein which is an ER membrane host cell protein. Further detailed 





with C-terminal region of NS5A named as NS5A-D3A. With the use of NMR 
titrations and molecular docking complex model of NS5A-D3B and MSP 
domain, it has been reveled that the NS5A-D3B peptide is able to occupy the 
MSP surface regions which are also critical for binding to all the Eph 
receptors including EphA4. This investigation prompted us to further 
exploration into competition of these interactions. To confirm this, we first 
saturated the VAPB-MSP (1–125) by addition of unlabeled NS5A-D3B at a 
molar ratio of 1:4 (MSP/D3B) as our previous titration experiment already 
demonstrated that no further perturbations were observed during to the binding 
of D3B after at molar ratio 1:3.  
Subsequently, the EphA4 ligand-binding domain (LBD) was gradually titrated 
into this mixture. Unlike the previous observation in the result section that 
addition of EphA4 LBD to VAPB-MSP even at a molar ratio of 1:2 started to 
trigger peak shift and disappearance of the MSP residues, in the pre-existence 
of D3B peptide, only several MSP peaks were observed to shift slightly when 
the molar ratio reached 1:10 (MSP:EphA4) (figure 4.8A). With the help of 
MSP domain sequential assignment residues corresponding to these shifted 
peaks were identified and mapped back to the MSP domain structure. 
Identified shifted residues were F42, V90, S92, W106, D116, and L119. 
Interestingly, the shifted residues are all located on the MSP surface perturbed 
by both D3B and EphA4 (figure 4.8B). These results thus suggest that in the 
pre-existence of D3B, EphA4 at low concentration is not able to bind to 
VAPB-MSP but at high concentrations, EphA4 will start to displace the D3B 





that NS5A does compete with EphA4 in binding with VAPB-MSP at lower 
ratios of Eph receptor.  
4.4 Discussions  
Study published in 2008, revealed the significance of the interaction between 
ligand binding domain of Eph receptor and cleaved and secreted MSP domain 
of VAPB (Tsuda et al., 2008). Several other studies have also demonstrated 
that Eph receptors regulate the survival of motor neurons in cell culture 
(Magal et al., 1996) and influence proliferation and apoptosis in the adult 
mammalian Central Nervous System (Ricard et al., 2006). Therefore, it was 
concluded that signaling through the interaction between Eph receptor and 
MSP domain of VAPB play role in the motor neuron survival or muscle 
function. Two identified point mutations P56S and T46I in MSP domain 
which leads to the accumulation of VAPB in the ER have been found be the 
cause in the patients with sporadic ALS. Extensive research has also 
demonstrated that P56S mutant leads the aggregation of wild type protein in 
the cells. Therefore, the mechanism of ALS disease due to the point mutation 
in VAPB protein was proposed in which these mutations lead to the reduced 
signaling through the interaction of secreted MSP domain and Eph receptors. 
This leads to the higher activity of Eph receptor through the interaction with 
ephrin. Recent report published in 2012 has showns that inhibition of EphA4 
receptor by genetic mutation or pharmacological compound can increase the 
disease onset time in rodent ALS model and rescue the degeneration of motor 
neuron in zebrafish ALS model (Van Hoecke et al., 2012).     
Moreover, various persistent viral infections by enterovirus and retrovirus 





ALS (Rowland et al., 2001; Verma et al., 2006). However, the mechanism of 
their association with ALS disease is unknown. In the recent study, HCV 
infection also has been found to be associated with ALS disease. In this 
section of study, we have investigated first time an association between ALS 
and HCV infection. 
Secondary structure characterizations of recombinantly expressed Eph 
receptors by using NMR and Circular Dichroism described their well folded 
nature in solution.  In the far UV CD spectra of all Eph receptor, positive 
signal at 196nm and negative signal at 212nm demonstrated their very similar 
secondary structure composition with β strands in very high proportion. 
However, intensity of signal at 228nm was different with different Eph 
receptors. This indicated some difference in the packing of LBD of various 
Eph receptors. Conclusively, CD characterization of expressed Eph receptors 
in E coli demonstrated their compact β sheet containing structures which is 
consistent with all the previous structural studies of Eph receptors. 
To compare the binding surface on MSP domain, all the Eph receptors 
including EphA2, EphA4, EphA5, EphA6, EphA7 and EphA8 were used for 
NMR titrations. MSP domain’s perturbation pattern of triggered by EphA4 
binding revealed identical binding surface with the previously published study 
by Lua et al in our lab. However, many extra residues which were perturbed in 
our study were found to be located near to the identified binding surface on 
MSP structure (figure 4.4B). Basically, residues on all the β strands except B-
strand were perturbed in NMR titration with EphA4. In addition, binding 
surface was proposed to be on C, F, G-strand and E-F loop of MSP structure. 





revealed that all the residues of binding pocket were disappeared in our NMR 
titrations. Due to the disappearnce of HSQC peaks in the titration, binding 
affinity of perturbed residues could not calculated by NMR. Interestingly, 
binding surface of EphA4 on MSP domain has also been found to overlap with 
the Nir2 peptide (FFAT motif containing) binding. Similarly, NMR titrations 
of MSP with other Eph receptors showed similar perturbation patterns. This 
indicates that all the tested ligand binding domain of Eph receptors interact 
with MSP domain of VAPB. However, some extra residues perturbation and 
saturation at very low molar ratios in case of EphA2 and EphA5 has indicated 
that these receptors possibly interact with MSP domain with different affinity 
or dynamics. Therefore, further investigation is required to shed light on this 
aspect. Due to the disappearance of HSQC peaks upon the addition of Eph 
receptors, chemical shift tracings could not be used to fit the data to obtain the 
Kd values. Nevertheless, shifted residues of MSP domain during the 
interaction with EphA2 and EphA5 allowed us to estimate dissociation 
constant by using chemical shift tracings. According to the dissociation 
constants values, the binding affinity of EphA2 receptor (~8.7 µM) with MSP 
was estimated 7 times higher than EphA5 receptor (~62 µM). As these values 
were calculated on the basis of shifted residues, therefore, overall 
thermodynamic parameter of binding of each receptor to MSP domain by 
using ITC can provide a better understanding of Eph receptor binding with 
MSP domain.   
In the chapter 3, we have demonstrated that C-terminal region of NS5A 
interacts with the MSP domain of VAPB protein. Strikingly, docking model of 





on MSP domain overlap with the binding region with Eph receptors on 
VAPB-MSP, and ALS-causing mutation T46I dramatically abolishes the 
binding affinity of the MSP domain to NS3A-D3. Therefore, in the NMR 
titration experiment, addition of EphA4 receptor in MSP domain saturated 
with NS5A-D3B did not compete with NS5A at lower molar ratios. However, 
perturbation of few residues (at higher molar ratios) which were common in 
the binding surfaces with NS5A-D3B and Eph receptors on MSP structure. 
This observation indicates that at higher concentration Eph receptor can 
compete with NS5A for binding with MSP. These studies may rationalize a 
recent report that a chronic HCV patient surprisingly developed an ALS-like 
syndrome (Akhvlediani et al., 2009; Bastos et al., 2011). We speculate here 
that in some chronic HCV patients, the VAPB or cleaved MSP are more 
involved in interaction with NS5A to facilitate the replication and other 
important functions required for HCV life cycle. However, in some cases 
NS5A protein may also abnormally accumulate in the cell.  Consequence of 
both or either of condition may perturb the physiological functions of the VAP 
proteins, in a similar way as the T46I mutation, which does not severely 
disrupt the MSP structure but considerably reduces the binding affinity to 
EphA4 (Lua et al., 2011). Subsequently, perturbation of normal function of 
VAPB protein may lead to the reduced signaling through MSP-Eph receptor 
interactions thereby enhancing the activity of Eph receptor through ephrin 
binding. Recent study by Van Hoecke et al. also revealed that ALS patients 
have higher activity or expression of EphA4 receptor and inhibition of EphA4 
activty by genetic or pharmacological means can modulate the 






Thus, in background of HCV infection, VAPB protein or MSP domain is 
involved in persuing the HCV genome replication on the replication complex. 
This condition may reduce the secretion of MSP domain outside the cell for 
the interaction with Eph receptor. Now, ephrins interact with Eph receptor and 
increase the activity of Eph receptor. Higher activity of Eph receptor leads to 
the larger size of motor neurons which are more susceptible for degeneration. 
Hence, the presence of HCV infection can develop ALS like syndrome. In 
addition, our present results strengthen our previous speculation that the 
VAPB-MSP domain might be a key convergent point for signaling pathways 
important for ALS pathogenesis (Lua et al., 2011).  
4.5 Conclusion  
The Amyotrophic lateral sclerosis (ALS) has been described as most common 
form of motor neuron disease which is characterize by rapid and degenerative 
compromise of motor neurons. Besides lot of study on ALS disease, the 
etiology or the cause of this disease is still unknown. Here, in our study in this 
chapter, first time shaded light on the association of ALS with HCV infection. 
We have proposed a molecular mechanism in which presence of HCV 
infection can lead to the development of ALS-like syndrome by reduced 
signaling through Eph receptor-MSP interaction due to the accumulation of 
NS5A. However, further in vivo investigations are required to test our 
hypothesis. We have also studied the interaction between MSP domain and 
Eph receptors which showed that all the Eph receptors binds to similar surface 































Characterization of NS5B- VAPB interaction 
5.1 Introduction 
Since the identification of hepatitis C virus, extensive research have been 
carried out to understand the biology of virus and to develop antiviral drugs. 
The RNA-dependent RNA polymerase (RdRp) activity of nonstructural 
protein 5B (NS5B) was first demonstrated by Behrens et al in 1996. Serine 
protease activity of NS3/NS4A complex generates the mature RNA 
polymerase from the HCV polyprotein. This enzyme is essential for the viral 
life cycle in the host cell. In addition, uninfected host cells do not contain any 
close structural homologues of this enzyme. Therefore, it was identified as a 
potential target for antiviral investigations (De Francesco et al., 2003).NS5B 
play multiple roles during the viral life cycle by interacting viral proteins and 
host proteins. Due to high rate of mutation during the viral life cycle, targeting 
host –viral protein interaction for antiviral development has become a 
potential approach in recent years.  
To study the interaction of NS5B with VAPB protein in vitro recombinant 
expression method was chosen. Recombinant expression of full length of 
NS5B was firstly achieved by using baculovirus expression system (Behrens 
et al., 1996) and then in E.coli (Yuan et al., 1997). However, these purified 
full length proteins were having fusion tag which might interface with the 
enzymatic activity. Moreover, poor solubility of full length NS5B and 
requirement of high salt, detergent and glycerol hampered its purification. 





enhances the solubility of NS5B without tag and its successful purification 
(Ferrari et al., 1999; Tomei et al., 2000). The C-terminal 21 residues 
correspond to a very hydrophobic sequence, which helps NS5B localization on 
to the membrane during replication complex formation. Enzymatic 
characterization of truncated NS5B revealed that its RdRp activity was 
comparable to the previous reports. Therefore, NS5BΔ21 construct was used 
to solve the crystal structure at 1.9Å resolution (Lesburg CA et al., 1999). 
Structural characterization showed that the structure of the catalytic domain 
contains 531 residues folded in the characteristic fingers, palm, and thumb 
subdomains. Therefore, we decided to clone two NS5B constructs: NS5BΔ21 
and NS5BΔ60 constructs to study the interaction with VAPB. NS5BΔ21 was 
cloned in two ways: N-terminal His-tag and C-terminal His-tag. After 
molecular cloning and expression, NMR titrations were used to study the 
interaction between VAPB and NS5B. 
5.2 Materials and methods 
5.2.1 Vector construction 
DNA sequence encoding NS5B were obtained by using pXJ40flag-NS5B 
plasmid (from Dr. Tan Yee Joe), which was having NS5B insert from subtype 
1b HCV-S1 isolate. The primers were designed to amplify NS5BΔ21 (C-
terminal 21 residues truncation) with restriction sites. BamH1 and Xho1 
restriction sites containing primers were used to clone NS5BΔ21 with N-
terminal His-tag in modified pET32a vector (pET32a-NS5BΔ21). Constructs 
NS5BΔ21 and NS5BΔ60 were cloned into pET22b vector with C-terminal His 





were used in the primer for cloning into pET22b vector. Cloning of all the 
constructs were done by method mentioned earlier in chapter 2. Sequence of 
cloned NS5B was confirmed by DNA sequencing.  
5.2.2 Protein Expression and Purification 
Recombinant plasmids (pET32a-NS5BΔ21, pET22b-NS5BΔ21, pET22b-
NS5BΔ60) were transformed into BL21 (DE3) star competent cells and 
obtained single colony was inoculated into 10 ml LB media containing 
ampicillin (final concentration of 100μg/ml) along with 0.5% filter sterilized 
glucose and kept for shaking at 37°C. This seed culture was used to inoculate 
1L LB media containing 100μg/ml ampicillin and 0.5% filter sterilized 
glucose and kept for shaking at 37°C and 200 rpm. When the OD600 of this 
culture reached to 0.6, induction was done with IPTG at final concentration of 
0.4mM. After IPTG addition culture were kept for shaking for 16 hours at 
20°C and 180 rpm. Subsequently, cells were harvested by centrifugation at 
6000 rpm using Beckman JA 8.1 rotor and disrupted by sonication in lysis 
buffer of pH 8.0 (50mM Tris-HCl, 300mM NaCl, 0.1% octyl-β-glucoside, 
10mM MgCl2, 20mM imidazole and protease inhibitor tablet of Roche) at 
4°C. Supernatant was obtained by centrifuging the lysate and allowed to bind 
with pre-equilibrated Ni-NTA beads with lysis buffer for 1 hour.   The resin 
was washed with buffer A (50mM Tris-HCl, 150mM NaCl, 20mM imidazole, 
pH 8.0). The protein elution was performed using buffer B (50mM Tris-HCl, 
500mM NaCl, 250mM imidazole, 10mM β-ME, pH 8.0). 
After Ni-NTA affinity chromatography, buffer exchange of eluted protein was 





A. Dialyzed sample was further purified by using HiTrap Heparin column (GE 
healthcare). After binding of the sample to the column, protein was etuted with 
the increasing gradient of  buffer B containing 20mM Tris, 2M NaCl and 
10mM β-ME at pH 7.5. For NMR experiments, NS5B protein was later 
dialyzed in 10mM phosphate buffer pH 6.8 containing 10mM DTT. The purity 
of protein was determined by running them on 12% SDS-PAGE. The 
concentration of protein was determined by measuring the absorbance at 280 
nm as mentioned in chapter 2. 
5.2.3 CD experiments  
Secondary structure characterization of purified protein was performed by 
collecting the far-UV CD spectrum. CD samples were prepared at 20 µM 
concentration in 5 mM phosphate buffer of pH 6.8. Far-UV CD spectra were 
collected from 190 nm to 260 nm wavelength at 25°C using Jasco J-810 
spectropolarimeter equipped with a thermal controller. A final CD spectrum 
was obtained by averaging data from three independent scans. 
5.2.4 NMR titration experiments  
For NMR experiments, 15N-labeled VAPB and MSP domain were prepared by 
growing cells in M9 medium according to the earlier mentioned method. All 
the NMR experiments were performed in 10mM phosphate buffer pH 6.8 at 
room temperature. 10% D2O was added to the samples prior to acquire spectra 
for spin lock. For NMR titrations, HSQC spectra of 50 µM 15N-labeled VAPB 





molar ratios. Acquired spectra were superimposed to identify the perturbed 
HSQC peaks.  
5.3 Results  
5.3.1 Expression and purification of truncated NS5B 
To study the interaction between NS5B and VAPB, various truncated NS5B 
were cloned successfully into expression vectors. C-terminal 21 residue 
truncated NS5BΔ21 DNA was cloned into pET vectors (pET32a and pET22b) 
with N-terminal His-tag and C-terminal His-tag respectively. NS5BΔ60 DNA 
was also successfully cloned in pET22b with C-terminal His-tag. 
Subsequently, expression of all three truncated NS5B was achieved using 
0.5% glucose addition in the media. Purification of expressed NS5BΔ21-NTH 
(N-terminal His-tag) and NS5BΔ21-CTH (C-terminal His-tag) was done by 
using Ni-NTA affinity chromatography followed by Heparin Affinity 
chromatography. Purity of samples at each step were monitored by running on 
12% SDS-PAGE. On SDS-PAGE gel, NS5BΔ21-NTH and NS5BΔ21-CTH 
band were observed between 50kDa and 75kDa band of protein marker (figure 
5.1B). Elution of first affinity chromatography was diluted before dialysis to 
avoid precipitation during dialysis. NS5B, RNA polymerase, which carries 
positive charge, can bind to heparin matrix, therefore heparin affinity 
chromatography was used for further purification. In the elution profile 
NS5BΔ21-CTH and NS5BΔ21-NTH both proteins were eluted in same 
gradient range (20% - 60%) of buffer B. Moreover, the behavior of both 






        
Figure 5.1 Expression and Purification of NS5BΔ21 protein. (A) PCR product 
of NS5B  Δ21 construct run on 1% agarose gel. (B) Ni-NTA affinity 
purification profile of NS5BΔ21-CTH on 12% SDS-PAGE. M: Precision Plus 
Protein™ Dual-Colour Standards, FT: Flow through, W: wash, B: Ni-NTA 
beads after binding with supernatant, E1: Elution1, E2: Elution2, E3: Elution3, 
E4: Elution4. Arrow shows the band of recombinant protein. (C) Hi-trap 
Heparin column chromatography elution profile of NS5BΔ21-CTH by using 
isocratic gradient of buffer B (20mM Tris, 2M NaCl and 10mM β-ME pH 
7.5). Arrow indicates the eluted peak of NS5BΔ21-CTH. Black bar indicates 










































CTH protein, lot of precipitation was seen during purification which indicated 
its poor solubility. Removal of salts for NMR experiments, leads to the 
precipitation during dialysis and concentration of NS5BΔ60-CTH protein. 
Therefore, due to the poor solubility, we could not do further structural 
characterization of this protein.  
5.3.2 Secondary structure characterization of truncated NS5B 
After purification of truncated constructs of NS5B, their secondary structure 
characterization was achieved by using CD. Far-UV CD spectra of both 
NS5BΔ21-CTH and NS5BΔ21-NTH showed the sign of well folded protein. 
In the far-UV CD spectra, presence of minima at 210 and 220 nm and positive 
signal at 192 nm clearly indicated the presence of high content of α-helix in 
compared to β-strands in the secondary structure of NS5B (figure 5.2). 1D-
NMR spectra of NS5BΔ21-CTH and NS5BΔ21-NTH also showed the similar 
results which indicated the presence of well structured fold in the sample of 
expressed NS5B. These studies are consistent with the previously published 
structural data.  
5.3.3 Binding studies between NS5B and VAPB 
Previous reports and the titration experiments of full length VAPB with 
NS5BΔ21 indicated that MSP domain of VAPB may be involved in binding 
with NS5B protein of HCV. Therefore, we tested the NS5B binding with MSP 
domain by using NMR titration experiments. Superimposition of titration 
spectra collected in presence of NS5BΔ21-NTH protein in different molar 







































Figure 5.3 Identification of interaction between NS5B and MSP domain. 
Superimposition of 1H-15N NMR HSQC spectra of MSP domain (1-125) in the 
absence of (black) and in the presence of unlabeled NS5BΔ21-NTH (red) at a 
molar ratio of 1:3 (A) and NS5BΔ21-CTH at a molar ratio of 1:2 (B) 














5.3A). Number of shifted peaks during the binding of NS5BΔ21-NTH was 
low. These perturbations of MSP HSQC spectra during the titration with 
NS5BΔ21-NTH clearly indicated their binding to each other. Subsequently, 
NS5BΔ21-CTH was also titrated with labeled MSP domain and HSQC spectra 
of MSP domain were monitored.   
Superimposition of titration spectra indicated the disappearance as well as 
shifting of HSQC peak of MSP domain during the titration (figure 5.3B). This 
result demonstrated that NS5BΔ21-CTH also interacts with MSP domain of 
VAPB. Overall pattern of perturbation of HSQC peaks with the addition of 
unlabeled NS5BΔ21-NTH and NS5BΔ21-CTH was similar. Interestingly, 
addition of NS5B does not cause major change in the structure of MSP 
domain as overall HSQC pattern of bound state does not have drastic change. 
With the help of MSP domain sequential assignment, perturbed residues were 
identified and mapped back to the MSP structure (data not shown). 
5.4 Discussion  
HCV RNA dependent RNA polymerase, NS5B was reported to interact with a 
SNARE-like protein VAPB (Tu et al., 1999; Hamamoto et al., 2005). 
However, this interaction was reported firstly in 1999 but characterization of 
binding could not be achieved until now. Therefore, we aimed to study this 
interaction to understand the host HCV interaction deeply in this direction. As 
the mechanism and the role of NS5B-VAPB interaction is not known, this 





To study the interaction, NS5BΔ21-NTH and NS5BΔ21-CTH were cloned 
and expressed in bacterial system. However, in this step we faced many 
problems but we succeeded in optimizing the expression by addition of 
glucose in the media as it helped in reducing the leaky expression. Ni-NTA 
affinity purification had lot of impurity and precipitation problem but after 
purification from heparin column, purity of sample was increased and the 
aggregation problem was also fixed to some extent. This shows that probably 
presence of impurity causes the precipitation of NS5B. Secondary structure 
characterization of purified NS5B sample by far UV-CD spectra, showed the 
presence of high content of α-helixes in the structure. CD spectra of both 
constructs indicated that they have well folded structure. These results are 
consistent with the previously published structure of NS5B. In 1999 Tu et al. 
reported the interaction between NS5B and MSP domain by using co-
immunoprecipitation method but further investigation about this interaction 
was not done. We, for the first time performed interactional studies by using 
chemical shift perturbation mapping which is a very powerful and a precise 
method to study and identify the involved residues in the interaction. 
Perturbation of HSQC peaks during NMR titration of NS5B with labeled 
VAPB indicated their interaction. Furthermore, to identify which domain or 
region of VAPB is involved in this interaction, various designed fragments of 
VAPB were titrated with NS5BΔ21-NTH. Perturbation of HSQC peak of 15N-
labeled MSP domain upon the addition of NS5BΔ21-NTH demonstrated that 
MSP domain of VAPB protein does bind to NS5B. NMR titration of MSP 
domain with NS5BΔ21-CTH also confirms their interaction. However, the 





shifting of same set of HSQC peaks upon the addition of NS5BΔ21-CTH 
indicated that probably binding of NS5BΔ21-NTH to MSP domain is much 
tighter then NS5BΔ21-CTH. Further investigation into the binding affinity is 






















































Conclusion and Future perspectives 
Conclusion 
VAP protein which was identified as a host ER membrane anchor for 
recruitment of HCV replication complex components NS5A and NS5B (RNA 
dependent RNA polymerase) proteins on the site of replication by interaction 
with them. This interaction is very important for the life cycle of HCV and can 
be targeted to design antiviral against HCV infection. 
In this thesis, the role of a host cell ER membrane protein VAPB, which helps 
in anchoring the viral component to ER membrane, was investigated 
extensively by studying the interaction between VAPB and viral proteins 
(NS5A and NS5B).  Implications of these interactions in triggering the ALS 
disease were investigated by studying the interaction between VAPB and 
various Eph receptors. In this study, interaction of VAPB with NS5A and 
NS5B was structurally characterized in vitro for the first time. We also aimed 
to identify which domain or fragment of these proteins is involved in the 
interaction. Nuclear Magnetic Resonance spectroscopy was utilized in this 
study to facilitate the deeper understanding of these interactions. 
To pursue our objectives, firstly, various constructs were designed and cloned 
into expression vectors. VAPB was dissected into 4 constructs (VAPB, MSP, 
VAPB150 and CC) which are devoid of transmembrane domain. Whereas, 
447 amino acids long viral protein NS5A, was dissected into 10 constructs 
which are devoid of N-terminal amphipathic helix. Structural characterization 





VAPB (1-195) is composed of two structural domains which are: β-strand 
dominant MSP domain and helical CC domain. Moreover, HSQC spectra of 
all constructs indicated that there is no significant packing between MSP and 
CC domain in the VAPB protein. Subsequent structural characterization of 
NS5A constructs of Singapore HCV isolate demonstrated that domain 1 is a 
well folded β-strand dominant domain, whereas domain 2 and domain 3 are 
intrinsically unstructured domains. Triple resonance heteronuclear NMR 
spectra were analyzed to achieve the sequential assignment of NS5A-D3. 
Helical conformations weakly populated over NS5A-D3 sequence was 
identified by calculating chemical shift deviation (CSD) plot from NMR 
assignments. 
Designed constructs of VAPB and NS5A were used to study the interaction 
between them. NMR titration results obtained from various combinations of 
both protein constructs demonstrated that NS5A full length binds to MSP 
domain. Further investigation revealed that 89 residue NS5A-D3 is majorly 
involved in the interaction with MSP domain. MSP domain titration with 
various N-terminally truncated domain 3 helped us in identifying that C-
terminal 41 residues fragment NS5A-D3B retains almost the same binding 
affinity and mode as the 89-residue D3. Furthermore, protein sequence 
alignment of NS5A protein from con1 and J1 isolate of HCV subtype 1b, and 
subtype 1a isolate H77 showed that D3B region of NS5A is very much 
conserved over major types of HCV genome (figure 1 appendix).  
Chemical shift perturbation during NMR titrations were also utilized to 
estimate the residue specific Kd (dissociation constant). The average Kd of 





D3, NS5A-D3A and NS5A-D3B remain largely unstructured even upon 
forming a complex with MSP domain. Therefore, due to the dynamic nature of 
the NS5A-MSP complex, it was designated as “fuzzy complex” which 
probably facilitates functional actions of NS5A during the replication process. 
Fuzzy nature of the NS5A-D3B and MSP complex explains why we could not 
get complex crystal and high quality ITC data after trying many times. As 
reflected from HSQC titration results, binding of NS5A-D3 and its fragments 
to MSP domain do not induce any structural folding, suggest that MSP–
NS5A-D3 fuzzy complex falls in “random” category of fuzzy complex. These 
types of fuzzy complexes are highly dynamic. Nevertheless, with the use of 
NMR spectroscopy, key residues involved in NS5A-VAPB complex 
formation were successfully mapped out on NS5A and VAPB, which allowed 
the construction of a complex model by use of a well-established NMR 
constraint-based docking procedure. Analysis of complex model revealed that 
NS5A-D3 binds to the one side of MSP fold which was also characterize 
previously to interact with FFAT-containing peptides and Eph receptor. 
Moreover, two ALS disease causing mutations, P56S and T46I were also 
found to be located on the NS5A-D3 binding region on MSP domain and 
NS5A-D3 interaction with T46I MSP mutant was dramatically abolished in 
NMR titration experiments. These results indicated that there might be some 
association between ALS disease and HCV infection.  
To investigate further, interaction of MSP domain with all available Eph 
receptors were studied by NMR titrations. Results obtained from these 
experiments demonstrated that all the tested Eph receptors interact with MSP 





perturbations of MSP domain HSQC caused by EphA2 and EphA5 get 
saturated very early compared to all other receptors which indicates that 
probably binding mode of EphA2 and EphA5 might be different than others. 
Although, interaction of all Eph receptors triggered the disappearance of most 
perturbed MSP domain peak, but in case of EphA2 and EphA5, many 
significantly shifted peaks could be identified which allowed us to fit the 
chemical shift deviation data to obtain dissociation constant of binding of 
these receptors with MSP domain. The average dissociation constants (Kd) of 
the interaction of EphA2 and EphA5 receptor were calculated as ~8.7 µM and 
~62.8 µM respectively. These data indicated the higher affinity of EphA2 
towards MSP domain than EphA5 receptor. Nevertheless, further investigation 
is needed understand difference in the perturbation pattern caused by these 
Eph receptors. Subsequently, competition between NS5A-D3B and EphA4 
receptor for binding with MSP domain experiment demonstrated that Eph 
receptor is unable to compete with NS5A-D3B for binding with MSP domain 
at low molar ratios. However, at higher concentration (1:10) Eph receptor 
starts displacing NS5A-D3B and interacts with MSP domain. Overlap of 
binding surface of NS5A-D3 and Eph receptor on MSP domain and 
competeion of NS5A-D3 with Eph receptor for interaction with MSP domain 
indicated the association of HCV infection with ALS like syndrome. Indeed, 
two recent reports (Akhvlediani et al., 2009; Bastos et al., 2011), in which 
chronic HCV patients have developed ALS like syndrome; also strengthen our 
discovery of association HCV infection with ALS disease. However, the 





Furthermore, results obtained in this work helped us to propose a mechanism 
of ALS development in the backgraound of HCV infection (figure A).  
According to this mechanism, in the presence of HCV infection, viral NS5A 
and NS5B proteins interact with MSP domain of VAPB protein and form a 
replication complex on the ER membrane. Due to high level of viral protein in 
the infected cells, MSP domain fails to secrete outside the cell thereby causing 
similar condition generated by two point mutations (P56S and T46I) in MSP 
domain in ALS disease. Thus, HCV infection may lead to the failure or 
reduction of MSP domain secretion outside the cell thereby decreasing the 
signaling through Eph receptor and MSP domain interaction. This facilitates 
the higher activity of Eph Receptor through the interaction with ephrin. Higher 
activity and expression of EphA4 in ALS patients has recently been reported 
in a study (Van Hoecke et al., 2012). Moreover, this study also shows that 
inhibition of EphA4 receptor through genetic or pharmacological inhibition is 
able to increase the disease onset time in rodent models of ALS and rescue the 
neurodegeneration in zebrafish models. These results indirectly suggest that 
interaction of MSP domain with Eph receptor is a key convergent point for 
signaling pathways important for ALS pathogenesis. Thus, higher activity of 
Eph receptor caused by HCV infection might trigger modulation of signaling 
through ephrin binding and lead to the larger size of motor neurons which are 
more susceptible for degeneration (figure A). However, for developing ALS 
like syndrome, HCV infection alone is not enough as the cause of this dease is 
yet not known. Research has suggested that various unknown environmental 
and/or molecular triggers are also required for causing ALS. Therefore, HCV 






Figure A Mechanism of ALS development during the HCV infection 
 
Figure B Model showing the interaction of VAPB with NS5A and NS5B on 
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ALS like syndrome. Here, we accept that further functional studies are needed 
to confirm the association of HCV infection and ALS disease.  
Extensive interactional studies of NS5B (RNA dependent RNA polymerase) 
with VAPB demonstrated that MSP domain of VAPB interacts with NS5B. 
However, more detailed and deeper investigation into this interaction is 
needed to understand it better.  
In a conclusion, in this thesis work, we have investigated that MSP domain is 
the one which interacts with NS5A. These finding alter the previous wrong 
notion that coiled coil domain of VAPB is responsible for interacting with 
NS5A. Model demonstrating the interaction of VAP protein with NS5A and 
NS5B on the RCs has shown in the figure A which shows that MSP domain of 
VAPB protein is involved in anchoring the viral proteins NS5A and NS5B. 
Moreover, our results also demonstrated that in NS5A protein C-terminal half 
of domain 3 (NS5A-D3B) is involved in the interaction with MSP domain. 
Overlap of binding surface of NS5A-D3 and Eph receptor on MSP domain 
and competition of NS5A-D3 with Eph receptor for binding with MSP domain 
has pointed towards molecular association of HCV infection and ALS 
pathogenesis. Our results also helped us to propose a molecular mechanism 
underlying this association.  
Future perspectives 
Investigation into MSP-Eph receptor interaction 
MSP-Eph receptor interactional studies by NMR have demonstrated that the 
ligand binding domain of all Eph receptors bind to the same surface on MSP 





that their interaction might be different with other receptors with respect to 
affinity or dynamics. Therefore, further investigation into the binding affinity 
of these receptors will be determined by ITC or NMR titration. Determination 
of binding parameters can facilitate the better understanding of the interaction 
of EphA2 and EphA5. Moreover, CPMG experiments will be acquired to 
understand the dynamics during the interaction with MSP domain. 
 Investigation into NS5B-MSP interaction 
By using NMR titrations with various constructs of VAPB, we have identified 
that MSP domain interacts with NS5B. However, residue level information of 
protein will be obtained by mapping the chemical shift perturbation. 
Sequential assignment of MSP domain can be utilized to identify the residues 
involved in the interaction.  
Complex structure of NS5B-MSP 
3D structure of the NS5B-MSP complex will be determined by using X-ray 
crystallography or NMR. Initially, crystallization method will be tried to get 
good quality crystal of complex by hanging drop vapor diffusion method. 
Otherwise, NMR spectroscopy will be used to determine the complex 
structure.  
 Determination of binding parameters 
ITC is the most quantitative means for measuring the thermodynamic 
properties of interaction. To determine the thermodynamic parameters of MSP 





MSP domain of VAPB in ITC experiment and thermodynamic parameters will 
be determined. Alternatively, Surface Plasmon resonance or NMR titration 
can be used to determine the binding parameters of this interaction. 
Mutational Studies of Interaction 
The ultimate evidence of protein-protein interaction is to detect a decrease in 
the interaction in the isogenic mutant altering the binding site of the protein. 
Thus, it is very important to find out the mutations that reduce the interaction 
of VAPB with NS5B. To identify the key residues involved in this binding, 
highly conserved amino acid residues present in the minimal binding region 
will be altered. They will be altered to alanine, such that this alteration can 
disrupt the local structure of binding site. We can further alter the charged 
surface (solvent-exposed) residues to polar residues with an equivalent size to 
explore more details, e.g., basic residues to glutamine and acidic residues to 
serine. Site-directed mutagenesis approach will be used to alter the binding 
site precisely. Effect of mutation on binding interaction will be revealed by 
analyzing the effect on perturbation of chemical shift of 15N-labeled mutant 
protein in NMR titrations with ligand. These mutational studies will provide 
us information about the critical residue involved in the interaction between 
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Table A1 Solutions for preparing resolving gel and 4% stacking gel for 
SDS-PAGE. 
 
Gel DD water 40% acrylamide( 
19:1) 
Gel Buffer 10% 
SDS 
Stacking  gel (10ml) 
 
   0.5 M Tris-HCl, pH 6.8  
4% 6.36 ml 1 ml 2.52 ml 0.1 ml 
 
TEMED    -          10µl 




   1.5M Tris-HCl, pH 8.8  
7.50%  
5.47 ml 
1.88 ml 2.5 ml 0.1 ml 
8%  
5.35 ml 
2 ml 2.5 ml 0.1 ml 
10%  
4.85 ml 
2.5 ml 2.5 ml 0.1 ml 
12%  
4.35 ml 
3 ml 2.5 ml 0.1 ml 
15%  
3.6 ml 
3.75 ml 2.5 ml 0.1 ml 
16%  
3.35 ml 
4 ml 2.5 ml 0.1 ml 
 
TEMED    -           5 µl 
















Figure 1. Sequence alignment 
 
 
S1      SGSWLRDVWDWICTVLTDFKTWLQSKLLPRLPGVPFFSCQRGYRGVWRGDGIMQTTCPCG 60 
Con1    SGSWLRDVWDWICTVLTDFKTWLQSKLLPRLPGVPFFSCQRGYKGVWRGDGIMQTTCPCG 60 
J1      SGSWLRDVWDWICTVLADFKTWLQSKLLPRLPGVPFFSCQRGYKGVWRGDGIMYTTCPCG 60 
H77     SGSWLRDIWDWICEVLSDFKTWLKAKLMPQLPGIPFVSCQRGYRGVWRGDGIMHTRCHCG 60 
        *******:***** **:******::**:*:***:**.******:********* * * ** 
 
S1      AQISGHVKNGSMRIVGPRSCSNTWHGTFPINAYTTGPCTPAPAPNYSRALWRVAAEEYVE 120 
Con1    AQITGHVKNGSMRIVGPRTCSNTWHGTFPINAYTTGPCTPSPAPNYSRALWRVAAEEYVE 120 
J1      AQITGHVKNGSMRIVGPRTCSNTWHGTFPINAYTTGPCTPSPAPNYSRALWRVAAEEYVE 120 
H77     AEITGHVKNGTMRIVGPRTCRNMWSGTFPINAYTTGPCTPLPAPNYKFALWRVSAEEYVE 120 
        *:*:******:*******:* * * *************** *****. *****:****** 
 
S1      VTRVGDFHYVTGMTTDNVKCPCQVPAPEFFTEVDGVRLHRYAPACKPLLREEVTFQVGLN 180 
Con1    VTRVGDFHYVTGMTTDNVKCPCQVPAPEFFTEVDGVRLHRYAPACKPLLREEVTFLVGLN 180 
J1      VTRVGDFHYVTGMTTDNVKCPCQVPAPEFFTELDGVRLHRYAPACKPLLRDEVTFQVGLN 180 
H77     IRRVGDFHYVSGMTTDNLKCPCQIPSPEFFTELDGVRLHRFAPPCKPLLREEVSFRVGLH 180 
        : ********:******:*****:*:******:*******:**.******:**:* ***: 
 
S1      QYLVGSQLPCEPEPDVAVLTSMLTDPSHITAETAKRRLDRGSPPSLASSSASQLSAPSLK 240 
Con1    QYLVGSQLPCEPEPDVAVLTSMLTDPSHITAETAKRRLARGSPPSLASSSASQLSAPSLK 240 
J1      QYTVGSQLPCEPEPDVTVVTSMLTDPSHITAEAARRRLARGSPPSLAGSSASQLSALSLK 240 
H77     EYPVGSQLPCEPEPDVAVLTSMLTDPSHITAEAAGRRLARGSPPSMASSSASQLSAPSLK 240 
        :* *************:*:*************:* *** ******:*.******** *** 
 
S1      ATCTTRHDSPDAGLIEANLLWRQEMGGNITRVESENKVVILDSFEPLRAEEDEREVSVPA 300 
Con1    ATCTTRHDSPDADLIEANLLWRQEMGGNITRVESENKVVILDSFEPLQAEEDEREVSVPA 300 
J1      ATCTTHHGAPDTDLIEANLLWRQEMGGNITRVESENKIVILDSFEPLRAEEDEREVSAAA 300 
H77     ATCTANHDSPDAELIEANLLWRQEMGGNITRVESENKVVILDSFDPLVAEEDEREVSVPA 300 
        ****:.*.:**: ************************:******:** *********..* 
 
S1      EILRKSRKFPRAMPIWARPDYNPPLLESWKNPDYVPPVVHGCPLPPIKGPPIPPPRRKRT 360 
Con1    EILRRSRKFPRAMPIWARPDYNPPLLESWKDPDYVPPVVHGCPLPPAKAPPIPPPRRKRT 360 
J1      EILRKTRKFPAAMPVWARPDYNPPLLESWKNPDYVPPVVHGCPLPPTKAPPIPPPRRKRT 360 
H77     EILRKSRRFARALPVWARPDYNPPLVETWKKPDYEPPVVHGCPLPPPRSPPVPPPRKKRT 360 
        ****::*:*. *:*:**********:*:**.*** *********** :.**:****:*** 
 
S1      VVLTESTVSSALAELATKTFGSSGSSAVDSGTASAPPDQPSDNGDAGSDAESYSSMPPLE 420 
Con1    VVLSESTVSSALAELATKTFGSSESSAVDSGTATASPDQPSDDGDAGSDVESYSSMPPLE 420 
J1      VVLTESTVSSALAELATKTFGGSGSSAVDSGTATGPPDQASAEGDAGSDAESYSSMPPLE 420 
H77     VVLTESTLSTALAELATKSFGSSSTSGITGDNTTTSSEPAPSGCPPDSDVESYSSMPPLE 420 
        ***:***:*:********:**.* :*.: ...:: ..: ..    ..**.********** 
 
S1      GEPGDPDLSDGSWSTVSEEAS-EDVVCC 447 
Con1    GEPGDPDLSDGSWSTVSEEAS-EDVVCC 447 
J1      GEPGDPDLSDGSWSTVSEEAS-EDVVCC 447 
H77     GEPGDPDLSDGSWSTVSSGADTEDVVCC 448 
        *****************. *. ****** 
 






Hepatitis C virus subtype 1b isolate con1   GenBank: CAB46677.1 
Hepatitis C virus subtype 1b isolate J1     GenBank: D89815.1  
Hepatitis C virus subtype 1a isolate H77    GenBank: AAB66324.1 
In S1 strain sequence domain 1 domain 2 and domain 3 are colored as blue, 
pink and green respectively. 
